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Aberrant DNA methylation patterns are a universal feature of cancer, yet
we understand relatively little of the cause and consequence of DNA
methylation in the cancer process. Colorectal cancer (CRC) morbidity
and mortality is a massive burden on the New Zealand, and worldwide,
health care system. CRC represents an exciting model for the study of
DNA methylation in cancer owing to the CpG island methylator
phenotype (CIMP) subtype, which has a high degree of cancer-specific
DNA methylation. This PhD is comprised of three chapters investigating:
a) aberrant DNA methylation in CRC b) the mechanisms underlying the
observed methylation patterns and c) the potential clinical utility of
cancer-specific DNA methylation. In the first chapter, genome-wide DNA
methylation is characterised using the high-density Illumina 450K
HumanMethylation beadchip. Three distinct methylation subtypes
(CIMP-High, CIMP-Low and CIMP-Negative) were identified within the
tumours analysed. Hypermethylation was detected at over 2,000 CpG
islands across the cohort, however many of these CpG islands were
hypermethylated in only a fraction of cases. In contrast to this, a set of
over 250 CpG islands were hypermethylated in more than 90% of
CIMP-H tumours. This was likened to the model of ‘mountains’ (the
small number of highly consistent events) and ‘hills’ (the large number of
events which occur at a very low frequency), which has previously been
used to describe driver and passenger mutation frequencies in cancer.
The consistently hypermethylated CpG islands are linked to biologically
relevant genes which play important roles in cellular differentiation and
cell fate decisions. During this PhD, another group demonstrated a
mechanistic link between activating BRAF and KRAS mutations and
the CIMP-High and CIMP-Low phenotypes. Prompted by this discovery,
I investigated the activity of the RAS/RAF pathway in the 20-30% of
CIMP-H tumours which lack characteristic BRAF/KRAS mutations. I
show that activation of the RAS/RAF pathway occurs even in
BRAF/KRAS wildtype tumours, and propose a model in which DNA
methylation is critical to the progression of CIMP tumours. Finally, I
investigate the capacity for aberrant DNA methylation marks to
iii
differentiate CRC from non-cancerous tissue and identify loci which could
be developed into biomarkers for improved detection of CRC.
This thesis contributes to our understanding of CRC epigenetics
through the identification of consistently hypermethylated regions and
suggests a mechanism by which hypermethylation occurs in a subset of
CIMP-High tumours. Loci identified in this study can accurately
discriminate CRC from non-cancerous tissue and could be developed into
a simple, cost-effective test for the detection of CRC.
iv
“A study is valid if results represent an unbiased estimate of the truth”
- Ransohoff et al., (2009)
“Innovation follows imitation”
- Pavan Soni
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Colorectal cancer (CRC) is the third most common cancer in the
developed world [1]. The majority of cases are sporadic, with less than
10% of cases attributed to an inherited genetic mutation [2]. CRC
involves the progression from adenoma to carcinoma, and involves the
accumulation of epigenetic and genetic mutations. CRC is a heterogenous
disease comprised of multiple subtypes, each with unique clinical features
and underlying pathways. The colorectum is a diverse area of tissue,
separated into the ascending, transverse and descending (includes rectum)
sections of the colon, with different CRC subtypes enriched in each of
these sections.
1.1.1 Chromosomal instability pathway
Chromosomal instability (CIN) pathway tumours are the most common
form of CRC, accounting for approximately 70% of all sporadic CRC
cases [2]. CIN tumours are characterised by structural chromosomal
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rearrangements and/or aneuploidy and carry mutations in a number of
tumour-suppressor genes (e.g., APC, SMAD4, TP53 ).
The most prevalent (81%) mutation in sporadic (non-hypermutated)
CRC occurs in the Wnt signalling pathway member APC [3]. APC
mutations are found in the earliest identifiable lesions (aberrant crypt
foci) and are detected at approximately the same frequency in advanced
and early lesions, suggesting these events are involved in initiation of
tumorigenesis [4]. APC is required for the phosphorylation and
subsequent degradation of β-catenin. When both APC alleles are
inactivated, β-catenin accumulates and migrates to the nucleus where it
functions as a transcription factor [5]. β-catenin, through the regulation
of a large number of target genes, prevents differentiation and induces a
stem-like gene expression program in CRC [6]. Non-APC mutations
which alter Wnt signalling, such as activating mutations in β-catenin and
AXIN1, are common in APC wildtype CRC and further support a
critical role for Wnt signalling (reviewed in Segditas and Tomlinson, 2006.
Oncogene).
Inherited CRC
Germline APC mutations are responsible for the inherited cancer
syndrome Familial Adenomatous Polyposis (FAP). FAP presents as
hundreds to thousands of adenomatous polyps in the colon and has an




The serrated pathway describes a subset of tumours which progress from
precursor polyps with a jagged appearance, where the epithelial edge has
repeated infolding. The serrated pathway has two characteristic
molecular features: activation of the RAS/RAF pathway through
activating mutations in either BRAF or KRAS, and an increased level of
DNA methylation (the CpG island methylator phenotype). Microsatellite
instability (MSI) caused by hypermethylation and silencing of MLH1 is a
common feature. The serrated pathway is involved in both sporadic and
inherited CRC.
CpG island methylator phenotype
The CpG island methylator phenotype (CIMP) is covered briefly here
and is described in detail in Chapter 3. CIMP was first identified in 1999
as a subset of colorectal tumours with a high degree of DNA
methylation [8]. The publication discriminated between age-dependent
methylation which is common to both cancer and older healthy tissue,
and cancer-specific methylation which is limited to tumour tissue. By
restricting the analysis to cancer-specific methylation a subset of tumours
were identified with significantly higher levels of DNA methylation
(termed CIMP). CIMP tumours were enriched in the proximal colon
(which includes the cecum and ascending section) and MSI compared to
non-CIMP. CIMP tumours were subsequently found to be enriched for
BRAF mutations and have methylation of MLH1 leading to MSI [9].
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The classification of CIMP has been further refined to include
CIMP-high (CIMP-H) and CIMP-low (CIMP-L). CIMP-H is enriched for
BRAF mutations and female patients, while CIMP-L is enriched for
KRAS mutations and male patients [10]. CIMP-L tumours have an
intermediate level of hypermethylation when compared to CIMP-H and
CIMP-Negative (CIMP-N) tumours.
High methylation phenotypes have been identified in other cancer
types. A high methylation phenotype was identified in a large study of
glioblastoma samples [11]. Glioblastoma CIMP (G-CIMP) tumours are a
subset of the proneural glioma subtype and are highly enriched for IDH1
mutations, exhibit low levels of copy number variation, and have
improved survival compared to non-CIMP gliomas [11]. G-CIMP
represents an epigenetically and clinically distinct group of tumours.
Breast tumours have also been stratified into high and low methylation
subtypes, and found these subtypes were associated with separate clinical
and molecular features [12]. A breast cancer CIMP subtype (B-CIMP),
associated with low metastatic risk and overall better survival, was later
proposed [13]. The authors noted that methylation occurred at genes
involved in metastasis and proposed the methylation profile accounted for
differences in expression between subtypes of breast cancer.
Serrated pathway precursor lesions
The precursor lesions of serrated pathway CRC are the sessile (flat)
serrated adenoma and traditional serrated adenoma, which account for
9% and 1% of colorectal polyps respectively [14]. Sessile serrated
adenomas (SSA) have high rates of BRAF mutation (70-81%), which is
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thought to be the initiating event in these lesions [15]. Traditional
serrated adenomas (TSAs) are the rarest serrated precursor lesion. These
adenomas have high rates of MLH1 hypermethylation and frequently
carry mutations in BRAF and KRAS (55% and 29%, respectively) [16].
The serrated pathway is comprised of three distinct subtypes with
unique molecular characteristics. These are: tumours with a BRAF
mutation and hypermethylation of MLH1 leading to microsatellite
instability (MSI), BRAF mutation with unmethylated MLH1
(microsatellite stable (MSS)), or tumours with a KRAS mutation which
are predominantly MSS [15]. Serrated pathway clinical features differ
depending on the molecular characteristics of the individual tumour, but
are more common in the proximal colon and are more prevalent in older
female patients.
Familial serrated pathway
The most common inherited CRC is hereditary non-polyposis colorectal
cancer (HNPCC, also referred to as Lynch syndrome). Patients with
HNPCC syndrome exhibit MSI, caused by germline mutations in the
mismatch repair (MMR) system [17]. HNPCC syndrome colorectal
cancers are resistant to 5-fluorouracil (5-FU) and are more common in
the proximal colon.
1.2 Epigenetics
Epigenetics is the study of chemical modifications which modify gene
expression without involving changes to the underlying DNA sequence.
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In vertebrates, this occurs at three levels: DNA methylation, histone
modifications, and non-coding RNA. Epigenetic modifications are
inherited mitotically from cell to cell and thus constitute a form of
cellular memory. Epigenetics plays a key role in facilitating the
differentiation of cells, which share an identical genome, into unique and
specialised cell types. The most well recognised description of epigenetics
and differentiation is Waddington’s model of a ball rolling down a hill
(Figure 1.1) [18]. Initially the ball (representing the undifferentiated cell)
has unlimited potential, but as it rolls down the hill it becomes trapped
in valleys from which it cannot escape, reducing it’s potential (becoming
more and more differentiated).
It is now accepted that epigenetics plays a role in many disease states.
In profiling healthy and disease epigenetic profiles we aim to understand
the contribution of aberrant epigenetic modifications to disease, and
how we might use knowledge of these aberrant modifications to improve
disease outcomes.
1.2.1 DNA methylation
DNA methylation consists of the addition of a methyl group to the fifth
carbon in a cytosine in a cytosine-guanine dinucleotide (CpG
dinucleotide). The majority of CpG loci in the genome are methylated,
with the exception of CpG sites concentrated around the beginning of
genes which remain largely unmethylated. In contrast to histone
modifications, which are considered a relatively plastic epigenetic mark,
DNA methylation is a stable modification.
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Figure 1.1: Reprint of Waddington’s classical model of epigenetics.
Conrad Waddington used the analogy of a ball rolling down a hill and
becoming trapped in valleys to represent cell fate decisions [18]. An
undifferentiated cell, shown as the ball at the top of the hill, has the
potential to land in any valley. However, once in a valley (having made a
cell fate decision), the ball is restricted in future potential.
1.2.2 Patterns of DNA methylation in healthy
tissue
Bimodal distribution in the mammalian genome
Methylated cytosines are prone to spontaneous deamination and
conversion to thymine and as a result CpG dinucleotides are depleted
from the majority of the genome [19]. Short regions of DNA exist with a
high concentration of CpG dinucleotides, termed CpG islands (CGIs).
CGIs are located at the beginning of approximately 70% of mammalian
promoters [20, 21]. The majority of CGIs are devoid of methylation in
7
adult healthy tissue [22].
CGIs are enriched for housekeeping genes, while genes which lack CGIs
tend to be associated with genes that are expressed in a cell type specific
manner [21]. CGIs lacking methylation are often associated with a very
open chromatin state (heterochromatin), lack nucleosomes and expression
from these CGIs is regulated by the binding of transcription factors [20].
The presence of transcription factors which are bound at the promoter
region are required to maintain the unmethylated state. For example,
the mouse aprt1 housekeeping gene promoter, which is bound by the
Sp1 transcription factor, overlaps with a CGI and is maintained in an
unmethylated state. When the binding site of Sp1 is mutated or deleted,
abolishing Sp1 binding, the aprt1 CGI becomes methylated [23].
Early studies and evidence for DNA methylation as a silencing
mark: X-chromosome inactivation
Mammalian female cells carry two X chromosomes yet only require
expression from one of these, and must therefore inactivate and repress
the second copy. The process of X inactivation has been studied as a
model of the regulation of gene expression and repression. Experiments
demonstrated that DNA on the inactive X chromosome had been
modified in such a way as to prevent expression, and this modification
was hypothesised to be the addition of DNA methylation [24]. When
DNA methylation was removed from the inactive X chromosome via
treatment with the demethylating agent 5-azacytidine expression was
reactivated [25].
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DNA methylation has since been confirmed as a silencing modification.
A study which compared the expression of methylated and unmethylated
strands of DNA demonstrate that methylation prevents transcription [26].
DNA methylation prevents expression through two distinct mechanisms.
First, DNA methylation can physically inhibit the binding of
transcription factors to promoter regions [27]. Alternatively, the presence
of DNA methylation facilitates the binding of a family of proteins which
specifically target methylated DNA (Methyl-CpG Binding Domain
(MBD) proteins). MBD proteins then recruit a suite of proteins which
bring about local changes in chromatin structure (through histone
modifications), repressing expression [28,29].
Alternative functions of DNA methylation
The effect of DNA methylation on gene expression is context dependent.
In contrast to DNA methylation in the promoter region, when
methylation is found in the gene body it is associated with expression of
the gene. One hypothesis to explain the association between gene body
expression and methylation is that gene bodies often contain additional
promoters which are methylated to prevent intragenic initiation of
expression [30]. Alternatively, the presence of DNA methylation in the
gene body may contribute to the presence of nucleosomes which facilitate
transcription across the intron-exon boundary [31].
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1.2.3 Establishing and maintaining global DNA
methylation patterns
DNA methylation patterns undergo drastic changes during the
progression from a single-cell zygote to multicellular adult, and the
epigenome must be reprogrammed when generating the primordial germ
cells that give rise to the next generation [32, 33]. The methylation
patterns first established in the early embryo must be flexible enough to
facilitate the development of multiple tissue types, yet rigid enough to
maintain cellular hierarchy. The tension between plasticity and stability
is balanced through multiple mechanisms, which are still being explored.
DNA methylation patterns are established and maintained by the DNA
methyltransferase (DNMT) family of genes. Knock out studies in mice
embryos demonstrate that Dnmt3A and Dnmt3B are required for de
novo methylation in embryonic stem cells, but are not required for
maintenance of existing methylation patterns [34]. DNA methylation
patterns are maintained through cell division by DNMT1. Following cell
division, the parental strand of DNA retains the inherited methylation
pattern (hemimethylated state). Hemimethylated DNA is preferentially
bound by DNMT1, which faithfully copies the methylation pattern from
the parental strand to the newly generated strand [35]. Demethylation
can occur by both passive or active mechanisms. Passively, DNA
methylation can be reduced over time in the absence of maintenance
methyltransferases as methylation is progressively diluted through cell
division. DNA methylation can also be reduced by the ten-eleven
translocation (TET) family of proteins. TET proteins oxidise the methyl
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group in the CpG dinucleotide (5mC) to hydroxymethylcytosine (5hmC),
then to 5-formylcytosine and finally 5-carboxylcytosine (reviewed in [36]).
Oxidised variants of methylated cytosine may be removed by base
excision repair, or, following cell division, might not be recognised by
DNMT1 as a methylation mark and therefore do not trigger copying of
methylation to the newly synthesised strand [36].
Epigenetic reprogramming of the zygote and establishing
primordial germ cell methylation patterns
Our understanding of epigenetic reprogramming in mammals is largely
driven by studies of the developing mouse embryo (reviwed in [37]).
Following fertilization the genome undergoes active demethylation, which
occurs asymmetrically in the paternally and maternally derived DNA
(reviewed in [38]). The most significant change in DNA methylation
occurs in the paternally derived genome, during or prior to the first
replication of the paternal DNA [32,39], reviewed in [38]. This is thought
to occur as an active process of demethylation largely driven by TET3
( [40]). Mice which lack TET3 do not undergo reduction of 5mC nor an
increase in 5hmC (a product of TET3-mediated demethylation) in the
paternal genome [41]. In female mice which have been depleted of TET3,
offspring are more likely to exhibit improper development [41]. The
maternally derived genome also undergoes demethylation in the early
embryo, although this change is smaller in scale [32]. While maternal
genome demethylation was initially thought to occur through a passive
process, the presence of 5hmC in the maternally derived genome
indicates active demethylation is occurring [32].
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Sperm and oocytes differ drastically in their DNA methylation profiles.
Sperm DNA is widely methylated with the exception of CpG-rich regions,
and promoter methylation is inversely correlated with gene expression,
while oocyte DNA is largely unmethylated (approximately 40%
methylation across the genome) and methylated regions are positively
correlated with transcription [42]. During the development of mouse
primordial germ cells (PGCs), which give rise to sperm or oocytes in
males and females respectively, two distinct stages of DNA demethylation
occur (reviewed in [43] and [38]). The initial stage of demethylation
appears to be through a mechanism involving the transcriptional
repression of Uhrf1, an important co-factor in DNMT1-mediated
maintenance methylation [44]. This inhibition of the maintenance
methylation system leads to passive demethylation of the genome. The
second wave of PCG demethylation occurs through TET1-mediated
oxidation of methylated cytosines, resulting in an increase in 5hmC
during this time [45]. The resulting 5hmC may be lost through active
mechanisms which further oxidise these cytosines, or lost through passive
dilution during replication [38].
1.3 DNA methylation in carcinogenesis
All known cancer types exhibit aberrant DNA methylation, although the
cause and effect of these methylation patterns are largely unknown.
While the majority of CpG loci in the healthy genome are methylated,
punctuated by unmethylated CGIs, cancer genomes exhibit an inversion
of this pattern, that is, genome-wide hypomethylation alongside
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hypermethylation of CGIs. Despite being a wide-spread phenomenon it is
unknown what, if any, role DNA methylation plays in the initiation and
progression of tumorigenesis. Early studies suggested DNA methylation
may act as a silencing mechanism by substituting for genetic mutations.
However, not all data supports this conclusion and more recent studies
have suggested an alternative role for DNA methylation in cancer.
1.3.1 Classical view: DNA methylation as a
substitute for mutation
Loss of function of a tumour suppressor gene is one mechanism for the
initiation of tumorigenesis. As transcription cannot be initiated from a
methylated promoter, aberrant methylation in cancer was predicted to
function in a similar manner to a loss of function mutation. This has
been demonstrated to occur in sporadic colorectal cancer with MSI [46].
A subset of tumours with MSI have no mutations in MLH1 and instead
show tumour-specific hypermethylation [47]. Data which demonstrated
the preferential hypermethylation of the wildtype, but not mutant,
CDNK2A allele in a colon carcinoma cell line support methylation as an
alternative mechanism of inactivation [48]. To further support DNA
methylation as a substitute for mutations, a study of methylation in
inherited tumours revealed that methylation preferentially occured at
wildtype, but not mutant, alleles. Two thirds of tumours carrying
mutations in mismatch repair genes (e.g., hMLH1 and hMSH2 ) had no
observable second mutation [49]. DNA methylation was detected in 40%
of tumours with a single hMLH1 germline mutation, while zero out of
eight tumours with mutations in both hMLH1 alleles had evidence of
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methylation [49]. The data support a model in which methylation acts as
a substitute for a secondary mutation when a single mutated allele is
inherited.
To further support the hypothesis that methylation promotes
carcinogenesis in a similar manner to mutation, methylation is often
found to occur at genes with a known role in cancer. That is, tumour
suppressor genes that are hypermethylated in certain cancers had often
already been identified as mutated in those same cancer types. Genes
that are rarely or never mutated in a cancer subtype, and therefore not
predicted to play a role in carcinogenesis, are rarely methylated. The
overlap of methylation and mutation occurring in the same tumour types,
while rarely being found in other tumour types, is suggestive of these
aberrant states playing a role in tumorigenesis.
1.3.2 Evidence against methylation as a substitute
for mutation
While it is clear that DNA methylation prevents transcription from a
methylated promoter, and this occurs at a number of tumour suppressor
genes which are critical in cancer, it is not clear whether DNA
methylation induces silencing or is responsible for maintaining it. Thus,
not all evidence supports a role for methylation in tumorigenesis, as not
all methylation is associated with changes in expression. In X
chromosome inactivation, DNA methylation is not responsible for
silencing and instead occurs after repression has occurred.
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Hinoue et al., (2012) performed a comprehensive analysis of
differentially methylated CpG islands in colorectal tumours [50]. Just
7.3% of hypermethylated genes also showed a significant decrease in
expression, corresponding to 24% of all downregulated genes in these
tumours. Forty-three percent of genes which were both hypermethylated
and downregulated in this study were also downregulated in other
colorectal tumours which showed no evidence of hypermethylation,
suggesting methylation was not required for silencing [50].
A cross-cancer study involving breast, colorectal, prostate,
glioblastoma, lung, acute myeloid leukemia (AML) and ovarian tumours
identified genes that were prone to hypermethylation and analysed the
expression profile of hypermethylated genes in corresponding normal
tissue [51]. Genes that were prone to hypermethylation were enriched for
tissue-specific gene ontology terms or developmental terms such as organ
development, while genes resistant to methylation were housekeeping
genes. This suggests that methylation is occurring in a tissue specific
manner, at genes which are not required in the adult healthy tissue from
which the cancer is derived. Specific examples include PAX6, which is
expressed in adult brain tissue but not other tissue types and is resistant
to methylation in glioblastoma but methylated in other cancers, and
GFI1, which is expressed during hematopoiesis and remains
unmethylated in AML while becoming hypermethylated in other cancers.
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1.4 Research direction and aims
The aim of this research was to characterise DNA methylation in
colorectal cancer. The genome-wide coverage of the Illumina 450K
humanMethylation beadchip, combined with a high quality dataset of
matched tumour and non-cancerous samples, would address some of the
limitations of previous analyses and provide an up-to-date description of
methylation in CRC. During this research, a number of key questions
were held in mind: Which DNA methylation changes contribute to the
initiation and development of CRC? How does aberrant DNA
methylation provide a selective advantage to the cell in which it occurs?






2.1 Sample preparation and pre-processing
2.1.1 Tissue samples
Colorectal tumour and adjacent non-cancerous tissue samples (located
approximately 10cm from the tumour) were collected from patients who
underwent surgery at the Dunedin hospital from 1996-2003. Samples
were excised, dissected by a registrar pathologist, snap frozen and stored
at -80◦. Samples were provided by Dr. Mark Thompson-Fawcett,
Professor Andre van Rij, and Professor John McCall from the
Department of Surgery, University of Otago. Clinical data and follow up
information was collected by Ms. Vicky Phillips from the Department of
Surgery, Univeristy of Otago. Ms. Fran Munro, of the Otago University
Department of Surgery, assisted with the organisation and storage of
samples. All clinical samples were collected with patient consent and




DNA was extracted using the Quick-gDNA miniPrep kit (Zymo Research,
Catalogue number D3025) as per the instructions for extraction from
solid tissue samples, with a number of modifications as described here.
Small segments, approximately 3mm squared, of tumour or non-tumour
tissue were homogenised in 500µL of Genomic Lysis Buffer for three 10
second bursts, or until all fragments were broken down, using a Polytron
Kinematica (Luzernerstrasse 147a, CH-6014 Littau/Luzern). Sample
lysate was centrifuged for five minutes at 10,000rpm. The supernatant
was trasferred to a Zymo-SpinTM Column in a Collection Tube and
centrifuged for two minutes at 8,000rpm. The collection tube and
supernatant flow-through were discarded. The Zymo-spin column was
transferred to a new collection tube, 200µL of DNA Pre-Wash Buffer was
added and the sample centrifuged at 10,000rpm for one minute. 500µL of
g-DNA Wash Buffer was added to the column, which was centrifuged at
10,000rpm for one minute and the flow-through discarded. The column
was then centrifuged a second time (a ‘dry spin’ to remove excess
ethanol). The spin column was transferred to a microcentrifuge tube
which had previously been autoclaved. 20µL of Milli-Q water, which had
been warmed to 50◦C, was added to the column which was incubated for
10 minutes at room temperature. The column was then centrifuged at
12,000rpm for 30 seconds. The elution was then re-applied to the column
and centrifuged a second time (a double elution to increase DNA
recovery).
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Extracted DNA quantity and quality was assessed using a NanoDrop
ND-1000 spectrophotometer (Nanodrop Technologies, USA) with the
DNA-50ng-cm/µL protocol, and DNA was stored at -20◦C. DNA was
considered to be of good quantity and quality if there was more than
50ng per µL, and if the ratio of absorbance at 260nm to the absorbance
at 280nm was approximately 1.8.
2.1.3 Bisulfite conversion
Bisulfite conversion of 1000ng of DNA per sample was carried out
using the EZ DNA methylation kit (Zymo Research, D5001). The CT
conversion agent used in bisulfite conversion is sensitive to light, therefore
all preparation of the conversion agent was carried out in a brown tube
which had been wrapped in tinfoil. Exposure to light was kept to a
minimum at all stages of the procedure. Dried CT reagent was combined
with 750µL of water and 210µL of M-Dilution buffer and was mixed with
frequent vortexing for 10 minutes. 6mL of M-Wash buffer was diluted
with 24mL of 100% ethanol to make a working solution of M-wash buffer.
For use in the Illumina Infinium humanMethylation450 beadchip,
bisulfite conversion was carried out as per the manufacturer’s
instructions. DNA was diluted with 5µL of M-dilution buffer, and made
up to a total of 50µL using Milli-Q water before being incubated for 15
minutes at 37◦C. Following incubation 100µL of CT conversion reagent
was added to the DNA and the sample was incubated overnight in a
thermocycler alternating between 95◦C for 30 seconds and 50◦C for 60
minutes, which was repeated 16 times. The sample was then held at 4◦C
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for no less than 10 minutes and no more than one hour. After incubation,
the sample was mixed with 400µL of M-binding buffer and loaded into
the provided Zymo-spinTM IC columns. The sample was then centrifuged
for 30 seconds at 12,000rpm and the flow-through was discarded. 100µL
of M-wash buffer was then added to the column and the column
centrifuged for 30 seconds at 12,000rpm. 200µL of M-Desulphonation
buffer was added to the column and the sample was incubated at room
temperature for 20 minutes, followed by a 30 second centrifuge at
12,000rpm. The flow-through was discarded. The sample was washed by
adding 200µL of M-Wash buffer to the column, which was then spun for
30 seconds at 12,000rpm. This wash was repeated once, and the
flow-through discarded. The Zymo-spin column was then transferred to a
microcentrifuge tube, and 10µL of Milli-Q water was added directly to
the column matrix. The column was spun for 30 seconds at 12,000rpm.
The elution was then re-added to the column and spun a second time (a
double elution) to enhance DNA recovery. Bisulfite converted DNA was
stored at -20◦C.
Bisulfite converted DNA was quantified using the Nanodrop
spectrophotometer under the RNA-40ng-cm/µL protocol, as bisulfite
converted DNA more closely resembles RNA (as per Zymo Research
Bisulfite conversion guide).
2.1.4 Measuring bisulfite conversion efficiency
Bisulfite conversion efficiency was measured using qRT-PCR and 100%
methylated and 100% unmethylated DNA references with primers
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designed for ALU repeat regions, as described previously [52].
2.1.5 Mutation status, MSI status, and
Weisenberger gene panel methylation status
KRAS and BRAF mutation status, and MSI (microsatellite instability)
status, was determined previously by Dr Sujatha Rao [53]. Methylation
status of the Weisenberger gene panel (CACNA1G, NEUROG1, SOCS1,
IGF2, RUNX3 ) was assessed previously using MethyLight, carried out by
Dr Donghui Zou following the protocol from [54]. Tumours were classified
as CIMP-H if three or more of the five markers were methylated
(methylated defined as Percentage of Methylated Reference (PMR) > 10),




The Illumina humanMethylation450 beadchip (often referred to as the
450K beadchip) utilises two technologies: the Infinium I assay and the
Infinium II assay 2.1. The Infinium I assay requires two probes per CpG
loci, each of which is designed to bind either the methylated or
unmethylated allele (a C or T base respectively after bisulfite conversion
has occurred). After the probe has bound to the target DNA sequence,
single base extension occurs and fluorescence is measured. In the
Infinium I assay, both the methylated and unmethylated probe
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incorporate the same nucleotide and thus fluoresce the same colour [55].
In contrast, the Infinium II assay utilises only a single probe per CpG
locus which incorporates either an Adenine or Guanine, depending on
whether the target sequence was unmethylated or methylated [55].
Patients were randomised to beadchips, with tumour and matched
non-cancerous samples run on the same beadchip. For each sample, 4µL
of bisulfite converted DNA which had been diluted to 50ng/µL was used
in the Illumina humanMethylation450 beadchip analysis, which was
carried out as per the manufacturer’s instructions at AgResearch Limited,
Invermay Agricultural Centre, Mosgiel New Zealand.
2.2.1 Calculating DNA methylation
The Infinium humanMethylation450 beadchips were processed using
BeadStudio. DNA methylation was measured using the β-value, which is
the ratio of methylated (M ) to unmethylated (U ) alleles (calculation is
found in Figure 2.2).
On the Illumina Infinium array, M and U represent the fluorescence
intensity of the methylated and unmethylated fluorescence measured
using either Infinium I and Infinium II assays while the 100 value is
included to regularise the β-value when M and U are small [56]. The
β-value is calculated using M and U measurements from approximately
30 bead replicates per target loci [57].
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Figure 2.1: Illumina Infinium assay types. A) The Infinium I assay
uses M and U beads, which are attached to a probe which will bind
to methylated or unmethylated target DNA respectively. Following
probe binding, single base extension of a labelled dinucleotide occurs
and fluorescence is measured at the methylated or unmethylated bead.
B) The Infinium II assay uses a single bead type, which is attached to a
probe which binds equally to methylated or unmethylated target DNA.
Single base extension occurs, incorporating either a labelled guanine if
target DNA was methylated or a labelled adenine if target DNA was
unmethylated. Figure modified from [55].
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Figure 2.2: β-value calculation
2.2.2 GenomeStudio methylation algorithms
GenomeStudio (Version 1.8) was used to interpret fluorescence
measurements. GenomeStudio includes normalisation protocols which
aim to minimise the effect of non-biological variation [58]. First, data was
normalised against internal controls. Internal controls are pairs of probes
which incorporate matched levels of green and red channel fluorescence.
For a given sample, probe fluorescence intensity was multiplied by a
common normalisation factor (identical for all samples, based on a
reference sample) and then divided by the average of all normalisation
controls which are in the same (red or green) channel as the sample.
GenomeStudio was used to perform a calculation of background
fluorescence intensity. Background signal, which was calculated
separately for red and green channels when on the 450K beadchip, was
calculated using internal negative controls which are thermodynamically
similar to real probes but do not have a target sequence [58]. The
average of negative control probes was then subtracted from the probe
signals to produce the background adjusted fluorescence.
2.2.3 Probe trimming
BeadStudio provides a detection p value as a measurement of probe
performance, which was calculated as the probability that the probe
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signal was significantly different from in-built negative controls. As per
the Illumina recommendation, probes which had a detection p value
greater than 0.05 in at least one sample were excluded from the analysis.
The humanMethylation450 beadchip contains probes which have the
potential to cross-react with other parts of the genome, leading to false
results [59]. These probes, which make up approximately 6% of probes
on the array, were removed from the analysis. In addition, probes which
were located on the X or Y chromsomes were removed from the analysis.
The Illumina array also contains probes which overlap with known
human SNPs. The presence of a SNP may affect the ability of a probe to
bind, particularly if it overlaps with the base preceding the CpG loci of
interest (for the Infinium I assay) or the Cytosine itself (when using the
Infinium II assay) [60]. SNP probes can therefore generate false
differences in DNA methylation measurements if probes are compared
between patients. The decision was made to retain SNP probes and
confine all comparisons of differential methylation to within tumour and
matched non-cancerous tissue pairs, bypassing the potential for different
SNPs to effect methylation measurements. Retaining SNPs and limiting
to within-pair analyses was supported by the publication which originally
identified the cross-reactive and potentially confounding probes on the
Illumina 450K beadchip [59].
2.2.4 Normalisation
Samples were run on the Illumina Infinium humanMethylation450
beadchips in four separate batches. A preliminary hierarchical clustering
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experiment demonstrated that within tissue group (tumour or
non-cancerous) samples clustered by batch, indicating the need to adjust
for batch effect (data not shown).
Batch effect was adjusted for using ComBat, which was accessed
through the SVA package [61, 62]. ComBat uses an empirical Bayes
approach to adjust for batch effects, assuming that batch effects will be
similar (e.g., an increase or decrease in DNA methylation) across many
genes [61]. A model is created by pooling information across many genes
in each batch, which is then used to adjust the data for batch effect [61].
ComBat was supported as a technique to adjust for batch effects at the
time of analysis, and was included as the batch adjustment method of
choice in the R packages SVA and ChAMP (designed to facilitate
Illumina humanMethylation450 beadchip methylation analysis) [62, 63].
2.3 Publicly available software
Several freely available software tools were used in the analyses described
below. The primary tool used was R (versions 2.15.0 - 3.3.0), a statistical
computing and graphics language. Numerous packages were installed
from either the comprehensive R archive network (CRAN) or
Bioconductor. Important packages are noted in the relevant methods
section, and a brief list of the most noteworthy packages can be found in
Table 2.1. In RStudio, functions were typed into the interface and the
output data was either written to .csv files (for tables) or saved as .pdf
images (for figures). Functions which played a critical role in the analysis
of the DNA methylation data are described below.
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Table 2.1: Notable R packages
Package name Version (latest) Description
base 3.3.0 The R base package, which contains many useful functions for the manipulation of data
BiocInstaller 1.22.2 Install and update Bioconductor and CRAN packages
cgdsr 1.2.5 R-based API for accessing the MSKCC Cancer Genomics Data Server (CGDS)
cowplot 0.5.0 Streamlined plot theme and plot annotations for ggplot2
datasets 3.2.0 The R datasets package - used in various examples for understanding functions
ggplot2 2.1.0 Implementation of the grammar of graphics
gplots 3.0.1 Tools for plotting data
IlluminaHuma 0.4.0 Contains the Illumina Infinium humanMethylation450 beadchip manifest
knitr 1.13.0 Used to create reports of R scripts
limma 3.28.5 Linear models for microarray data
markdown 0.7.7 Used to create markdown reports of R scripts
missMethyl 1.6.2 Contains the gometh function
plyr 1.8.3 Tools for splitting, applying and combining data
pROC 1.10.0 Creates ROC curves
reshape 0.8.5 Required to reshape matrices for use in ggplot2
reshape2 1.4.1 Required to reshape matrices for use in ggplot2, a re-booted version of reshape
rmarkdown 0.3.10 Used to create markdown reports of R scripts
rstudio 0.98.100 Utilities and tools for Rstudio interface
scales 0.4.0 Scale functions for visualisation
stats 3.3.0 The R stats package
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Gene ontology was performed using the public Protein ANalysis
THrough Evolutionary Relationships (PANTHER) database. GO-slim
biological process gene lists were tested for whether they are
overrepresented among a list of differentially methylated genes. GO-slim
biological process is a manually curated list of genes which are grouped
according to biological processes such as e.g., cellular differentiation.
PANTHER was accessed from the main web page
(http://pantherdb.org/). A list of genes associated with differentially
methylated CpG islands was used as the input file, Homo sapiens was
selected as the organism, Statistical Overrepresentation test with default
settings was selected and submitted. This takes the user to a new
window, at which point the Reference List was changed from a generic
Homo sapiens list to a user supplied list of all CpG islands which were
tested in the differential methylation analysis (n=12,600 CpG islands).
The list of differentially methylated CpG islands was tested for
overrepresented terms using the Fisher’s exact t-test, adjusted for
multiple testing using the Benjamini-Hochberg procedure. The resulting
list of overrepresented GO terms was sorted either by fold enrichment or
p value, and was exported as a .csv file.
The Multiple experiment Viewer (MeV), which is included as part of
the TM4 microarray software suite, was used to perform significance
analysis of microarrays (SAM) [64]. DNA methylation values were
imported into MeV and samples were marked as either tumour or
non-cancerous. SAM was initialised using the Two-class paired option, as
described in more detail below.
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2.3.1 Visualising data
Heatmaps were produced to visualise hierarhical clustering results and
metagene scores. Heatmaps were generated using either the TM4 MeV
(multiple experiment viewer, version 4.9.0) or a modified version of the
heatmap.2 function from the gplots R package [65]. The function was
modified by Associate Professor Michael Black so as to be able to include
more than a single colour bar above the heatmap. This allowed multiple
lines of clinical information to be included for each sample.
Boxplots were used to visualise differences in metagene scores between
groups of tumours. Boxplots were drawn using the boxplot function of
the base R package, and with the geom boxplot function of ggplot2 [66].
Histograms and barplots were created in Excel or using the geom bar
function of gggplot2 [66].
2.4 Statistical analyses
Throughout this thesis several different methods were used to test for
statistical significance of results. Tests which were used to identify
differentially methylated regions are described in greater detail in the
section below. For comparison of group variables (e.g., the frequency of
mutations or metagene scores) the t-test was used. This was
implemented using the t.test function within R [67].
To adjust for multiple testing either the Benjamini-Hochberg procedure
(false discovery rate (FDR) adjustment) or the Holm-Bonferroni
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(family-wise error rate (FWER)) was used [68, 69]. The FDR is a more
powerful (allows more discoveries) approach which will also include more
false positives, while the FWER procedure is more stringent. When
choosing to implement adjusting for multiple testing the need for power
or stringency was considered, and a test was chosen on the basis of the
needs of the experiment. In some instances, e.g., PANTHER DB, a
default adjustment method was supplied by the developer and this
method was chosen when applicable.
The FDR is the proportion of results which appear to be significant,
but are actually false positives (false discoveries). The FDR adjustment
is carried out by ranking all p values from smallest to largest and
applying the calculation: p < (i/m)/Q, where i is the rank of the p value
being considered, m is the total number of p values being considered, and
Q is the FDR rate that has been chosen. The largest p value which meets
the criteria of p < (i/m)/Q is considered significant, and all p values
smaller than this are also considered significant. The FWER correction
controls the family-wise error rate. The FWER takes a p value threshold
(e.g., p < 0.05) and divides it by the number of tests being considered.
The resulting value, which is much lower than 0.05, is the new threshold
for statistical significance.
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2.5 Characterising DNA methylation
2.5.1 Identification of differentially methylated loci
Three approaches were used to identify differentially methylated loci,
each of which is described in detail in the following paragraphs. First,
DNA methylation was assessed at the individual CpG level using
significance analysis of microarrays (SAM) to identify loci which were
hyper- or hypo-methylated in tumour samples relative to their matched
non-cancerous tissue counterparts. Methylation at individual CpG loci
was also assessed using LIMMA (Linear Models for MicroArray data).
The third method interrogated the collective DNA methylation profile of
each CpG island using the statistical Wilcoxon Signed-rank method,
which was combined with a measurement of the absolute difference in
mean methylation in tumour and normal tissue samples.
DNA methylation data was exported from R Studio and imported into
the TM4 MeV (multiple experiment viewer, version 4.9.0) software suite
to test for differentially methylated loci. This was carried out using
SAM [70]. Under the Statistics tab, Significance Analysis of Microarrays
was selected, and the Two-class paired test was used. The two-class
paired test matches each tumour sample with the corresponding
non-cancerous sample from the same patient, and calculates the strength
of the relationship between DNA methylation level at the locus and
tissue sample type (tumour or non-cancerous). The test was run using
10,000 permutations, and the Median number of false significant genes
was set to 0, which identified 45,052 CpG loci as differentially methylated.
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This number of probes was deemed impractically large in terms of
visualisation and computation. The 45,052 CpG loci were ranked
according to fold change, and the 20,000 loci with the greatest DNA
methylation fold change were retained for further analysis. The threshold
of 20,000 loci was an arbitrary cut-off which aimed to balance the
challenges of visualising and managing such a large dataset against the
need to present a genome-wide view of methylation changes.
LIMMA was used to test for the presence of differentially methylated
loci between CIMP-H BRAF mutant and BRAF wildtype tumours.
LIMMA fits a linear model to the methylation data and uses this model
to determine which loci, if any, have undergone significant changes.
LIMMA uses empirical Bayes to modify the test statistic, shrinking large
standard errors and increasing small standard errors (i.e., standard errors
are brought towards the mean). LIMMA was performed using the limma
package for R [71]. Results were screened by p value following
adjustment for multiple testing using the FDR correction.
The Wilcoxon Signed-Rank (WSR) test was used to identify
differentially methylated CpG islands. The WSR is a paired (i.e., tumour
data is directly tested against paired non-cancerous data),
non-parametric alternative to the t-test, which does not assume the data
is normally distributed [72]. CpG loci were grouped into CpG islands
(n=13,933) and labelled according to the nearest gene, based on the data
in the Illumina 450K humanMethylation manifest which provides
annotation for CpGs. To increase the number of DNA methylation
measurements per CpG island, loci which are located at the edge of CpG
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islands (CpG island shores) were included as a part of the CpG island.
These loci have previously been shown to be biologically informative in
DNA methylation analyses [73]. For this analysis, any CpG island which
had fewer than five DNA methylation measurements (including those
located in island shore regions) was excluded (n=12,600 CpG islands
remaining). The WSR test was performed for each of the 12,600 CpG
islands, comparing DNA methylation values in tumour and matched
non-cancerous tissue, and the resulting p values were adjusted for
multiple testing using the False Discovery Rate (FDR). A CpG island
was considered to be statistically differentially methylated if the adjusted
p value was < 0.005 (n = 4,828 CpG islands). In addition to the
statistical test for differential methylation, a test for the absolute
difference in methylation between tumour and matched non-cancerous
samples was added. For each of the 4,828 statistically different CpG
islands, the difference between the mean DNA methylation value in the
tumour and non-cancerous sample was calculated. A CpG island was
considered significantly hypermethylated in a tumour if the mean
methylation in the tumour sample was higher than the matched sample
by β-value 0.1 or greater. Only CpG islands which were both statistically
significant (WSR adjusted p value < 0.005) and biologically significant
(mean tumour β-value - mean non-cancerous β-value > β-value 0.1) were
carried through for further analysis.
2.5.2 Clustering and visualisation of tissue samples
Tumour and non-cancerous tissue samples were grouped into subtypes on
the basis of unsupervised hierarchical clustering using Euclidian distance
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and complete linkage. Hierarchical is an alternative to k-means clustering
and does not require the user to specify the number of groups in the
dataset. Clustering was calculated using DNA methylation values at the
20,000 differentially methylated CpG loci identified by SAM (see above).
Clustering accurately differentiated tumour from non-cancerous samples,
with the exception of two non-cancerous samples which clustered with
tumour samples. These were manually removed from the analysis under
the assumption these samples were contaminated with nearby tumour
tissue at the time of collection. Seven tumour samples clustered with
non-cancerous tissue, and these were manually re-assigned to the lowest
methylation cluster of tumour samples.
A heatmap was created to visually represent the sample clustering.
The heatmap was created using a modified version of the heatmap.2 R
package. The modified version of heatmap.2 allowed for multiple bars
representing clinical (horizontal bars) or genomic (vertical bars)
attributes to be added to the heatmap.
Clustering results were compared with the results of the Weisenberger
five gene panel [9]. The original publication did not recognise CIMP-L
tumours in their classification, and so a modified version of the panel was
used. In the modified version of the panel, a tumour was classified as
CIMP-H if 3 or more of the 5 genes were hypermethylated, CIMP-L if
1-3 genes were hypermethylated, and CIMP-N if 0 genes were
hypermethylated. Hypermethylation of the five genes (CACNA1G,
NEUROG1, RUNX3, SOCS1 and IGF2 ) was previously assessed using
MethyLight by Dr Donghui Zou, where hypermethylated was defined as
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Percentage of Methylated Reference (PMR) > 10 as per author
instructions.
2.5.3 Annotation
CpG loci were annotated using the annotatePeaks.pl in the HOMER
(Hypergeometric Optimisation of Motif EnRichment) software suite.
HOMER was supplied with genomic regions (CpG loci coordinates taken
from the Illumina 450K humanMethylation beadchip manifest) and the
relevant genome data (hg19). For every differentially methylated CpG,
annotatePeaks.pl used the loci coordinates and identified the nearest
transcription start site (TSS). Distance from the nearest TSS was
calculated, and each CpG was then assigned to one or more genomic
annotations. Genomic annotations may overlap (e.g., a loci may be
assigned to both TSS and to a CpG island). The list of genomic
annotations annotatePeaks.pl recognises are: a) Transcription start site
(TSS), defined as the region from -1kb to +100bp around a recognised
TSS. b) Transcription termination site (TTS), defined as the region from
-100bp to +1kb around a TTS. c) Exons. d) 5’ untranslated region
(5’UTR). e) 3’ untranslated region (3’UTR). f) CpG island. g) Repeat
sequence. h) Intron. i) Intergenic.
2.5.4 Gene ontology
Differentially methylated loci were assessed for enriched gene ontology
(GO) terms. Individual CpG loci were assessed using the gometh
function of the missMethyl R package [74]. Gometh is a modified version
of an earlier function goseq which takes into account the varying number
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of CpG loci per gene, and is ideally suited for analysing individual
differentially methylated loci [75]. Hyper- and hypo-methylated CpG loci
were grouped according to their genomic annotation and analysed
together (e.g., identifying GO terms enriched among hypermethylated
loci located in the TSS, or hypomethylated loci located in CpG islands).
The gometh function takes a character vector of differentially methylated
CpG IDs and a list of all CpGs which were tested for differential
methylation. Gometh then calculates the likelihood of a gene being called
differentially methylated given the number of CpG loci in the gene.
Gometh returns a matrix of the most enriched GO terms, GO ID, the
ontology category, number of genes in the category, number of
differentially methylated loci which are in the category, and an adjusted
p value.
Gene ontology analysis for differentially methylated CpG islands was
carried out using PANTHER (Protein Analysis THrough Evolutionary
Relationships) [76]. PANTHER is a curated dataset of protein (and their
respective genes) classifications and descriptions. PANTHER requires a
list of genes (rather than individual CpG loci), and was therefore well
suited for an analysis of CpG islands. Differentially methylated CpG
islands were annotated with the gene symbol of the nearest TSS as per
the Illumina humanMethylation 450K beadchip manifest. These gene
names were passed to PANTHER, along with a list of all gene names
which were tested for differential methylation to be used as a background,
and the organism was set to Homo sapiens. A statistical
overrepresenation analysis was carried out, which uses the Fisher’s exact
test to identify enriched GO terms among the differentially methylated
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genes. To adjust for multiple testing, the Benjamini-Hochberg (FDR
adjustment) correction was applied to all p values.
2.6 Accessing publicly available data
Data was accessed from both The Cancer Genome Atlas (TCGA) and
the Gene Expression Omnibus (GEO) for the purposes of validation or to
expand my analyses into additional tissue/cancer types. During the
course of this project multiple methods were used to access publicly
available data.
To access DNA methylation data from the TCGA website,
tissue/tumour types and data platform type (e.g., Illumina 450K
humanMethylation beadchip) were selected from a drop-down menu. For
each tissue type, level 3 methylation data was downloaded as a zipped
file which contained a clinical data file and a matrix with β-values for
each locus.
TCGA RNA-seq data, along with BRAF and KRAS mutation status,
was accessed using the CGDS-R R package [77]. The CGDS-R package
provides an interface with the Cancer Genomic Data Service, hosted by
the Memorial Sloan-Kettering Cancer Center. Data was downloaded
using the getProfileData and getClinicalData functions [77]. These
functions allow the user to download expression and mutation data for
selected genes rather than downloading genome-wide data, saving
considerable time and storage space [77].
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DNA methylation measurements from whole blood (GSE100227) [78–
80] and serum (GSE68777) [81] samples were downloaded from the Gene
Expression Omnibus (GEO) [82]. Blood and serum methylation data was
in the form of β-values from Illumina Infinium humanMethylation450
beadchips.
2.7 Analysis of RAS/RAF pathway
activity
2.7.1 Affymetrix array data
Affymetrix Gene Chip Human genome U133 Plus 2.0 array data for CRC,
but not matched non-cancerous tissue, was previously generated by Dr
Sujatha Rao [53].
2.7.2 Comparison of BRAF mutant and BRAF
wildtype tumours
The mutation status of the genes BRAF and KRAS had been previously
analysed in a subset of the tumours used in chapter 3. Mutation analysis
was carried out by Dr Sujatha Rao using PCR and DNA sequencing of
exon 2 of KRAS (the G12V mutation) and exon 15 of BRAF (V600E
mutation) [53].
LIMMA was used to identify differentially methylated and differentially
expressed regions between BRAF mutant and BRAF wildtype tumours,
using the method described above for the comparison of DNA
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methylation in tumour and non-cancerous samples. Loci were considered
differentially methylated or differentially expressed if the FDR adjusted p
value was < 0.05.
2.7.3 Metagene analysis
To analyse the activity of a set of genes which are under the control of
the BRAF signalling pathway, singular value decomposition (SVD) was
used to generate a metagene. A metagene is a single value between 0 and
1 which represents the overall level of activity of a set of genes for a given
sample. A metagene is created through the factorisation of a matrix
of e.g., gene expression values for a set of samples [83]. The matrix of
expression data was first scaled using the scale function in R to have a
mean of 0 and a standard deviation of 1. SVD was performed using the
svd function in the R base package (for a description of the underlying
mathematics of SVD refer to [84]). The resulting metagene values were
rescaled to have a range of 0-1.
To test for differences in metagene scores between tumour groups (e.g.,
CIMP-H vs CIMP-N, BRAF wildtype vs mutant), R was used to
implement the Welch t-test, with a cutoff of p < 0.05 indicating a
significant difference.
2.8 Candidate biomarkers
Candidate biomarkers were identified and tested using the R package
pROC [85]. pROC was used to generate receiver operator characteristic
(ROC) curves and to calculate partial area under the curves (pAUCs).
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For a given loci to be tested, samples must be sorted from lowest DNA
methylation value to highest DNA methylation value. The lowest DNA
methylation value is then treated as the threshold, above which any
sample is classified as ‘positive’ (tumour sample) and below which a
sample is classified as ‘negative’ (non-cancerous). The sensitivity and
1-specificity are recorded for this threshold, and the process is repeated
using the next highest DNA methylation value. Sensitivity and
1-specificity scores are then plotted on a scatter plot and a line is drawn
between the points to generate an ROC curve. The curve was smoothed
using a binormal method [85]. Partial area under the curve (pAUC)
values were calculated using the trapezoid rule, with 95% confidence
intervals calculated using 10,000 iterations as recommended by the
authors of the pROC package [85]. The optimal cut-off point (threshold)
was calculated using the Youden index, which is the point on the ROC
curve which has the greatest vertical distance above the diagonal line [86].
The Youden index represents the cut-off which achieves the greatest sum
of sensitivity and specificity values.
2.8.1 Measuring candidate biomarker effectiveness
Two measurements were used when discussing the effectiveness of a
candidate biomarker: Sensitivity/specificity and positive predictive value
(PPV)/negative predictive value (NPV). The values are calculated using
the formula:
Sensitivity (%): Number of true positives/(Number of true positives +
Number of false negatives) X 100
Specificity (%): Number of true negatives/(Number of true negatives +
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Number of false positives) X 100
PPV (%): Number of true positives/(Number of true positives +
Number of false positives) X 100
NPV (%): Number of true negatives/(Number of true negatives +








When this work began in 2012 the mechanistic basis of CIMP was
unknown. It was unclear why some regions in the genome became
hypermethylated in an individual tumour sample while others remained
unchanged. The basis of this chapter is the characterisation of DNA
methylation in CRC through a comparison of non-cancerous samples and
matched tumour tissue using the Illumina Infinium
humanMethylation450 beadchips. The 450K platform facilitates
genome-wide DNA methylation analyses and represents a substantial
improvement over previous techniques to characterise methylation. The
results are discussed in the context of three potential models of DNA
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methylation in CIMP tumours.
3.1.1 DNA methylation regulates cell identity
Regulation of tissue identity is a critical challenge for multicellular
organisms. The ability to have specialised cells perform different roles
provides a powerful selective advantage. To achieve this, cells which share
a common genome must possess a mechanism for regulation of gene
activity. DNA methylation is a mechanism for highly stable, yet
remarkably plastic, regulation of gene expression which can be inherited
somatically in a cell-to-cell manner.
DNA methylation is able to alter the dynamics of DNA-binding
proteins. Methylation can inhibit DNA binding through physically
blocking proteins from accessing binding sites, yet methylation is also a
target of specific methyl-binding domain proteins [87]. Methyl-binding
domain proteins themselves often recruit complexes of proteins which are
able to bring about changes in local chromatin structure. Through the
control of gene expression and chromatin dynamics DNA methylation,
alongside histone modifications, is responsible for the regulation and
maintenance of tissue identity - a process which is fundamentally altered
in cancer.
DNA in the nucleus is broadly partitioned into two groups:
euchromatin, an open conformation of DNA with high accessibility which
allows transcription to occur, and heterochromatin, a compressed
chromatin state in which genes are repressed. The state of chromatin can
be influenced by histone modifications, nucleosome density and proximity
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to the nuclear envelope [88]. Lamina associated domains (LADs) are
inactive heterochromatic regions which are associated with proteins in
the nuclear lamina, a network of fillaments and proteins attached to the
inside of the nuclear envelope [89]. LADs heavily overlap (80%) with
regions termed large organised chromatin lysine modifications (LOCKs),
which are regions of heterochromatin with repressive histone
modifications [90]. LOCKs and LADs tend to increase in size during
differentiation, suggesting they restrict regions of the genome in more
differentiated cell types [90], [91].
Alongside changes in LOCKs and LADs, DNA methylation profiles
change during differentiation. During differentiation the methylome of
embryonic stem cells (ESCs) undergoes a genome-wide decrease in
methylation levels, creating partially methylated domains [92]. Partially
methylated domains are large regions which typically have methylation
levels below 70% and are punctuated by methylation at specific loci.
Genes with a role in pluripotency progressively gain methylation in more
differentiated cell types, with terminally differentiated cell types
exhibiting the highest level of methylation at these loci. Genes associated
with pluripotency, such as POU5F1 (OCT4 ) and KLF4 have lower levels
of methylation around the transcription start site in ESCs compared to
more differentiated cells. The low level of methylation found at
pluripotency genes is consistent with both their function and higher level
of expression in ESCs. More differentiated cell types exhibit methylation
around the transcription start sites of HOX genes, while genes involved in
cell adhesion and G-protein signalling have higher levels of gene body
methylation (which is associated with transcription) relative to ESCs [93].
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During differentiation DNA methylation accumulates at loci involved in
alternate cell lineages and loci associated with stem-ness [94], resulting in
cell-type specific DNA methylation patterns [73].
During cellular differentiation, changes in DNA methylation occur at
relatively few loci. However, the loci involved play important roles in
controlling cell lineage. A study which profiled the methylome of various
immune cell types found that between terminally differentiated cell types,
differences in DNA methylation were relatively small [95]. However,
differences in CGI methylation were enriched at genes with an
immune-related function. Intragenic CGIs, sometimes referred to as
‘orphan’ CGIs, were enriched for differences in methylation. When DNA
methylation was compared between immune and brain cells,
hypomethylation in brain tissue intragenic CGIs was associated with
increased expression relative to immune cells [95]. A comparison of the
methylome of mouse haematopoietic cells revealed that during the
transition from multipotent progenitors to a myeloid cell fate, the
myeloid-specific genes Mpo and Cxcr2 underwent hypomethylation and
upregulation [96]. Several hypotheses have been proposed to explain
observations of cell and stage-specific methylation patterns. For example,
DNA methylation may prevent de-differentiation: hypermethylation of
genes which are involved in pluripotency are permanently silenced upon
methylation. Additionally, DNA methylation changes may facilitate
differentiation either through hypomethylation of select transcription
factors which drive differentiation, or through hypermethylation of key
repressors [97].
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DNA methylation, differentiation, and cancer
The cancer methylome has been described as globally hypomethylated,
punctuated by regions of promoter-associated hypermethylation [20].
Partially methylated domains, which cover approximately a third of each
chromosome in healthy tissue, become even more hypomethylated in
cancer. Such large hypomethylated regions have been termed
hypomethylated blocks. These blocks have been observed in multiple
cancer types, and are associated with highly variable gene expression [98].
LOCKs, the large heterochromatic regions which expand during
differentiation, are lost entirely in cancer [90]. Notably, LOCKs are
reduced in size during the generation of induced pluripotent stem cells.
The loss of LOCKs observed in cancer parallels changes to the epigenome
during the generation of iPSCs, providing a link between
de-differentiation and cancer.
Aberrant DNA methylation patterns in CRC are found at regions of
the genome which are differentially methylated between different tissue
types [73]. Thus, cancer-specific DNA methylation patterns occur at
regions which appear to be involved in the control of cell identity. A
deeper investigation into the link between cell identity and cancer
demonstrated that the same regions which are involved in cell identity
have aberrant DNA methylation patterns in a wide range of cancer types,
suggesting this is a universal feature of cancer [98]. Regions of DNA
which have tissue-specific methylation patterns, which are usually tightly
controlled, exhibited high variability in all cancer types [98], [99]. This
points to cancer as a state in which the stringent epigenetic control over
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cell identity has broken down.
3.1.2 CpG island methylator phenotype
The CpG island methylator phenotype (CIMP) describes a subset of
colorectal tumours that exhibit a high frequency of CpG island (CGI)
hypermethylation. CIMP tumours have a unique clinical profile including
better prognosis and a later average age of onset compared to non-CIMP
tumours. First described in 1999 [8], the legitimacy of CIMP as a distinct
subset was the subject of intense debate [100], [101], [102] and an
accurate classification of CIMP remains elusive [103]. At the beginning of
this PhD the preferred method to determine CIMP was based on small
panel of genes, though many publications opted to use in-house
classification methods [103].
CIMP cancers were first described when authors discriminated between
age-related DNA methylation, common to both tumour and
non-cancerous tissue, and cancer-specific methylation, which was limited
to tumour samples [8]. CIMP tumours were defined as those with
methylation at three or more of a small panel of genes (MINT1, MINT2,
MINT31, CDKN2A (p16), and hMLH1 ). CIMP tumours were initially
not associated with gender, age or stage, but were strongly enriched
within the proximal region of the colon [8]. CIMP was also identified in
preneoplastic adenomatous polyps, suggesting DNA methylation is an
early event in tumorigenesis [104]. CRC has been classified into
methylation subtypes on the basis of numerous panels of genes and
hierarchical clustering. CRC was initially split into two methylation
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subtypes, CIMP and non-CIMP. The use of additional markers and more
sophisticated panels led to the definition of three, and eventually four
methylation subtypes which are described below.
High methylation phenotype
High methylation phenotype CRC tumours have been described by
numerous publications and referred to variously as CIMP-H, CIMP1, and
High Methylation Epigenotype (HME) [8], [9], [10], [105], [50]. In this
work, CIMP-H will be used to describe the subgroup of tumours with the
highest degree of hypermethylation. CIMP-H tumours have a high
frequency of BRAF mutations (53% - 71%) and exhibit a relative lack of
KRAS mutations (16%) and p53 mutations (11%) [106], [105]. CIMP-H
tumours are enriched within the proximal section of the colon
(86%) [50], [106]. Microsatellite instability (MSI), primarily caused by
hypermethylation of the mismatch repair gene MLH1, is common in
CIMP-H tumours (80%) [106].
Intermediate methylation phenotype
In 2006 it was proposed that CIMP was comprised of two distinct
subtypes of tumours with aberrant methylation profiles, CIMP-H and
CIMP-Low (CIMP-L) [10]. CIMP-L described tumours with an
intermediate level of methylation relative to CIMP-H and non-CIMP
tumours. Using a panel of five genes (CACNA1G, CDKN2A (p16 ),
CRABP1, MLH1, and NEUROG1 ) (the Ogino panel), tumours were
classified as CIMP-H if more than three genes were hypermethylated,
CIMP-L if between one and three genes were methylated, and
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CIMP-Negative (CIMP-N) if none were hypermethylated [10]. The newly
defined CIMP-L tumours were reported to be enriched among men (p =
0.01) and strongly enriched in KRAS mutant tumours (p = 0.0003) [10].
This association with KRAS mutation has subsequently been
confirmed [50], however the association with male patients has been
challenged [50], [107]. MSI status and mutations in BRAF and p53 are
rare in CIMP-L tumours [106]. Similar to CIMP-H tumours, CIMP-L
tumours are also enriched (60%) in the proximal section of the
colon [106]. Hypermethylation in CIMP-L tumours occurs at a subset of
the CGIs hypermethylated in CIMP-H tumours, with approximately 20%
of all loci hypermethylated in CIMP-H being methylated in CIMP-L [50].
CIMP-N tumours are comprised of two subtypes
CIMP-N is the common term to describe CRC with very low levels of
hypermethylation. CIMP-N has been split into two distinct subtypes in
two recent publications [3], [50]. A clustering analysis of 125 colorectal
tumours and 29 non-cancerous tissue samples identified four DNA
methylation subtypes using loci with highly variable levels of
methylation [50]. The first subtype, CIMP-H, exhibited high levels of
DNA methylation and was enriched for female patients and proximal
colon tumours as described previously. This subtype included all tumours
classified as CIMP-H under the Weisenberger five-gene panel method, all
tumours with MSI status, and contained all BRAF mutant tumours. The
second subtype had clinical characteristics consistent with the CIMP-L
subtype identified by Ogino et al., 2006. Tumours of this subtype had
hypermethylation at a subset of the loci hypermethylated in CIMP-H
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tumours and a high number of KRAS mutations. Unlike previous
authors, Hinoue et al., divided the non-CIMP cluster of tumours was
divided into two subtypes. The first non-CIMP group was more common
in the distal colon and had a high frequency of p53 mutations, while the
second non-CIMP group lacked mutations or hypermethylation and was
enriched in the rectum. Two non-CIMP clusters were reported by the
TCGA, and these exhibited similar clinical features to the two non-CIMP
subtypes described by Hinoue et al., [3].
Classification controversy: finding the right definition of CIMP
Analysing the literature on CIMP in 2012, there was no clear definition
of what constituted a CIMP-H tumour. From 2006 to 2012, the
Weisenberger five gene panel was often described as the gold standard on
the classification of CIMP-H, despite the original paper not describing a
CIMP-L phenotype. During this time a number of studies were published
describing three methylation subtypes (high, intermediate or low) under
various aliases [10], [105], [108]. Subsequent publications which utilised
genome-wide DNA methylation data and hierarchical clustering to
classify CIMP-H have found comparable results to the Weisenberger
panel. In 2012, as noted above, two independent CRC studies described a
fourth methylation subtype using the Illumina 27K methylation
array [50], [3]. A diagnostic marker panel was proposed by Hinoue et al.,
which would be able to classify CIMP-H and CIMP-L tumours with high
accuracy [50]. However, the proposed diagnostic marker panel did not
stratify CIMP-N into the new subtypes, nor was the panel tested in an
independent data set or validated by other publications. While it was
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clear that a number of methylation-based subtypes associated with
clinical features exist in CRC, accurately defining the groups remained a
challenge.
Two key issues surround many of the previous analyses of differentially
methylated regions in CIMP: a small number of loci analysed per gene
was used as the basis for differential methylation, and a lack of
consistency or discussion on what constitutes differential methylation.
Illumina methylation arrays have contributed much of the knowledge
regarding differentially methylated regions in cancer. Initially these
arrays interrogated only a small number of CpG loci: the GoldenGate
array held approximately 1,500 probes, the Illumina 27K array held
approximately 27,000 probes. Despite extensive use, one issue with these
analyses is the small number of CpG loci per gene or CGI. The small
number of loci used in these analyses provides only low confidence calls of
hypermethylation across a CGI or gene. Analyses of differentially
methylated regions also suffer from inter-lab variation and a lack of
validation. Different methods to identify differentially methylated regions
include various statistical analyses (Wilcoxon signed rank and rank sum
test [50], linear mixed-effects models [109]), raw differences in DNA
methylation (whereby a difference of greater than β-value 0.2 between
tumour and non-cancerous tissue indicates hypermethylation) or a binary
split (e.g., loci with a methylation score less than X are considered
hypomethylated and greater than X are considered hypermethylated,
regardless of the methylation score in corresponding non-cancerous
tissue [108], [110]).
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In addition to different definitions of what constitutes a
hypermethylated gene, the major publications regarding CIMP often use
different criteria to classify CIMP (e.g., the Weisenberger panel of genes,
the Ogino panel of genes, or clustering on the basis of unique probe sets).
One study which analysed the impact of different classification
demonstrated the use of the most stringent, compared to the least
stringent, thresholds for CIMP resulted in a statistically significant
difference in the frequency of CIMP [111].
Summary of CIMP characteristics
While it is accepted that a subset of tumours with a higher degree of
DNA methylation exist, the lack of consistency in classifying CIMP has
led to varied reports of clinical and molecular features associated with
the subtype. A recent meta-analysis of CRC CIMP publications collated
clinical and molecular associations when tumours were classified using
either the Weisenberger CIMP panel, the Toyota panel (MINT1, MINT2,
MINT31, CDKN2A (p16), and hMLH1, described in Toyota et al., 1999),
a mixture of both panels or genome-wide hierarchical clustering [112].
The meta-analysis found CIMP is strongly associated with BRAF (OR
34.87, 95% CI: 22.49-54.06; p < 0.00001) but not KRAS (OR 0.47, 95%
CI: 0.30-0.75; p = 0.001), is associated with MSI status (OR 12.85, 95%
CI: 8.84-18.68; p < 0.00001), older aged patients (95% CI: 1.15-4.38, p =
0.0008) and location in the proximal colon (OR 6.91, 95% CI: 5.17-9.23;
p < 0.00001). Although the meta-analysis included 25 studies of CIMP
in CRC, the majority (21/25) classified CIMP on the basis of
methylation at a small panel of genes, and tumours were only classified
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as CIMP-positive or CIMP-negative with no separation of the
intermediate subtype. Finally, a meta-analysis of four publications that
assessed survival time and CIMP status found CIMP was associated with
shorter overall survival (hazard ratio 1.73, 95% CI: 1.27-2.37; p =
0.0005) [112].
Pan-cancer CIMP
Although CIMP was first described in CRC, a high methylation
phenotype has subsequently been reported in multiple tumour types.
CIMP has now been reported in breast [13], [113], gastric [8], [114],
lung [115], glioblastoma [11] and ovarian cancers [116]. Without an
understanding of the mechanistic basis of CIMP, it was unclear whether
these high methylation subtypes shared an underlying cause or represent
unique entities. Studies of pan-cancer CIMP can address the question of
whether methylation is targeted to the same loci in different tissue types,
or whether each tissue has specific methylation patterns.
A challenge in the analysis of pan-cancer CIMP is the accurate
detection of whether or not a given tissue displays a distinct CIMP
subtype. Studies which have used a small number of CGIs may stratify
tumour samples into higher and lower frequencies of methylation, but
this does not necessarily imply the existence of two distinct subtypes.
Many instances of CIMP in other tissue types have been classified
using a small panel of genes resembling either the Weisenberger five gene
panel or the loci originally used when describing CIMP (MINT1, MINT2,
MINT31, CDKN2A (p16), and hMLH1 ). For example a CIMP subtype
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in hepatocellular carcinoma was described and characterised using eight
CGIs, five of which are used in the classification of CRC CIMP [117].
While this is not necessarily a flawed decision, this assumes that genes
hypermethylated in CRC are the same genes which will be
hypermethylated in other tumour types, that is, that CIMP is a universal
feature of cancer with no tissue specificities. To address these issues,
Moarii et al., performed a genome-wide analyses of DNA methylation
profiles from more than 2,000 tumours from five tissue types (colon,
breast, bladder, lung, and gastric) [118]. To determine whether or not
distinct CIMP subtypes exist in these tissues the authors assessed the
empirical cumulative distributive distribution ∆ (K ), which is a
statistical method to identify the number of clusters in a dataset [118].
The ∆ (K ) values support three methylation subtypes for both colon and
breast cancer, and two subtypes for lung, gastric and bladder cancer. A
pan-cancer signature of CIMP was detected when tumours were clustered
using the top 5% of CGIs with the highest level of variation in DNA
methylation across tumours from each tissue. The pan-cancer signature
was comprised of 89 CGIs which were in the top 5% of variable CGIs
from each tissue type, indicating CIMP affects a common set of loci
independent of tissue. A pan-cancer signature of CIMP is supported by a
study of DNA methylation involving over 5,000 tumours from 15 tumour
types [99]. A set of 89 loci were identified which were consistently
differentially methylated between tumour and non-cancerous tissue
samples across tumour types. These 89 loci were highly accurate at
differentiating CIMP from non-CIMP samples in more than 80% of
tumour types analysed. Common DNA methylation features across
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CIMP from independent tissue type suggests a common mechanism exists
in CIMP.
3.1.3 Development of CIMP
At the beginning of this thesis the mechanistic basis of CIMP was
unknown and represented an active area of research. In CRC, unlike
glioma, no single mutation or event was attributed to the development of
CIMP [119], [120]. The mechanics of how CIMP progressed after
initiation were also unknown, and a question of interest was whether
methylation at CGIs accumulates stochastically, or is targeted to specific
loci.
As stated earlier, CIMP is associated with unique clinical features
which include a high prevalence of BRAF mutation, MSI, location in
the proximal colon and enrichment in older, female patients. CIMP is
now believed to develop from a distinct type of precursor, the serrated
adenoma (reviewed in [15]). Serrated adenomas, named for the jagged
appearance of the epithelium, were initially considered benign but have
recently been recognised as having malignant potential [15]. They can be
classified as either ‘traditional serrated adenomas’ (TSA) or ‘sessile (flat)
serrated adenomas’ (SSA) depending on their morphology. Clinical data
support SSAs as a precursor of CIMP-H CRC [15]. SSAs are associated
with BRAF mutations (78%), location in the proximal colon and are
prevalent in female patients [14]. Serrated morphology is associated with
both CIMP-H and CIMP-L subtypes.
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The instructive model of DNA methylation in cancer
An early question in the study of CIMP was whether DNA methylation
accumulated randomly or as the result of an instructive program. In
2006/2007 a flurry of studies were published supporting the non-random
nature of aberrant DNA methylation in cancer. A genome-wide study
allowed researchers to profile the regions of the genome which
accumulated DNA methylation, leading to the proposal of the
‘instructive’ model of DNA methylation [121]. Four pieces of evidence
were presented to support the instructive model: i) DNA methylation
patterns do not appear to be the result of selection. The authors
predicted that if DNA methylation were occurring as a result of selection
it would be enriched in gene ontology categories such as apoptosis and
cell-cycle control, as methylation-associated silencing of these genes
would provide a selective benefit. Instead, the authors observed that
DNA methylation was strongly enriched in cell adhesion, signal
transduction, ion transport and cell-cell signalling pathways. ii)
Aberrantly methylated CGIs are enriched for short sequences of DNA.
The sequence motifs were proposed to act as targets of the DNA
methylation machinery. Although no DNA-binding proteins specific for
these motifs have yet been identified, the presence of shared features
among hypermethylated CGIs supports a model in which loci containing
these motifs are targeted for methylation. iii) Methylated CGIs exhibit a
non-random distribution throughout the genome. Approximately 20% of
all hypermethylated CGIs were clumped together into clusters containing
two or more islands. iv) Expression analysis revealed that 86% of
methylated genes were not expressed in corresponding non-cancerous
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tissue. The absence of expression in non-cancerous tissue has been cited
as evidence against methylation providing a selective advantage [121],
although an alternative argument is explored below. Under the
hypothesis that methylation provides no selective advantage, an
alternative model states that widespread DNA methylation is targeted to
a subset of CGIs across the genome. Keshet et al., proposed EZH2, a
polycomb group (PcG) protein, as a potential factor responsible for
targeting DNA methylation to specific regions of the genome [121].
Chromatin immunoprecipitation experiments demonstrate that in
addition to catalysing methylation of H3K27, EZH2 is required for
binding of DNA methyltransferases (DNMTs) and DNA
methylation [122]. H3K27me3-marked genes, described below, are
associated with DNA sequence motifs which match the sequence motifs
identified in methylated CGIs, providing a mechanistic link between
targeting of H3K27me3 and DNA methylation [123].
EZH2 is a PcG protein responsible for marking histone tails with
methylation which, depending on the location of methyl groups, can lead
to activation or repression of nearby genes [124]. Tri-methylation of
H3K27 is a silencing mark which represses gene expression. In embryonic
stem cells, H3K27me3 is often found alongside the activating mark
H3K4me3 in a state termed ‘bivalent’ [125]. Bivalent domains are
considered ‘repressed but poised’, which is thought to facilitate rapid
activation of genes required for development. During the process of
cellular diffferentiation bivalent domains resolve to a monovalent state
but do not become hypermethylated, however, bivalent genes have a high
tendency to become hypermethylated in cancer [126], [127]. The
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relationship between DNA methylation patterns in cancer and embryonic
stem cell H3K27me3 profiles is suggestive of a stem cell origin of
cancer [128]. The distribution of SUZ12, another member of the
polycomb repressive complex, was mapped in ESCs and found to overlap
significantly with CpGs which are hypermethylated in a variety of cancer
cell lines [129]. The data suggest that of the genes described as
hypermethylated in CRC, a subset are pre-marked for methylation by
H3K27me3 modifications and the binding of trans-factors [128]. However,
not all H3K27me3-marked genes become hypermethylated, and not all
hypermethylated genes are H3K27me3 marked. It is unclear why or to
what degree individual tumours differ in hypermethylation, and how this
differs between the CIMP subtypes.
A landmark study on the relationship between histone modifications
and DNA methylation has been carried out using prostate cancer
tumours and cell lines [130]. In prostate cancer, genes which were held in
a repressed state by H3K27me3 in healthy tissue were characterised by a
lack of H3K27me3 and an abundance of DNA methylation [130]. The
reprogramming, from repression through plastic histone modifications to
stable DNA methylation, was termed “epigenetic switching”. Epigenetic
switching was observed at known cancer-specific hypermethylation
targets such as GATA4 and MYOD1 which are normally repressed in
embryonic stem cells [130]. Outside of cancer, it has been observed that
when H3K27me3 is removed from an imprinted region in non-cancerous
tissue DNA methylation accumulates [131]. These data demonstrate that
DNA methylation and H3K27me3, which are mutually exclusive, can
switch places, altering the mechanism of repression. The epigenetic
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switching hypothesis proposes that genes which are temporarily repressed
by histone modifications become locked into an inactive state by DNA
methylation, preventing normal cellular development and locking cells
into an undifferentiated, proliferative state.
Stem/Progenitor origin of cancer theory
The classical model of aberrant DNA methylation in cancer proposes that
methylation acts as a silencing mark, repressing gene activity in a similar
manner to a loss of function mutation. Contrary to this hypothesis, much
of the observed DNA methylation does not correlate with a decrease in
gene expression. Less than 10% of hypermethylated genes in CIMP-H
tumours correlated with reduced expression compared to matched
non-cancerous tissue, while less than a quarter of downregulated genes
were associated with hypermethylation in CIMP-H tumours [50]. Further,
of the genes that are both hypermethylated and downregulated in
CIMP-H tumours almost half are also downregulated in CIMP-N
tumours even in the absence of DNA methylation. The findings uncouple
DNA methylation and downregulation of genes in CIMP tumours, and
question the role of DNA methylation in cancer initiation or progression.
The progenitor origin hypothesis provides a potential explanation for
the conflict described above. This hypothesis suggests that aberrant
DNA methylation in cancer is a reflection of the epigenome of a
progenitor or stem-like tumour-initiating cell [132]. The model is
consistent with the epigenetic switching hypothesis described above,
whereby genes which are transiently repressed in progenitor cells become
irreversibly repressed through DNA methylation. When this occurs at
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loci required for differentiation, the progenitor cells are unable to
differentiate and are locked into a proliferative state. Thus the role of
DNA methylation in cancer is causing a reduction in cellular plasticity
and preventing differentiation. The model is supported by the data,
described above, which show that aberrant DNA methylation in cancer
resembles a stem-like methylation pattern and occurs at loci involved in
tissue identity.
A variation on this hypothesis suggests that methylation may instead
be a reflection of the expression profile of the tissue from which the
cancer is derived. A pan-cancer analysis of DNA methylation patterns
identified over 1,000 genes hypermethylated in at least one of seven
different tumour types [51]. Notably, there was considerable variation in
what genes became hypermethylated with approximately half of all genes
exhibiting hypermethylation in only a single tumour type. The authors
concluded differences in DNA methylation profiles between tumour types
could be explained as a result of the differences in expression patterns
between tissue types [51]. DNA methylation was more likely to be
observed at genes which were already repressed in the tissue of origin,
and thus methylation profiles were a reflection of the tissue rather than
driver events. This implies that DNA methylation is a passenger event
and plays no direct role in tumour progression. However, this does not




The epigenome is involved in cellular differentiation and the maintenance
of cell identity and is fundamentally altered in cancer. Genome-wide
studies of methylation have begun to profile the regions of DNA with
aberrant methylation marks in cancer, but the cause and consequence of
these changes are unknown. The classical model, in which DNA
methylation silences genes in a similar manner to mutations, is an
oversimplification. The new models which are seeking to explain
methylation patterns in cancer and how they relate to the role of the
epigenome in corresponding healthy tissue are in the early stages and
require validation. In CRC the CIMP subtype is of particular interest as
a model of cancer-specific methylation patterns, yet the subtype is
defined using numerous panels of genes (5-10 loci examined) or
hierarchical clustering methods (approximately 1,000 loci examined).
3.1.4 Aims
The aim of this chapter was to characterise genome-wide DNA
methylation patterns in colorectal cancer. Previous studies have begun to
describe the distribution of methylation, but there is great room for
improvement. Analyses of hypermethylation in colorectal cancer have
used lab-specific thresholds for hypermethylation and have often relied on
very few data points to classify loci as hypermethylated. In this chapter
DNA methylation of 94 colorectal tumour and matched non-cancerous
tissue were analysed using high density methylation beadchips.
Genome-wide DNA methylation patterns of tumour and non-cancerous
tissue are compared and hypermethylation patterns are described. Three
64
genes, EYA4, TLX1 and TFIPI2 are hypermethylated in 92%, 90% and
90% of all tumours analysed. These genes have potential as a clinical
biomarker for the accurate and cost effective detection of colorectal
cancer. In CpG island methylator phenotype tumours hypermethylation
is consistent, with a set of 132 genes hypermethylated in all cases.
Consistent hypermethylation occurs against a background of variable
hypermethylation observed in all tumours.
3.2 Results
3.2.1 Illumina Infinium humanMethylation450
beadchip
Illumina Infinium humanMethylation450 beadchip data was available
for 64 patients at the beginning of this thesis, prepared by Dr Donghui
Zou. I selected a further 30 tumour samples to be analysed, preferentially
selecting tumours which were right-sided so as to increase the number of
CIMP-H samples in the study.
DNA was extracted from frozen CRC or matched non-cancerous tissue
using Quick-gDNA miniPrep kits (Zymo Research, Catalogue number
D3025). DNA quality and quantity was assessed using a NanoDrop
ND-1000 spectrophotometer (Nanodrop Technologies, USA). For each
sample, 1,000ng of DNA was bisulfite converted using an EZ DNA
methylation kit (Zymo Research, D5001). Bisulfite conversion involves
the deamination of cytosines to uracil while leaving methylated cytosines
unchanged, and is the basis of many approaches which differentiate
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methylated from unmethylated DNA. Bisulfite conversion is the current
gold standard used to measure DNA methylation levels.
Bisulfite conversion efficiency was assessed using qRT-PCR with
primers designed for ALU repeat regions, with 100% methylated and
100% unmethylated DNA used as references, as described previously [52].
Bisulfite converted DNA was transported on ice to the Invermay
AgResearch centre where samples were processed and applied to the
Illumina humanMethylation450 beadchips following the manufacturer’s
protocol. For each sample, 4µL of bisulfite converted DNA which had
been diluted to 50ng/µL was used. Matched tumour and non-cancerous
samples were run on the same beadchip, and sample pairs were
randomised to different beadchips.
3.2.2 Significance Analysis of Microarrays
To identify differentially methylated CpGs between tumour and matched
non-tumour tissue significance analysis of microarrays (SAM), which
calculates a non-parametric t-test between tumour and normal tissue
samples for each CpG on the array, was used. SAM uses permutation
based estimations of the number of false positives identified in each
analysis. Keeping the estimated false positives at zero, SAM identified
45,052 differentially methylated CpGs. To limit this analysis to only the
most differentially methylated CpGs, and therefore most biologically





Hierarchical clustering of samples was carried out using the 20,000
differentially methylated probes (Figure 3.1). While a number of previous
publications opt to use probes with high variance for clustering, this may
introduce a bias. When using β-values, the standard deviation is
influenced by the mean DNA methylation value measured across all
samples for a given probe, with probes which have a mean DNA
methylation β-value close to 0.5 having a larger potential variance than
probes with a mean β-value close to either 0 or 1 [133]. To avoid this
bias, differentially methylated probes were used when clustering. Only
2/94 non-cancerous samples clustered with tumour samples (omitted
from further analysis), and 7/94 tumour samples clustered as
non-cancerous tissue. The two non-cancerous samples which clustered
with tumour samples may be the result of tumour contamination or
might indicate the presence of inflammatory bowel disease [134]. The
seven tumour samples found in the non-cancerous cluster were manually
reassigned as CIMP-N tumours, as they exhibit low levels of differential
methylation. The hierarchical clustering dendrogram supported three
distinct tumour groups: a heavily methylated cluster designated CIMP-H
(n=32), a cluster with a very low level of methylation designated




Clinical data was available for 26, 10 and 37 CIMP-H, CIMP-L and
CIMP-N tumours respectively (Figure 3.3). Consistent with previous
studies, CIMP-H tumours were enriched (21/26, 81%, p value = 0.016
Welch t-test) in the proximal colon and were associated with BRAF
(V600E) mutations (14/26, 54%, p value < 0.001) (Table
3.1) [9], [50], [105]. CIMP-H tumours had a higher rate of MSI (35%)
compared to CIMP-L (10%) or CIMP-N (16%) tumours, but the
difference between groups was not significant (p value = 0.133). CIMP-N
tumours were enriched (19/37, 51%, p value = 0.016) in the distal colon
and rectum.
To compare the CIMP classifications derived from our clustering
analysis to those derived from the Weisenberger panel of genes [9],
MethyLight was used to assess the methylation status of (CACNA1G,
NEUROG1, SOCS1, IGF2, RUNX3 ) [54]. MethyLight analysis was
carried out by Dr Donghui Zou. The original Weisenberger five gene
panel did not recognise the CIMP-L subtype. To discriminate CIMP-L
from CIMP-H and CIMP-N tumours the criteria proposed by [10] was
adapted to the Weisenberger panel, whereby > 3 hypermethylated genes
indicated CIMP-H, 1-3 indicated CIMP-L and 0 hypermethylated genes
indicated CIMP-N. The concordance between the genome-wide cluster
analysis and the Weisenberger five gene panel approach was 84%, 8%,
and 64% for CIMP-H, CIMP-L, and CIMP-N tumours, respectively
(Table 3.1). Tumours classified as CIMP-L under the panel method were
redistributed into both CIMP-H and CIMP-N hierarchical clustering
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subtypes. All further references to the CIMP status of our samples is
based on the hierarchical clustering classification presented here.
3.2.4 Analysis of differentially methylated probes
Distribution of differentially methylated probes
The 20,000 most differentially methylated CpGs identified by SAM were
annotated using the online probe software tool HOMER. At the CpG
dinucleotide level, hypermethylation was more common, with 73% of the
differentially methylated CpGs being hypermethylated in tumours.
However, multiple probes were commonly found in the same gene;
consequently there were similar numbers of hypermethylated (n=3,278)
and hypomethylated genes (n=3,441). The majority (74%) of
hypermethylated CpGs occurred in CGIs rather than island shores (20%)
or shelves (1%) (Figure 3.4). This is consistent with previous studies
finding 70-80% of CpGs hypermethylated in CIMP-H tumours were
located within CGIs but differs from a study using a custom-designed
NimbleGen microarray which found cancer-associated DNA methylation
occurred more frequently in the shores and shelves [109], [129] [73].
In contrast to the hypermethylated CpGs, hypomethylated CpGs were
more frequently located in CGI shore or shelf regions (12% and 11%
of hypomethylated CpGs, respectively) compared to CGIs themselves
(1.3%) (Figure 3.4). Hypomethylated CpGs were most strongly enriched








Figure 3.1: Representative section of hierarchical clustering heatmap.
Unsupervised hierarchical clustering using Euclidian distance was applied
to the DNA methylation β-values of 20,000 CpG loci to split tissue
samples into groups. Tumour samples cluster on the left side of the
heatmap, non-cancerous samples on the right. Individual probes are
clustered along the Y axis, tissue samples clustered along the X axis.
DNA methylation value is indicated by colour, yellow indicates high








Figure 3.2: Fine resolution of tumour sample clustering. The clustering
dendrogram is compatible with three tumour subtypes. Tumour
subtypes have been classified as CIMP-H (yellow indicator bar above
dendrogram), CIMP-L (blue indicator bar) and CIMP-N (pink indicator
bar). Individual probes are clustered along the Y axis, tissue samples
clustered along the X axis. DNA methylation value is indicated by colour,
yellow indicates high methylation and blue indicates low methylation.
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Figure 3.3: Clinical features of CIMP subtypes. Six clinical features are
indicated by the colour bars above the heatmap. Colon section is divided
into three types: right-sided (pink), which includes the caecum, ascending
section and hepatic flexure, transverse (red) and left-sided (green) which
includes the left splenic flexure, descending section, sigmoid and rectum.
Panel tissue subtype refers to the classification of the tumour sample
using the Weisenberger five gene panel, where a tumour is classified as
CIMP-H (gold) if > 3 of the 5 panel genes are hypermethylated, CIMP-L
(blue) if 1-2 genes are hypermethylated and CIMP-N (pink) if 0 genes
are hypermethylated. MSI status, BRAF and KRAS mutation status are
indicated by black bars, with MSS or wildtype status indicated by grey






































































Figure 3.4: Genomic distribution of differentially methylated probes.
Differentially methylated probes were grouped into one or more genomic
features: Transcription start site (TSS), exon, intron, intergenic region,
transcription termination site (TTS), 3’ untranslated regions (3’UTR),
enhancer, 5’UTR, CpG island (CGI), CpG island shore (CGI shore),
and CpG island shelf (CGI shelf). Some features, such as TSS and CGI,
may overlap. The number of hyper- or hypo-methylated CpGs in each
genomic feature is expressed as a percentage of the total number of
differentially methylated probes.
73












BRAF mutant 14 (44%, 54%) 0 (0%) 3 (6%, 8%) <0.001
BRAF wildtype 12 (38%, 46%) 10 (77%, 100%) 34 (72%, 92%)
KRAS mutant 5 (16% 19%) 5 (38%, 50%) 6 (13%, 16%) 0.039
KRAS wildtype 21 (66%, 81%) 5 (38%, 50%) 31 (66%, 84%)
MSI 9 (28%, 35%) 1 (8%, 10%) 6 (13%, 16%) 0.133
MSS 17 (53%, 65% 9 (69%, 90%) 31 (66%, 84%)
Colon location
Proximal 21 (66%, 81%) 7 (54%, 70%) 18 (38%, 49%) 0.016
Distal 5 (16%, 19%) 3 (23%, 30%) 19 (40%, 51%)
Differentiation
Moderate 10 (31%, 38%) 9 (69%, 90%) 30 (64%, 81%) 0.012
Moderate, mucinous 7 (22%, 27%) 1 (8%, 10%) 5 (11%, 14%) 0.197
Poor 4 (13%, 15%) 0 (0%) 2 (4%, 5%) 0.209
Well 4 (13%, 15%) 0 (0%) 0 (0%) 0.075
Weisenberger gene
panel CIMP status
CIMP-H 27 (84%) 1 (8%) 7 (15%) <0.001
CIMP-L 4 (13%) 1 (8%) 7 (15%)
CIMP-N 1 (3%) 11 (85%) 30 (64%) <0.001
Age (SD) 73.6 (7.7) 69.2 (11) 69 (12.3) 0.07
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The Illumina 450K beadchip contains more CpGs located in CGIs than
in CGI shores or shelves. To determine whether or not CGIs were truly
enriched for differential methylation, the number of differentially
methylated CpGs was displayed as a percentage of the total CpGs per
genomic feature (Figure 3.5). 10% of all CGI probes exhibited differential
methylation (< 1% of which was hypomethylation), compared to 4% of
island shore probes (< 1% hypomethylation) and 2% of island shelf
probes (< 1% hypermethylation), indicating CGIs are the primary
genomic feature of aberrant DNA methylation in CRC.
Gene ontology
Gene ontology can be used to determine whether differentially
methylated regions are enriched within certain classes of genes. The R
package missMethyl, which contains the function gometh, was selected to
identify groups of genes which are over-represented among the list of
genes with differentially methylated CpGs. Gometh takes a list of
differentially methylated CpGs and compares it against a list of all CpGs
included in the analysis post filtering. This corrects for potential bias
associated with studies of differentially methylated regions, which did not
take into account the variation in number of CpGs per gene on each
array [135]. Genes with a significantly differentially methylated CpG are
scored as a 1, and genes with no differentially methylated CpGs a 0. The
resulting vector of 1s and 0s is used in combination with a reference table
indicating the total number of CpG sites in each gene and calculates the
likelihood of each gene containing differentially methylated probes by

































































Figure 3.5: Fraction of the total number of CpGs from each genomic
feature affected by differential methylation. CpGs were grouped by
genomic feature (transcription start site (TSS), exon, intron, intergenic
region, transcription termination site (TTS), 3’ untranslated regions
(3’UTR), enhancer, 5’UTR, CpG island (CGI), CpG island shore (CGI
shore), and CpG island shelf (CGI shelf)). The percentage of CpGs from
each genomic feature was calculated to identify the regions of the genome
which are most highly affected by differential methylation.
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consortium website, are then tested to identify terms which are enriched
for differentially methylated genes [136]. DNA methylation patterns are
known to vary depending on where the CpG loci are located within the
gene, for example promoter regions are generally devoid of methylation in
non-cancerous tissue, while gene body CpGs are often methylated. To
account for these differences, genes were grouped according to where
within the gene (e.g., promoter, gene body, etc.,) the differentially
methylated probe was located. Different categories of genes were then
assessed for enriched GO terms separately.
The majority (87%) of the 12,054 CpGs located in the promoter region
are hypermethylated. The hypermethylated probes are found in the
promoter regions of 1,594 unique genes, for which the top 20 most
enriched GO terms are displayed in (Table 3.2). Of the top 20 ontology
terms for hypermethylated promoter regions, 12 relate to development,
differentiation or generation of cells, in particular neurogenesis or brain
development, while four terms relate to cell-cell signalling. Because CGIs
and promoter regions often overlap, CGI probes share similar GO terms
to promoter region terms (Table 3.4). Terms relating to development,
generation or differentiation of cells, make up 13 of the top 20 most
enriched GO terms for CGIs and 16 out of 20 for CGI shores with
hypermethylated CpGs (Table 3.5). Hypermethylated CGI shelves have
no significant enrichment for GO terms.
Hypomethylated promoters are enriched for very different GO terms.
Among hypomethylated promoters, the top four GO terms, and seven of
the top 20 terms, relate to glucoronidation. Glucoronidation is the
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modification of a substrate through the addition of glucoronic acid, and
is commonly involved in the metabolism of xenobiotic compounds. Eight
GO terms relate to the detection of chemical stimulus, primarily as it
relates to sensory systems such as smell (Table 3.3). Despite the overlap
between promoter region and CGI regions, there was no significant
enrichment for GO terms among hypomethylated CGI or CGI shore
probes.
Intergenic region CpGs are located further than 2,000bp upstream of
the transcription start site (TSS), or are more than 2,000bp downstream
of the end of the 3’ region, of any known genes. Despite their great
distance from genes, changes in methylation at these loci may effect gene
expression, as has been shown with long-range SNPs [137]. In this study,
CpGs in intergenic regions were associated with the closest known gene
and analysed using missMethyl. Intergenic hypermethylation occurred
near genes involved in cell fate commitment and organism development
(11/20 of the top GO terms, Table 3.6). This might reflect
hypermethylation which has spread outwards from CGIs and promoter
regions involved in these processes. However, intergenic hypermethylation
was also enriched for the GO terms Regionalization, Pattern specification
and the Regulation of multicellular development, which are absent from
hypermethylated CGIs and promoters. These GO terms may indicate a
previously unrecognised role for intergenic hypermethylation in higher
level patterning of the developing organism. GO terms relating to the
regulation of transcription are also prominent in hypermethylated
intergenic regions (8 GO terms). There were fewer hypomethylated CpGs
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Table 3.2: Gene ontology terms enriched within hypermethylated
promoter CpGs





Synaptic transmission 161/685 4.87E-17
Synaptic signaling 161/685 4.87E-17
Trans-synaptic signaling 161/685 4.87E-17
System development 584/4169 6.39E-17
Neurogenesis 301/1621 5.86E-16
Neuron differentiation 275/1431 5.86E-16

































DM/N: Number of differentially methylated probes in this gene ontology
category / Total number of probes associated with this gene ontology category.
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Table 3.3: Gene ontology terms enriched within hypomethylated
promoter CpGs
GO term DM/N p value (FDR
adjusted)














sensory perception of smell
59/332 2.08E-11
Olfactory receptor activity 59/332 2.08E-11












Detection of stimulus 71/639 1.77E-09













Signaling receptor activity 92/1219 8.60E-08
Flavonoid glucuronidation 10/17 1.20E-07




DM/N: Number of differentially methylated probes in this gene ontology
category / Total number of probes associated with this gene ontology category.
Table 3.4: Gene ontology terms enriched within hypermethylated CGIs









Cell-cell signaling 317/1160 8.73E-30





Generation of neurons 416/1540 2.98E-28
Synaptic transmission 226/685 7.73E-28
Synaptic signaling 226/685 7.73E-28
























DM/N: Number of differentially methylated probes in this gene ontology
category / Total number of probes associated with this gene ontology category.
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Table 3.5: Gene ontology terms enriched within hypermethylated CGI
shores












Neuron differentiation 212/1431 1.40E-14
























Animal organ development 312/2991 6.39E-11
Single-organism behavior 80/416 8.08E-11
Organ morphogenesis 140/924 2.89E-10
DM/N: Number of differentially methylated probes in this gene ontology
category / Total number of probes associated with this gene ontology category.
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located in intergenic regions and these were associated with fewer (n=12
categories which achieved statistical significance) significant GO terms
(Table 3.7). These were strongly enriched for terms relating to the
detection of chemical stimulus and sensory perception.
Enhancer regions are affected by both hypermethylation (23% of
hypermethylated probes) and hypomethylation (44% of hypomethylated
probes). A large proportion (73%) of hypermethylated CpGs which were
found in enhancer regions overlap with CGIs, therefore GO terms are
similar between hypermethylated enhancers and CGIs. In contrast,
hypomethylated enhancers do not overlap with hypomethylated CGIs,
but 53% of hypomethylated enhancer probes are also classified as
intergenic. Hypomethylated enhancers share some of the GO terms
associated with intergenic regions but are enriched with a diverse range
of terms such as: cell signaling (4/20 terms), cell membrane functions
(5/20 terms), and cell adhesion (2/20 terms) (Figure 3.8).
3.2.5 Analysis of differentially methylated CGIs
The above data address the identification and analysis of individual CpG
loci with hyper or hypomethylation. It is difficult to predict the impact
of changes in DNA methylation when only a single CpG loci is affected.
Methylation across an entire region, such as a CGI, is more likely to
have a biological impact, either through inhibition of protein binding,
recruitment of methylation-specific binding proteins, or changes in local
chromatin structure.
83
Table 3.6: Gene ontology terms enriched within hypermethylated
intergenic CpGs


















Cell fate commitment 27/256 1.75E-13










































DM/N: Number of differentially methylated probes in this gene ontology
category / Total number of probes associated with this gene ontology category.
Table 3.7: Gene ontology terms enriched within hypomethylated
intergenic CpGs







sensory perception of smell
28/332 2.52E-07
Olfactory receptor activity 28/332 2.52E-07











Sensory perception of smell 28/357 3.97E-07














Detection of stimulus 32/639 2.20E-06




Plasma membrane 79/4531 6.98E-06
Cell periphery 80/4634 6.98E-06




DM/N: Number of differentially methylated probes in this gene ontology
category / Total number of probes associated with this gene ontology category.
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Table 3.8: Biological processes enriched within hypomethylated
enhancer CpGs






Cell adhesion 122 3.57E-06
Biological adhesion 122 3.57E-06
Synaptic transmission 71 0.000228359
Synaptic signaling 71 0.000228359

















System process 116 0.004272713
Collagen catabolic process 15 0.004704773












Locomotory behavior 28 0.010079158
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Identifying differentially methylated regions
A number of previous analyses have used the Illumina
HumanMethylation 27K beadchip to identify differentially methylated
regions, as described in the introduction section. These analyses were
limited to analysing a small number of CpGs per gene. The Illumina
450K beadchip provides greater coverage and therefore a more robust
view of genes that are differentially methylated in cancer.
DNA methylation values for probes from the CGI itself, the island
shores and shelves were all combined to produce a single vector of values
for each gene in non-cancerous and tumour samples. Any gene which
contained fewer than four CpG loci was removed from the analysis
(n=12,600 genes remaining). The Wilcoxon Signed Rank (WSR) test was
employed to identify differentially methylated genes when comparing
tumour and matched non-cancerous tissue from the same individual.
Following correction for multiple testing using the False discovery rate
(FDR), a p value < 0.005 was considered significant.
As an additional threshold for the detection of differentially methylated
regions, genes were only considered significantly hypermethylated if the
mean DNA methylation of the tumour was greater than the mean of the
non-cancerous sample. To identify a biologically meaningful threshold to
define a gene as hypermethylated, different ∆ β-values were tested as a
cutoff. The β-value is the ratio between the fluorescence signal of the
methylated to the unmethylated probe and has a value between 0 and 1.
The ∆ β-values 0.1, 0.2, 0.3 and 0.4 represent small to large overall
changes in CGI DNA methylation. For each of the four ∆ β thresholds
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the number of hypermethylated genes was recorded for each CIMP
subtype and for all tumours together. Two further measurements were
recorded for each threshold: the average number of hypermethylated
genes per subtype and the number of unique hypermethylated genes i.e.,
the number of genes when duplicates across tumours from the same
subtype were ignored (Table 3.9). At all thresholds the CIMP-H subtype
had the greatest number of hypermethylated genes (Figure 3.6).
A surprising finding was that although CIMP-L tumours have more
genes hypermethylated per tumour on average compared to CIMP-N
tumours, overall there are fewer unique genes affected by
hypermethylation in CIMP-L tumours compared to CIMP-N tumours
(Figure 3.7, Figure 3.6). To investigate this, the ratio between the
average number of hypermethylated genes and the number of unique
genes was calculated in order to measure the spread of methylation in
each subtype (Figure 3.8). A higher ratio indicates that methylation is
more likely to be found at the same regions across tumours from the
same subtype. CIMP-L tumours, which have a low frequency of
hypermethylation but a high ratio score, therefore have a low number of
unique hypermethylated genes (Figure 3.8). Each of the 13 CIMP-L
tumours has, on average, more methylation than a CIMP-N tumour but
this methylation is found at largely the same loci in each sample. In
contrast, methylation in CIMP-N is more sporadic in it’s location leading
to a higher number of unique genes with hypermethylation. An
interesting observation from these data is that at ∆ β-value 0.1 CIMP-L
tumours have a ratio score similar to CIMP-H despite hypermethylation
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Figure 3.6: The effect of ∆ β-value threshold on the number of unique
hypermethylated genes. Hypermethylated genes were defined as those
with both a p value < than 0.005 under the WSR test and a biologically
significant difference in the mean β-value of tumour and non-cancerous
tissues (∆ β). For every gene associated with a CGI, the mean β-value
of CpGs in the CGI, island shore and island shelf was calculated for each
tissue sample. For each gene, the mean β-value of the non-cancerous
tissue sample was subtracted from the mean β-value of the matched
tumour tissue (∆ β). The number of differentially methylated genes
in CIMP-H, CIMP-L, CIMP-N, as well as the difference between the
number of differentially methylated genes in CIMP-H and CIMP-N
tumours, was calculated when a differentially methylated gene was
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Figure 3.7: The effect of ∆ β-value threshold on the average number
of hypermethylated genes per tumour. Hypermethylated genes were
defined as those with both a p value < than 0.005 under the WSR test
and a biologically significant difference in the mean β-value of tumour
and non-cancerous tissues. For every gene associated with a CGI, the
mean β-value of CpGs in the CGI, island shore and island shelf was
calculated for each tissue sample. For each gene, the mean β-value of
the non-cancerous tissue sample was subtracted from the mean β-value of
the matched tumour tissue (∆ β). The average number of differentially
methylated genes per tumour in CIMP-H, CIMP-L, CIMP-N, as well as
the difference between the average number of differentially methylated
genes per tumour in the CIMP-H and CIMP-N subtypes, was calculated
when a differentially methylated gene was defined as one with a ∆ β-








































Figure 3.8: Ratio of number of unique to average number of
hypermethylated genes. The number of unique hypermethylated genes
and the average number of hypermethylated genes was calculated using
a ∆ β-value greater than 0.1, 0.2, 0.3 or 0.4. The ratio of the number of
unique hypermethylated genes to the average number of hypermethylated
genes was calculated and then expressed as a percentage.
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Table 3.9: Effect of adjusting the cutoff for defining a hypermethylated gene




0.1 759 238 196 563
0.2 536 148 87 449
0.3 269 59 18 251
0.4 67 10 1 66
Hypermethylated
islands (unique)
0.1 2228 723 1222 1006
0.2 1528 535 801 727
0.3 1030 290 313 717
0.4 629 80 23 606
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Analysis of hypermethylated genes
Further analysis of hypermethylated genes is based on the threshold of ∆
β-value 0.1. ∆ β-value 0.1 was selected as the threshold which captured
the greatest difference between CIMP-H and CIMP-N tumour types
(Figure 3.6, Figure 3.7). Using ∆ β-value 0.1, 2,276 unique CGIs were
hypermethylated in at least a single tumour (2,228 in CIMP-H tumours,
723 in CIMP-L, and 1,222 in CIMP-N). PANTHER was used to identify
over represented biological processes in the list of genes associated with
the 2,276 hypermethylated genes. 95% of the genes mapped to gene IDs
in the PANTHER database, with 51 significantly enriched gene ontology
terms (p value < 0.05). To limit the analysis to the most relevant
ontology terms, results were filtered by PANTHER’s fold enrichment
score analysis. Fold enrichment is calculated as the number of observed
genes from an ontology group divided by the number of genes that are
expected to be from that group. Hypermethylated CGIs are strongly
enriched for ontology terms relating to development. Development,
segment specification, pattern morphogenesis and specification make up
the majority (16 out of 28) of gene ontology terms with a fold enrichment
score greater than 2 (Table 3.10). The majority (98%) of
hypermethylated genes are identified in CIMP-H tumours, with 1,007
genes hypermethylated exclusively in CIMP-H tumours.
The 2,276 hypermethylated genes were compared against the list of
2,075 hypermethylated genes from the analysis of individual CpGs
located in the CGI region. 1,249 out of 2,075 (60%) of genes described as
hypermethylated on the basis of individual CpGs alone are validated by
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the CGI-wide analysis. This finding highlights the importance of
CGI-wide analyses over the use of one or a small number of individual
probes when attempting to identify differentially methylated genes.
Individual tumours exhibited wide variation in the frequency of
hypermethylated genes, ranging from 2 to 1498 hypermethylated genes
per tumour (mean 397). The number of hypermethylated genes ranged
from 2-727 (mean 196) in CIMP-N tumours, 78-485 in CIMP-L (mean
237) and 327-1498 in CIMP-H tumours (mean 759). Although the mean
number of hypermethylation events in each CIMP group differed
significantly, a continuum in hypermethylation frequency was observed
with no clear boundary to divide the CIMP-H, CIMP-L and CIMP-N
tumours (Figure 3.9). The overlapping ranges of hypermethylated genes
between the three tumour classes indicates that the classification of
CIMP-H tumours could be determined by both the number and the
identity of hypermethylated genes.
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Table 3.10: Biological processes associated with hypermethylated genes































































































































































DM/N/E: Number of hypermethylated genes in this gene ontology category
/ Total number of genes on the 450K methylation array associated with this
gene ontology category / Expected number of hypermethylated genes to be
associated with the ontology category.
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Figure 3.9: CIMP subtypes overlap in the number of hypermethylation
events per tumour. The number of hypermethylated genes was calculated
for each tumour. Tumour samples were colour-coded by CIMP subtype.
3.2.6 CIMP-H tumours display hypermethylation at
a core set of genes
A surprising finding was the wide range of genes (1,222 different genes)
hypermethylated in CIMP-N tumours, despite these tumours having on
average a low number of hypermethylated CGIs (mean 196 per CIMP-N
tumour, see Figure 3.7). I hypothesised that the majority of
hypermethylated genes in CIMP-N, and to a lesser extent CIMP-H, were
hypermethylated in a small number of tumours. These rare
hypermethylation events might represent a type of biological noise, and
by identifying and removing them it would be possible to focus on the
critical hypermethylation events. To test this, each gene was scored for
the number of times it was hypermethylated in the dataset of 92 tumours




























































































































































Figure 3.10: Frequency of hypermethylation of genes across all tumours.
Each hypermethylated gene was scored for the number of times it
was hypermethylated in the dataset, which was then expressed as a
percentage. The figure shows the frequency of hypermethylation for all
2,276 genes, many gene names have been omitted for clarity. Few genes
are hypermethylated in the majority of tumours while many genes are
hypermethylated in a small percentage of the tumour population.
CGIs were in fact only hypermethylated in a small number of cases, but
also revealed the existence of a smaller set of CGIs which are
hypermethylated in a very high proportion of the tumour population.
Three CGIs are methylated in the majority of tumours
analysed
Three CGIs, associated with the genes EYA4, TLX1 and TFPI2, were
hypermethylated in more than 90% of tumours (Figure 3.11). EYA4 has





































































































Figure 3.11: Frequency of hypermethylation at core genes across all
tumours. Each hypermethylated gene was scored for the number of times
it was hypermethylated in the dataset, which was then expressed as a
percentage. When considering all tumour samples, a small number of
genes (n=20) are hypermethylated in the majority (>80%) of cases.
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early Barrett’s esophagus [138]. Hypermethylated TFPI2 has been
documented in relation to inflammation of the colon [139] as well as in
oral squamous cell carcinoma [140], and is a predicted tumour
suppressor [141]. TLX1, also known as HOX11, is hypomethylated in
T-cell lymphoblastoma leukemia but is a novel hypermethylation target
in colorectal cancer.
CIMP subtype specific analysis of frequently hypermethylated
genes
Tumours were subdivided by CIMP status and the frequency of
hypermethylation at each gene was recalculated. To visualise the number
of frequently or rarely hypermethylated genes, ten bins were created for
each of the three CIMP subtypes. The first bin contained all genes which
were hypermethylated in at least 10% of the tumours in a particular
CIMP subtype. The second bin contained only those genes
hypermethylated in more than 20% of tumours from the subtype, and so
on. The number of genes in each bin was counted and plotted (Figure
3.12). In the CIMP-H subtype 258 genes were hypermethylated in more
than 90% of tumours (Appendix A), and 132 were hypermethylated in all
CIMP-H tumours (Table 3.11). The 258 genes hypermethylated in more
than 90% of tumours, which make up 13% of all hypermethylated genes
in those CIMP-H tumours, was termed the core subset of
hypermethylation targets. A core hypermethylation subset also exists in
CIMP-L tumours, and is comprised of 40 genes (6% of all
hypermethylated genes in CIMP-L) (Table 3.12). The CIMP-L core
subset is almost entirely found within the CIMP-H core subset, with the
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exception of HOXA5 and RXFP3, which are hypermethylated in 72%
and 84% of CIMP-H tumours respectively. Unlike CIMP-H and CIMP-L,
no core hypermethylation subset exists for CIMP-N tumours. In addition
to the core hypermethylation subset, many hypermethylation events
occur very rarely (< 10% of cases per CIMP subtype), here referred to as
the stochastic subset. The stochastic subset of genes makes up just over
a third of hypermethylated genes in CIMP-H and CIMP-L, but comprises
for more than half of all genes hypermethylated in CIMP-N tumours
(Table 3.13). This data supports the earlier finding that
hypermethylation in CIMP-H and CIMP-L tumours, but not CIMP-N
tumours, is likely to occur at the same loci (Figure 3.8). Consistent
hypermethylation of the core subset of genes in CIMP-H and CIMP-L
tumours is consistent with a model in which CGIs are targeted for
hypermethylation. The low frequency at which each gene is
hypermethylated in CIMP-N tumours is suggestive of a stochastic model









































Figure 3.12: Number of genes hypermethylated in each threshold
group. Genes were grouped according to a threshold of hypermethylation
frequency, ranging from > 10% - 100% of tumours, at which they were
hypermethylated in the three CIMP subtypes. The number of genes
which occurred in each group was then scored for each of the three CIMP
subtypes.
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Table 3.11: Subset of 132 genes hypermethylated in 100% of CIMP-H
tumours
ADCYAP1 ALX4 BDNF BRUNOL4 CALCA
CALCR CCDC140 CCNA1 CHRM2 CIDEA
COL12A1 COMP CYP26C1 DBX1 DGKG
DLX5 DLX6AS EBF1 EBF2 EMX2
EMX2OS EN1 ESRRG EVX2 EYA4
FEZF2 FGF14 FGF3 FLJ41350 FLJ42709
FLJ45983 FOXG1 GALR1 GATA4 GDF6
GDNF GFRA1 GRID1 GSC HAND1
HELT HLA-L HPSE2 INS-IGF2 IRX4
ISL2 ISLR2 LBXCOR1 LHX1 LHX4
LHX5 LHX8 LHX9 LMX1A LMX1B
LOC401463 LOC645323 MKX MPPED2 MSC
MSX1 NELL2 NEUROG1 NKX2-1 NKX2-3
NKX6-1 NKX6-2 NPR3 NR2E1 NR5A2
NRG2 NRN1 NXPH1 OLIG2 ONECUT1
OTP OTX2 PAX1 PAX2 PAX3
PAX5 PAX6 PAX9 PCDH8 PDGFRA
PHF21B PRDM13 PRDM6 PRDM8 PRMT8
RASGRF1 RFX4 RGS20 RNF220 ROBO3
RORA RUNX3 SALL1 SFRP2 SFTA3
SHISA3 SHOX2 SIM1 SIM2 SIX6
SLC32A1 SLC6A15 SLITRK5 SNCA SOX21
T TBR1 TBX1 TBX15 TBX2
TBX5 TFPI2 TLX1 TLX3 TMEM200B
TMEM90B TWIST1 UNCX VAX1 VAX2
VCAN VSTM2A WNT3A WT1 ZIC1
ZIC4 ZNF331
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Table 3.12: Core subset of 40 genes hypermethylated in > 90% of
CIMP-L tumours
CCNA1 NR2E1 ZIC4 MSX1
CYP26C1 PAX3 ALX4 PAX6
DLX5 SALL1 FGF3 PAX9
EYA4 SIM1 FOXG1 RASGRF1
FEZF2 SIM2 GDF6 RXFP3
GATA4 TBX15 GDNF SLC32A1
GFRA1 TFPI2 HOXA5 SOX21
HOXA2 VAX2 IRX4 TLX1
LHX1 WT1 LHX8 TWIST1
LOC283392 ZIC1 MAR13 UNC5C








CIMP-H 258 (11.6%) 856 (38.4%)
CIMP-L 40 (5.5%) 253 (34.9%)
CIMP-N 0 (0%) 635 (51.9%)
Gene ontology analysis of frequently hypermethylated genes
PANTHER was used to identify statistically enriched gene ontology
terms among the lists of hypermethylated CGIs. The gene ontology
results for the 132 genes hypermethylated in 100% of CIMP-H tumours
are shown in (Table 3.14). Of the 18 terms with a fold enrichment score
greater than 2, 12 relate to development, pattern specification or
differentiation. Other terms include metabolic processes, regulation of
transcription, and negative regulation of apoptotic processes. The results
suggest that hypermethylation which occurs consistently in CIMP-H
tumours is found near genes with roles in development and the regulation
of cell fate. This supports previous work which has shown that
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hypermethylation is more likely to occur at regions of the genome which
contain bivalent histone chromatin marks and are involved in organism
development [125], [126].
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Table 3.14: Biological processes associated with CIMP-H core
hypermethylation targets




































































DM/N/E: Number of hypermethylated genes in this gene ontology category
/ Total number of genes on the 450K methylation array associated with this
gene ontology category / Expected number of hypermethylated genes to be
associated with the ontology category.
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Core hypermethylation targets are enriched for bivalent
chromatin
Cancer-specific hypermethylation is enriched at loci which are marked
with bivalent chromatin in ESCs [50], [125], [126]. As described in the
introduction, bivalent domains are regions of chromatin which have both
activating H3K4me3 and repressive H3K27me3 histone marks in ESCs.
To investigate bivalent markings in light of the highly consistent
methylation at loci in CIMP-H tumours, a publicly available list of
bivalent genes was downloaded [126]. Hypermethylated genes were
grouped according to their prevalence in the tumour population (i.e., a
list of genes hypermethylated in more than 10% of tumours analysed, a
second list of genes hypermethylated in more than 20% of tumours etc.,).
These groups of genes were compared to the list of bivalent genes to
determine how many hypermethylated genes overlap with bivalently
marked regions (Figure 3.13). Bivalent domains overlap with 31.6% of all
genes analysed (n=12,600 genes with CGIs which were tested for
differential methylation) and with 65.7% of hypermethylated genes,
validating the findings of previous publications. Bivalent genes make up a
smaller fraction of all genes hypermethylated in CIMP-H tumours
(66.5%) compared to genes hypermethylated in CIMP-L and CIMP-N
tumours (75.5% and 74.5% respectively). CIMP-N and CIMP-L tumours
have a lower frequency of hypermethylation and this is clustered around
genes which have bivalent markings. This is most apparent when looking
at the data for genes hypermethylated in more than 60% of CIMP-N
tumours (n=28 genes), of which 100% have bivalent chromatin. One









































































































































































































Figure 3.13: Consistently methylated genes are highly enriched for
bivalent genes. A list of bivalent genes was cross-referenced with the
total list of genes on the Illumina 450k beadchip, and the percentage
of overlap was calculated. Genes on the array were grouped according
to the frequency of hypermethylation among CIMP subtypes and cross-
referenced with the list of bivalent genes.
hypermethylation, even in tumours with very low levels of
hypermethylation. If bivalent domains are prone to hypermethylation,
the lower percentage of overlap observed in CIMP-H tumours might
indicate CIMP-H tumours have more ‘off-target’ hypermethylation which
occurs at non-bivalent genes. Consistent with this observation, the 132
genes which are hypermethylated in 100% of CIMP-H tumours are highly
enriched for bivalent domains (89%) (Figure 3.13). Together, this data
supports a model in which hypermethylation in CIMP-H tumours is
comprised of hypermethylation at a consistent set of genes, which is
strongly associated with bivalent chromatin, as well as a large and
variable set of genes.
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3.3 Discussion
This chapter aimed to characterise DNA methylation in CRC using the
high density coverage of the Illumina Infinium humanMethylation450
beadchip and a large New Zealand cohort of matched tumour and
non-cancerous tissue. At the beginning of this thesis the Illumina 450K
beadchip was a new piece of technology [55]. Statistical techniques
developed to analyse data from the 450K predecessors, the Infinium
HumanMethylation27 beadchip (often referred to as the 27K array) and
the GoldenGate Methylation Beadarray, were still in early development
with little consensus as to the correct approaches to use [142]. In 2012, a
small number of bioinformatics pipelines, mostly in the form of R
packages, were being made available. IMA (Illumina Methylation
Analyzer) was one example of a package which was designed to provide a
range of tools for the analysis of 450K methylation data [143].
Importantly, the accompanying IMA publication states the goal of the
package is to provide a range of statistical techniques but does not make
any recommendation regarding which technique should be used. The
approaches used in this thesis were an attempt to characterise DNA
methylation using simple measurements and observations. Statistical
techniques and software were supported by some publications, even if no
consensus was available.
More than 20,000 differentially methylated CpG loci were identified
genome-wide. Differentially methylated CpGs were used to cluster
tumour samples into methylation-based subtypes and, consistent with a
number of previous studies, three methylation subtypes (high,
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intermediate, and low levels of methylation) were identified. In addition
to individual CpGs, methylation of CGIs was also assessed. More than
2,000 hypermethylated genes were identified, many of which represent
novel findings, while others provide validation of previous studies. A
novel approach in this study was the analysis of the frequency of
hypermethylation across the dataset to discriminate between rarely and
frequently hypermethylated genes. The data provide novel insights into
the distribution of aberrant methylation in the epigenome of CRC and
expand our understanding of the hypermethylation phenotype. Here I
explain the rational behind the analyses and discuss hypotheses which
are consistent with the data presented above.
3.3.1 Clustering for CIMP subtypes
To stratify tumours into methylation-based subtypes, unsupervised
heirarchical clustering was applied to 20,000 differentially methylated
CpGs. A number of previous publications performed clustering using
CpG loci with high variance [50], [3]. However, variance was not used as
a criteria for clustering in this analysis, because β-value data has a
known bias in which probes with a mean value close to the median
methylation value have higher variance. When using β-values the
standard deviation is influenced by the mean DNA methylation value
measured across all samples for a given probe, with probes which have a
mean DNA methylation β-value close to 0.5 having a larger potential
variance than probes with a mean β-value close to either 0 or
1 [133], [144]. To avoid this bias, clustering was performed using
differentially methylated CpGs instead.
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The unsupervised hierarchical clustering accurately split samples into
tumour and non-cancerous tissue. Tumour tissue samples were split into
three subtypes according to the hierarchical clustering tree (Figure 3.2).
This was a contentious finding, given two publications identified four
methylation subtypes earlier in 2012 [50], [3]. In these two publications,
CIMP-N was split into two subtypes which differed with respect to
location in the colon and mutation frequency. When examining the
clustering dendrogram in Figure 3.2 it is plausible that the majority of
CIMP-N tumours could be split into one of two groups - however, a small
number of CIMP-N tumours fall outside of these two groups and reside
in separate clusters within CIMP-N (Figure 3.2). To describe CIMP-N as
being comprised of two groups would require manually re-grouping
individuals into one of the two groups. As the publications by Hinoue et
al., [50] and the TCGA [3] did not include their clustering trees it is
difficult to compare those findings with the data here. The difference in
the number of subtypes identified could be due to the choice of probes
used for clustering or the underlying clustering technique used. Both
Hinoue et al., and the TCGA publication used recursively partitioned
mixture model (RPMM) based clustering, which may be a more accurate
methodology for dealing with methylation β-values [50], [3], [145].
However, a recent publication performed RPMM clustering of CRC
samples using 10,000 variable CpG sites and found no evidence of a
fourth CIMP subtype [107]. The same publication tested their finding in
two independent data sets, and in both cases identified three methylation
subtypes only. Using the data available, I judged the inter-tumour
variation in methylation of CIMP-N tumours to be low compared to the
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difference in methylation between CIMP-N and CIMP-L/CIMP-H
tumours, and treated CIMP-N as a homogenous group for this study.
The CIMP-H subtype was enriched for tumours from the proximal
colon and female patients, as previously observed [9], [10]. Notably, only
84% of CIMP-H tumours in the dataset were classed as CIMP-H using
the Weisenberger panel [9]. The Weisenberger panel was not designed to
identify CIMP-L tumours, but an attempt was made to classify tumours
as CIMP-L if they had 1-2 panel genes hypermethylated. This had an
extremely poor outcome, with only 8% of tumours labelled as CIMP-L
under the panel approach classified as CIMP-L by genome-wide
clustering method. This data raises concerns regarding the use of small
gene panels to classify CIMP, and surrounding the general lack of
agreement and definition of CIMP subtypes which is so prevalent in the
CRC literature.
An unexpected finding during this analysis was that a small number of
tumours classified as CIMP-H had fewer hypermethylated genes than
some CIMP-L tumours, and a small subset of CIMP-N tumours had a
higher number of hypermethylated genes than some CIMP-L tumours.
Thus, there was no distinct boundary in the number of hypermethylated
genes between the CIMP subtypes, despite a difference in the average
number of hypermethylated genes between the subtypes. The lack of
distinct boundaries between CIMP groups might be explained by a
variable number of stochastic hypermethylation events that contribute to
the overall frequency of hypermethylated genes in each tumour (discussed
in detail below).
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3.3.2 Identifying aberrant DNA methylation
To identify cancer-specific methylation patterns, two separate approaches
were used. In the first approach, methylation of individual CpG loci was
assessed using SAM (significance analysis of microarrays), which relies on
a t-test based calculation and permutation testing. An important
advantage of SAM is that it is a non-parametric test which does not
assume the data is under a normal distribution. The second approach
(WSR, also non-parametric) assessed methylation data from multiple
CpG loci, treating CGIs as discrete windows of the genome. The high
density of the 450K beadchips enabled the use of the WSR test to
interrogate methylation at all CpGs in each island and island shore. The
benefit of this method is selection for genes with the greatest changes in
methylation, and is an improvement on previous methods that identified
hypermethylated genes on the basis of one or two differentially
methylated CpGs. The use of a threshold based on the difference in
β-values for tumour and non-cancerous samples is fairly widespread and
often uses a cutoff of ∆ β-value 0.2 [55], [146], [147], [148]. To identify a
meaningful definition of differentially methylated, a range of ∆ β-values
were tested and the difference between the number of hypermethylated
genes in CIMP-H, CIMP-L and CIMP-N tumours was compared. The
difference in the number of hypermethylated genes between CIMP-H and
CIMP-N tumours was fairly flat between ∆ β-value 0.2 - 0.4. However, at
∆ β-value 0.1 there was a substantial jump in the difference between the
number of hypermethylated genes in CIMP-H and CIMP-N tumours, and
this was chosen as the cutoff point. The rationale for this decision was
that a biologically meaningful definition would be one which captures the
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greatest difference between CIMP-H and CIMP-N tumours.
Using this technique over 2,000 significantly differentially methylated
genes were identified. This is comparable to a previous study that
mapped differential methylation to 1,465 RefSeq genes [64]. Many of
these hypermethylation events are novel observations, although some
have been identified previously including GATA4/5 [3], SFRP2 [149],
and the previously proposed serum and stool CRC marker genes
EYA4 [107] and TFPI2 [150]. EYA4 and TFPI2, along with TLX1, were
the three most frequently hypermethylated genes in the dataset.
Although, to the best of our knowledge, TLX1 hypermethylation has not
been previously associated with CRC, one study showed it is methylated
in a high frequency of early stage breast cancers [151]. Activation of
TLX1 through either chromosomal relocation [152] or promoter CGI
demethylation [153] is associated with T-cell acute leukaemia. Notably,
multiple members of the LHX, LMX, NKX, PAX and TBX families of
transcription factors were hypermethylated in all CIMP-H tumours.
These transcription factor families have roles in development, spatial
patterning and tissue homeostasis, and the aberrant silencing or
expression of these genes has been associated with tumour growth
kinetics and malignancy potential. PAX genes are widely expressed and
associated with maintaining tissue homeostasis or wound repair and may
play a role in maintaining progenitor cell pluripotency [154]. Loss of
expression and hypermethylation of PAX genes in cancer was recently
reviewed in [155].
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A novel approach in this study was to analyse the frequency of each
hypermethylation event in the tumour population. Previous publications
described the overall number and type of genes which were
hypermethylated, but did not differentiate between genes which were
hypermethylated in a single case and those hypermethylated in a
majority of cases. By stratifying genes based on the frequency at which
they were hypermethylated in tumours, it became apparent that
hypermethylated genes could be grouped into high or low frequency cases.
Mutations observed in tumours are commonly classified as driver or
passenger events, the former being few in number, high in frequency and
common to multiple tumour types, while the latter occur in many
different genes and appear sporadically. This mutation landscape of
tumours has been described as comprising ‘mountains’ (rare genes that
are mutated frequently) and ‘hills’ (the many genes that are mutated
rarely) [156]. Hypermethylation of genes also resembled this model, with
many genes hypermethylated in a small number of tumours, and a
smaller set of genes hypermethylated in the majority of the population.
When scoring only CIMP-H tumours the number of ‘mountains’ was
much higher than observed in CIMP-N tumours. Strikingly, 258 genes
are hypermethylated in more than 90% of CIMP-H tumours. This core
group of genes were highly enriched for roles associated with
differentiation, cell fate commitment, morphogenesis, and development. A
potential explanation for the observed enrichment is that
hypermethylation of these genes occurs in undifferentiated cells located in
the colonic crypts, preventing the activation of these genes and locking
the cells in an undifferentiated state. These undifferentiated cells
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proliferate and, with the accumulation of additional mutations, give rise
to a tumour.
3.3.3 Models to describe consistent
hypermethylation in CIMP-H
To explain the hypermethylation of 258 genes in the majority of the
CIMP-H tumour population I discuss three potential models. The first
model relies on natural selection, following disruption of the strict
controls maintaining normal epigenome homeostasis, to shape all tumours
towards a similar pattern (convergent evolution). The epigenome is, at
least in part, shaped by both the genome and the activity of proteins
which interact with the genome. An example of how the epigenome can
be altered by a change in protein activity comes from a study of CGI
methylation near the aprt1 gene in a mouse model. The aprt1 promoter
overlaps with the CGI and, so long as the promoter is bound by the Sp1
transcription factor, remains unmethylated in mouse tissue [23]. When
Sp1 binding sites in the aprt1 promoter were deleted or mutated, the
overlapping CGI became heavily methylated [23]. The accumulation of
methylation might represent a marker of dysregulated pathways in which
transcription factor binding is no longer occurring.
In the second model, CIMP-H tumours reflect the epigenetic state of
the tumour-initiating cell. Tumour DNA methylation profiles have
previously been shown to reflect their tissue of origin [51]. A plausible
explanation for the drastically different epigenetic profiles of CIMP-H
compared to CIMP-N tumours is that the tumour-initiating cell was in a
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different developmental state (e.g., progenitor compared to terminally
differentiated). The developmental state of tumour-initiating cells has
been shown to influence the characteristics of tumours [157]. Chow et al
used a single event, activation of the Sonic HedgeHog pathway, to
transform both Neural Stem Cells (NSCs) and Neural Progenitor Cells
(NPCs) into tumour-initiating cells. The tumours derived from NSCs and
NPCs displayed different molecular characteristics, demonstrating the
association between differentiation stage (or epigenetic state) of a
tumour-initiating cell and the tumour subtype. The epigenetic state or
differentiation stage of a cell might influence a resulting tumour through
the pattern of histone modifications or the complement of transcription
factors being expressed. I observed 89% of the genes hypermethylated in
all CIMP-H tumours were PcG targets. In non-malignant cells,
H3K27me3 (the repressive histone modification laid down by PcG
proteins) provides a transient repression of transcription factors that,
when activated, cause differentiation [158], [159]. This suggests tumours
derived from cells at different stages of differentiation would acquire
different hypermethylation profiles, given the established relationship
between H3K27me3 and DNA methylation [126].
The third model involves mutation of an upstream factor, e.g.,
transcription factor or chromatin remodeler, causing a specific set of
genes to become hypermethylated (the “instructive model”) [160], [121].
A study of gliomas, which also display the CpG island methylator
phenotype (G-CIMP), demonstrated that the introduction of a single
mutation in IDH1 into primary human astrocytes rearranges the
epigenome to match G-CIMP tumours [120]. This demonstrates that, at
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least in some tumour types, a single mutation can reproducibly induce
genome-wide changes in methylation. Tahara et al., (2014) analysed CRC
mutations and found the chromodomain genes CHD7/8 frequently had
non-silent mutations in CIMP-H tumours [161]. While the exact function
of the CHD7 protein is poorly characterised it is thought to have a role
in chromatin organisation and the control of gene expression, particularly
in embryonic stem cells [162]. Enrichment for CHD7 and/or CHD8
mutations in CIMP-H tumours points to a disruption of local chromatin
in regions which are targets of CHD7/8 binding, which may then impact
on the methylation status at these loci. Further, the authors showed that
genes previously identified as differentially methylated in CRC are
frequently bound by CHD7. The activating BRAF V600E mutation is
tightly correlated with the CIMP-H subtype [9]. In 2014, a study
proposed BRAF mutations as the cause of hypermethylation in CIMP-H
tumours [163]. Activating mutations in BRAF lead to constitutive
activation of the ERK pathway and, through a phosphorylation cascade,
stabilize the DNA-binding protein MAFG. MAFG binds to selected loci
and recruits a silencing and methylation complex which includes CHD7
and DNMT [163]. This finding has been validated in a publication by the
same lab and an independent lab which used a mouse model of serrated
CRC [164], [165]. However, not all CIMP-H tumours carry the BRAF
mutation, suggesting either MAFG activity is increased via a different











The serrated pathway describes a class of adenomas with jagged infolding
of the epithelial edge, which are currently believed to be the precursor
lesions from which CIMP-H and CIMP-L tumours develop. BRAF and
KRAS mutations have previously been associated with the
hypermethylator phenotypes, and recently a model has emerged which
mechanistically links those mutations with the hypermethylator
phenotype. In the new model, hypermethylation is attributed to
stabilisation of the MAFG protein through mutant BRAF signalling
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(described here briefly and discussed in detail below, Figure 4.1) [163].
The DNA-binding protein MAFG recruits a complex of proteins,
including the chromatin remodelling protein CHD8 and DNA
methyltransferase DNMT3B, to selected regions of the genome. The
MAFG complex induces increased DNA methylation and local changes in
chromatin, and leads to the CIMP-H phenotype [163]. A similar model,
involving accumulation of the ZNF304 protein due to mutant KRAS
signalling, has been described which underlies the CIMP-L
phenotype [166]. These models can not be used to explain 20-30% of
CIMP-H tumours which do not possess BRAF (or KRAS ) mutations,
and the mechanism behind CIMP in these wildtype tumours is unclear. I
hypothesised that the mechanism of CIMP in these tumours was
BRAF/KRAS mutant-independent activation of the RAS/RAF pathway.
The aim of this chapter was to utilise a bioinformatics approach to test
for activated RAS/RAF signalling in CIMP-H double wildtype tumours.
4.1.1 The EGFR-RAS-RAF-MEK-ERK
phosphorylation cascade: the RAS/RAF
pathway
BRAF encodes a serine-threonine protein kinase which functions as part
of a molecular cascade including EGFR, KRAS, BRAF, MEK, and ERK
(Figure 4.1). The cascade is known by various names but here it is
referred to as the RAS/RAF pathway. The RAS/RAF pathway is
responsible for transmitting extracellular growth signals to the nucleus,
and regulates important cellular functions including proliferation,
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differentiation, senescence, and cellular migration [167], [168]. The
RAS/RAF pathway is of special interest in cancer research due to the
prevalence of BRAF/KRAS mutations in serrated pathway CRC, as well
as in melanoma [167,169].
The two major RAS/RAF pathway mutations detected in CRC are
KRAS and BRAF. KRAS mutations are common in CRC, affecting
approximately 40% of CRCs, and are concentrated in codons 12 and 13
(80% of observed mutations are within these two codons) [3]. These
mutations lock the KRAS protein into a constitutively active state where
it binds to downstream RAF proteins [170]. KRAS mutations have been
linked to the CIMP-L phenotype in CRC and are more prevalent in
men [10, 50]. Outside of CRC, KRAS mutations are common in solid
cancers including pancreas (90%), thyroid (50%), bladder (50%) and lung
(30%) [171]. In CRC, mutations in BRAF are rarer than KRAS
mutations (4-18% of tumours) and are primarily (90%) V600E
mutations [167]. V600E mutations result in constitutive activation of the
BRAF protein, leading to high activity through the RAS/RAF pathway
and the phosphorylation of downstream proteins [3], [172], [169].
4.1.2 KRAS/BRAF mutations and the serrated
pathway in CRC
While the majority of CRC tumours are thought to arise due to
mutations in APC activating the Wnt pathway, approximately 20-30% of
tumours arise through the serrated pathway [170]. The serrated pathway

















Figure 4.1: Extracellular signals are propagated through the RAS
protein to RAF-MEK-ERK and PI3K-AKT-mTOR, leading to
proliferation and survival signalling. Activated RAF leads to the
phosphorylation of MAFG, which is stabilised by phosphorylation and
accumulates in the cell. Activated RAS stabilises ZNF304 through
upregulation of USP28 and PRKD1, although the exact mechanism
of how this occurs is unknown (depicted as dashed line between RAS
and ZNF304). MAFG and ZNF304 bind target loci and recruit a
methylation/silencing complex of proteins.
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three molecular subtypes: CIMP-H microsatellite instable (MSI),
CIMP-H microsatellite stable (MSS), and CIMP-L MSS tumours [173].
Three precursor lesions with serrated morphology have been defined:
hyperplastic polyps (common in the adult Western population but
considered to have low malignant potential), sessile serrated adenomas
(SSAs, flat lesions characterised by crypts with an abnormal horizontal
growth pattern), and traditional serrated adenomas (TSAs, relatively
rare polyps which are common in the distal colon and are poorly
characterised) [15].
Activation of the RAS/RAF pathway is thought to be the initiating
event in the serrated pathway, primarily due to the high frequency of
these mutations in early serrated lesions. Over 60% of serrated aberrant
crypt foci, the earliest known lesions in CRC, were found to have a
BRAF mutation while only 3% of non-serrated foci had BRAF
mutations [174]. BRAF mutations, and to a lesser degree KRAS
mutations, are found at a very high frequency in hyperplastic polyps,
SSAs and TSAs [175–178]. A mouse model study which used various
techniques to induce activation of the RAS/RAF pathway demonstrated
that upregulation of the RAS/RAF signalling cascade induced serrated
phenotype lesions in the mice [170].
The role of BRAF and KRAS mutations in tumorigenesis is
complicated and not completely clear. BRAF V600E (activating)
mutations have been most comprehensively studied in melanoma, where
they occur in 50-70% of cases [167, 169]. Activation of the RAS/RAF
pathway drives a burst of cellular proliferation which is followed by
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senescence [179]. In melanoma this produces small lesions called
melanocytic nevi, which are characterised by β-galactosidase and
p16/INK4a expression, arrested growth and low malignant
potential [179]. One consequence of activating BRAF mutation appears
to be upregulation of IGFBP7, which plays a role in the induction of
senescence and apoptosis in melanoma [179]. In the colon, hyperplastic
polyps are lesions which share features with melanocytic nevi e.g., a high
frequency of BRAF mutations, upregulation of p16/INK4a and nuclear
localisation of β-galactosidase [15], [180]. SSAs are colorectal lesions
which are also frequently BRAF mutant, but unlike hyperplastic polyps,
SSAs have high malignant potential. SSAs with signs of dysplasia are
rare, suggesting that once the lesion has escaped from senescence,
progression to full dysplasia occurs rapidly [181]. Escape from senescence
and progression to full dysplasia occurs when p16/INK4a and IGFBP7
become silenced. Two independent publications have documented
methylation-induced silencing of p16/INK4a and IGFBP7, suggesting
DNA methylation could play a role in tumour progression in BRAF
mutants [180], [182].
4.1.3 The role of the RAS/RAF pathway in
methylator-phenotype cancers
BRAF and KRAS mutations are common in CIMP-H and CIMP-L
tumours respectively, although mutations in these genes are almost never
found concomitantly in CRC [183]. Two recent publications have
proposed constitutive signalling from mutant KRAS and BRAF as the
underlying cause of hypermethylation in CIMP-L and CIMP-H,
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respectively [163,166].
Activating BRAF mutations stabilise the DNA binding protein
MAFG and lead to hypermethylation at target loci
CIMP-H tumours are enriched for a characteristic activating mutation
BRAF V600E which leads to constitutive upregulation of the RAS/RAF
pathway. Using methylation of MLH1 as a proxy for the CIMP-H
phenotype, the effect of BRAF/MEK inhibitors in a BRAF V600E
mutant CRC cell line (RKO) revealed this mutation is critical for
hypermethylation [163]. Inhibition of the RAS/RAF pathway led to the
reduction of methylation at the MLH1 promoter and re-expression of this
gene, linking BRAF V600E mutations to the CIMP-H phenotype. To
identify a mechanism which links BRAF mutation to CIMP-H, an RNAi
screen was used to identify genes which, when knocked-down, abolished
the methylation phenotype [163]. MAFG and CHD8 were identified as
critical genes involved in methylation of MLH1, and these two proteins
were both found bound to the MLH1 promoter. CHD8 is a
chromodomain helicase DNA binding protein which is proposed to bring
about local changes in chromatin architecture [184], [185]. A previous
study demonstrated CHD7 and/or CHD8 mutations were common in
CIMP-H tumours and proposed that CHD7 and/or 8 proteins, through
their ability to modify chromatin, regulate the CIMP-H phenotype [161].
MAFG is a DNA-binding protein which, under normal conditions, is
unstable and prone to degradation. Activation of the RAS/RAF
signalling cascade phosphorylates MAFG, stabilising the protein and
causing it to accumulate in the nucleus [163]. In BRAF V600E cells,
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MAFG levels are increased relative to wildtype [163]. Further
experiments demonstrated that, upon binding to DNA, MAFG recruits a
complex of proteins including CHD8 and DNMT3B. This complex was
shown to bind to DNA and initiate methylation of target loci,
presumably through localised changes in chromatin structure and
DNMT3B activity [163]. MAFG is a DNA binding protein that targets a
consensus sequence which was identified in the promoter region of 50/57
genes commonly methylated in CIMP-H tumours [163]. These data
strongly support BRAF V600E mutations as a driver of the CIMP-H
phenotype in CRC.
KRAS mutations and the CIMP-L phenotype
Seventy percent of CIMP-L tumours have upregulation of the RAS/RAF
pathway, although this frequently occurs through KRAS rather than
BRAF mutations. Despite RAS/RAF being in the same pathway, CIMP-
L tumours exhibit hypermethylation at a subset of the loci affected by
hypermethylation in CIMP-H tumours.
To identify the mechanism of hypermethylation in KRAS mutant
CIMP-L tumours an RNAi screen was carried out, using methylation of
the INK4-ARF locus as a proxy for CIMP-L status [166]. The RNAi
screen identified the DNA-binding zinc finger protein ZNF304 as a
critical regulator of DNA methylation at INK4-ARF. Further
experiments demonstrated that activated KRAS stabilises ZNF304
through upregulation of both USP28, a nuclear-localised deubiquitinase,
and PRKD1, a serine/threonine protein kinase which phosphorylates
USP28 and facilitates USP28’s activity as a deubiquitinase [166]. ZNF304
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binds to DNA in a sequence specific manner and recruits a repressor
complex which includes SETDB1, KAP1 and DNMT1. Knockdown of
either ZNF304 or KRAS resulted in de-repression of 50/50 previously
identified CIMP marker genes, indicating ZNF304 is responsible for the
inactivation of these genes in CIMP-L tumours [166], [105], [186].
Why does KRAS mutation, which lies upstream of BRAF, lead to a
less severe methylator phenotype? The differential activity of BRAF and
KRAS mutations is the subject of much debate and is largely unresolved
[167,170]. Unlike RAF mutations, KRAS signals through the PI3K/AKT
signalling pathway which might explain the difference in the phenotypes
presented by these mutations. However, no link between the PI3K/AKT
pathway and USP28/PRKD1/ZNF304 has yet been demonstrated.
4.1.4 Aims
This chapter is based around the observation that a subset of CIMP-H
tumours are BRAF wildtype. The recently proposed model of CIMP-
H development requires BRAF mutant-dependent stabilisation of the
MAFG protein, which targets DNA methylation to selected CGIs. The
presence of BRAF wildtype CIMP-H tumours identifies a gap in our
understanding of CIMP-H development. Three plausible explanations
for the CIMP-H phenotype in the absence of BRAF mutations were: 1)
Upregulation of RAS/RAF pathway activity through a mutation other
than BRAF, 2) the stabilisation of the MAFG protein through RAS-
RAF -independent effects, 3) an alternative mechanism of methylation
which acts independently of MAFG. Invoking the principle of parsimony,
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upregulation of RAS/RAF signalling in a BRAF mutant independent
manner was selected as the working hypothesis, since this hypothesis
differed the least from a known mechanism of action. The aims of this
chapter were to measure RAS/RAF activity levels using a metagene
approach and to assess whether CIMP-H BRAF wildtype tumours have
high or low levels of RAS/RAF pathway activity through a comparison




In the data analysed in Chapter 3, 46% percent of CIMP-H tumours with
mutation data lacked the characteristic BRAF V600E mutation. Seven
CIMP-H tumours (22%) lacked mutations in either BRAF or KRAS. The
rate of BRAF wildtype tumours in tumours classified as CIMP-H in the
literature varies between publications (Table 4.1). Although many
publications do not identify the number of CIMP-H tumours which are
wildtype for both BRAF and KRAS, Ogino et al (2006) noted 29% of
CIMP-H tumours are double wildtype [10]. Hinoue et al (2012) observed
double wildtype samples make up approximately 20% of CIMP-H
samples [50]. The observation of CIMP-H tumours without mutations in
either BRAF or KRAS prompted an investigation into the DNA
methylation and gene expression profiles of CIMP-H BRAF mutant and
CIMP-H BRAF wildtype tumours. I hypothesised BRAF wildtype
CIMP-H tumours would exhibit high RAS/RAF signalling activity,
which would be similar to the RAS/RAF signalling observed in BRAF
mutant tumours.
Table 4.1: Rate of BRAF wildtype CIMP-H tumours in the literature.
Publication BRAF wildtype frequency
Ang et al., 2010 75%
Hinoue et al., 2011 * 39%
Luo et al., 2014 40%
Yagi et al., 2009 29%
Weisenberger et al., 2006 27%
Ogino et al., 2006 ** 29%
* Authors state approximately 20% of CIMP-H are double wildtype.
** Found 29% of CIMP-H tumours were double wildtype.
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4.2.1 CIMP-H tumours are a homogeneous group
CIMP-H tumours were initially predicted to be a homogeneous group
with respect to methylation and expression profiles, independent of
BRAF and KRAS mutation status. To confirm this, the methylation
profiles of BRAF wildtype and BRAF mutants were compared. Because
KRAS mutations lead to a similar, if less severe, methylation phenotype
to BRAF mutants, tumours with mutations in either KRAS or BRAF
were grouped together and compared with tumours that were
KRAS/BRAF double wildtype. Within the dataset of 32 CIMP-H
tumours, 26 of which had mutation status data available, 14 samples
were BRAF mutant, five were KRAS mutant and seven were
KRAS/BRAF double wildtype.
CIMP-H BRAF mutant and CIMP-H BRAF wildtype DNA
methylation profiles
DNA methylation profiles of CIMP-H BRAF mutant and CIMP-H
BRAF wildtype tumours were analysed using SAM (Significance analysis
of microarrays, see methods). No probes were statistically differentially
methylated between the two groups of tumours. To confirm this finding,
a different statistical test, LIMMA, was used. LIMMA identified zero
CpGs with statistically significant differences in DNA methylation after
adjustment for multiple testing (FDR correction). As an additional test
for evidence of probes which were differentially methylated between the
two groups, DNA methylation values of BRAF mutant and BRAF
wildtype samples were plotted for the top 10 probes from the LIMMA
analysis (Figure 4.2). The boxplots indicate a slight trend for BRAF
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mutant samples to have lower methylation than BRAF wildtypes,
although this was not significant and the average difference between
samples was < 0.1β-value for each of the top 10 CpGs. This data
demonstrate BRAF mutant and BRAF wildtype tumours are
comparable with respect to their DNA methylation profiles. This
confirms the BRAF wildtype CIMP-H tumours are true CIMP-H
tumours with a methylator phenotype and can not be explained by
classification errors.
Differentially expressed genes between tumours with wildtype
and mutated RAS/RAF pathway members
Activating BRAF mutations cause constitutive activity through the
RAS/RAF pathway, which targets many genes. CIMP-H BRAF mutant
and CIMP-H KRAS/BRAF double wildtype tumours would be predicted
to have a number of differentially expressed genes as a result. However,
when gene expression was compared between the two groups using
LIMMA, no statistically significant differences in expression were
identified. The absence of differentially expressed genes, or differentially
methylated genes, between BRAF mutant and KRAS/BRAF double
wildtype tumours supports the assertion that CIMP-H tumours are a
homogeneous group. This result suggests that CIMP-H KRAS/BRAF
wildtype tumours have upregulation of this pathway, despite the absence


























































































































































































































































































Figure 4.2: CIMP-H BRAF mutant and BRAF wildtype tumours do
not have significantly different levels of DNA methylation. The top 10
ranked probes from the LIMMA analysis are shown here. Although there
is a trend for BRAF mutant samples to have lower methylation than
BRAF wildtype samples this does not achieve statistical significance.
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4.2.2 Measuring RAS/RAF pathway activity using
a metagene
Constitutive activity through the RAS/RAF signalling pathway stabilises
the MAFG protein in CIMP-H tumours, but does not alter the
transcription of MAFG [163]. Therefore MAFG transcription cannot be
measured directly as a test for RAS/RAF activity. An alternative
approach is to compare the expression of a collection of genes under the
control of the RAS/RAF pathway as an approximation of the signalling
which would also be responsible for stabilising MAFG. RAS/RAF
pathway signalling can be measured through the use of a metagene. A
metagene is a single value representation of the expression profiles of a
range of genes, and is an established technique for measuring the activity
of a collection of genes [187], [188]. To identify a set of informative genes
for the metagene, a literature search was carried out to find previously
identified targets of RAS/RAF pathway signalling. Two gene lists were
selected from the literature, with each selected list based on different
techniques to identify a RAS/RAF pathway signature [189], [190]. The
first gene list (mg1, n=58 genes) was derived using 10-fold cross
validation with the Student’s t-test, which identified genes whose
expression was associated with a BRAF mutation in CRC samples
(n=381 CRC tumours) [190]. The second list was produced through a
differential expression analysis using LIMMA, comparing expression of
genes in 668 CRC tumours which were either BRAF mutant or
BRAF /KRAS double wildtype [189]. The output of this publication was
two gene lists, whereby a tumour was predicted to be a BRAF mutant if
the average expression of the first gene list was lower than the average
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Table 4.2: Metagene mg1 component gene list
ACSL6 CEBPA MOCS3 SLC7A11
AGR2 CEP68 MORC4 SMCR7L
AHR CR616309 PCDH21 SNHG11
AIFM3 DIDO1 PLAGL2 SOX8
ANXA10 DNAH2 POFUT1 SPINK1
ARID3A DUSP18 PRDX5 TFF2
ASCL2 EPDR1 PTPRO TNNC2
ASXL1 ETV5 QPRT TNNT1
AXIN2 GGT7 RAB27B TRIM7
BX427767 GPR143 RAB32 UNKL
BX647159 HOXD1 REG4 VAV3
C10orf47 KCNK5 RNF43 ZIC5
C10orf59 LOC157860 SHROOM2 ZSWIM3
C13orf18 LOC388610 SHROOM4
C20orf142 MLH1 SLC39A5
Fifty-eight genes differentially expressed in BRAF mutant CRC tumours
compared to BRAF wildtype CRC tumours. Gene list taken from [190].
expression of the second gene list [189]. The two gene lists were used to
create two separate metagenes (mg2 and mg3, respectively).
Developing the mg1 metagene to analyse RAS/RAF pathway
activity using a published RAF signature
The metagene was created and tested using our Affymetrix Gne Chip
Human genome U133 Plus 2.0 array data. The mg1 gene set contains 58
genes (Table 4.2), which correspond to 103 Affymetrix probes (Appendix
B) [190]. Singular Value Decomposition (SVD) was used to create a
metagene which captures the expression levels of the 103 Affymetrix
probes as a single value for each of the tumours. Higher metagene scores
are predictive of higher activity through the RAS/RAF pathway,
therefore CIMP-H tumours and BRAF -mutant tumours are predicted to
have higher metagene scores.
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Tumour samples were sorted according to metagene score and visualised
using a heatmap (Figure 4.3). The metagene scores did not appear to
stratify tumours by CIMP subtype or by BRAF/KRAS status.
To test for statistically significant differences in the mg1 metagene
scores between tumour subtypes the Student’s t-test was used. Metagene
scores were significantly higher in BRAF mutant tumours compared to
RAS/RAF double wildtype tumours (p value = 0.013, 95% CI; 0.038 -
0.303), as expected (Figure 4.4A). Metagene scores between CIMP-H and
CIMP-N tumour subtypes were not statistically significant, although this
is trending towards significance (p value = 0.079, 95% CI; -0.014 - 0.246)
(Figure 4.4B). When CIMP status and mutation status were combined,
the difference in metagene scores between CIMP-H BRAF mutant and
CIMP-N KRAS/BRAF double wildtype tumours was significant (p value
= 0.024, 95% CI; 0.024 - 0.318) although this was not as significant as
mutation status alone (Figure 4.5). This is contradictory to the model
proposed by Fang et al., (2014) in which RAS/RAF signalling drives
CIMP status [163]. Alternatively, it might indicate the mg1 metagene is
































































































































































































Figure 4.3: Mg1 does not stratify tumours by mutation status or CIMP
status. Columns represent tumours, rows represent probes which align to
















































































Figure 4.4: BRAF and CIMP-H tumours have significantly higher mg1
scores compared to KRAS/BRAF wildtypes and CIMP-N tumours.
Metagene scores were compared between tumour subgroups using
the Welch t-test. (A) BRAF mutant tumours have higher metagene
scores than KRAS mutants (p value < 0.01, 95% CI; 0.075 - 0.398) and
KRAS/BRAF double wildtypes (wt) (p value < 0.05, 95% CI; 0.038 -
0.303). (B) CIMP-H tumours have higher metagene scores than CIMP-
L (p value < 0.05, 95% CI; 0.067 - 0.469) but not CIMP-N (p value =



































































Figure 4.5: CIMP-H BRAF wildtype tumours have activation of the
KRAS/BRAF pathway. Mg1 metagene scores for combined CIMP and
mutation subtypes were compared using the Welch t-test. CIMP-H
KRAS/BRAF double wildtype tumours have metagene scores higher
than CIMP-N KRAS/BRAF double wildtype. CIMP-H KRAS/BRAF
double wildtype tumours have higher metagene scores than CIMP-
N KRAS/BRAF double wildtype tumours (p value < 0.05, 95% CI;
0.024 - 0.318). CIMP-H KRAS/BRAF double wildtype tumours have
comparable metagene scores to CIMP-H BRAF mutant tumours. *, p
value < 0.01.
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An effective metagene to identify differential activity of the
RAS/RAF pathway
Two additional metagenes were created to test for differential activity of
the RAS/RAF pathway. The new metagenes were based on data from a
publication which analysed 668 CRC samples and identified genes that
were differentially expressed in BRAF mutant samples compared to
BRAF wildtype samples [189]. The signature produced by the original
publication was comprised of two lists of 32 genes each, where a sample
was predicted to be BRAF mutant if the median expression of genes in
the first list was lower than the median expression of the second list [189].
One metagene was created using the 32 genes in the first gene list,
referred to as the mg2 metagene, and a second metagene created from
the second list of genes (mg3 metagene) (Table 4.3A) [189]. The list of
Affymetrix probe IDs included for each metagene can be found in
Appendix C. Tumour samples were sorted according to metagene score
and visualised in a heatmap (Figure 4.6). When sorted by the mg2
metagene score, BRAF mutant and CIMP-H tumours were substantially
enriched on the right side of the heatmap with high metagene scores.
Compared to the mg1 metagene, the mg2 metagene is more able to rank
tumours according to biologically informative groups (Figure 4.6,
compared to Figure 4.3).
Metagene scores differ significantly between the subgroups of tumours.
CIMP-H tumours have higher metagene scores than CIMP-N tumours (p
value = 4.7e-4, 95% CI; 0.108 - 0.361), and BRAF mutant tumours have
higher metagene scores than either KRAS mutant (p value = 1.532e-6,
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A BRAF signature comprised of two gene lists used to make two metagenes.
A) The 32 genes which comprise the mg2 metagene. B) The 32 genes which
comprise the mg3 metagene. The original publication compared the average
expression of the 32 genes in column A to the average expression of the 32
genes in column B, with a tumour predicted to be a BRAF mutant if the
average expression of mg2 was lower than the average expression of mg3. In
the training set this achieved 95.8% sensitivity and 86.5% specificity [189].
144
95% CI; 0.24 - 0.49) and KRAS/BRAF double wildtype tumours (p
value = 1.569e-5, 95% CI; 0.175 - 0.431), as predicted (Figure 4.7).
BRAF mutant CIMP-H tumours have significantly higher metagene
scores than KRAS/BRAF double wildtype CIMP-N tumours (p value =
0.000014, 95% CI; 0.226 - 0.477). This data supports the mg2 metagene
as an effective measurement of differential RAS/RAF pathway activity.
KRAS/BRAF double wildtype CIMP-H tumours have significantly
higher metagene scores than CIMP-N KRAS/BRAF double wildtype
tumours (p value = 0.005, 95% CI; 0.135 - 0.591), despite the absence of
characteristic mutations in these CIMP-H tumours. However, CIMP-H
KRAS/BRAF double wildtype tumours are not significantly different
from CIMP-H BRAF mutants (p value = 0.9, 95% CI; 0.233 - 0.209)
(Figure 4.8). CIMP-H KRAS/BRAF double wildtype tumours exhibit
high levels of RAS/RAF pathway signalling and in this respect, more
closely resemble BRAF mutant tumours than CIMP-N double wildtype
tumours.
The metagene described above was created using the first gene list in
the BRAF signature [189]. The second gene list was used to create a
third metagene (mg3) (Table 4.3B), and metagene scores were analysed
in tumour subgroups using the Welch t-test. Metagene mg3 scores were
significantly different between BRAF mutant and KRAS/BRAF doulbe
wildtype tumour subgroups (p value = 1.101-7, 95% CI; 0.286 - 0.549),
and were significantly different between the CIMP subtypes (p value =
1.727-8, 95% CI; 0.248 - 0.471) (Figure 4.9). When mutation subtype and
CIMP subtype were combined, CIMP-H BRAF mutants have
































































































































































































Figure 4.6: Mg2 stratifies tumour samples by BRAF/KRAS mutation
status and CIMP status. Columns represent tumours, rows represent

















































































Figure 4.7: Mg2 scores are significantly higher in BRAF mutant and
CIMP-H tumours. Metagene scores were compared between tumour
subgroups using the Welch t-test. (A) BRAF mutant tumours have
higher metagene scores than KRAS mutants (p value < 0.01, 95% CI;
0.240 - 0.490) and KRAS/BRAF double wildtypes (p value < 0.01, 95%
CI; 0.175 - 0.431). (B) CIMP-H tumours have higher metagene scores
than CIMP-L (p value < 0.01, 95% CI; 0.186 - 0.549) and CIMP-N (p




































































Figure 4.8: Mg2 metagene scores demonstrate CIMP-H BRAF/KRAS
tumours have activation of the RAS/RAF pathway. CIMP-H
KRAS/BRAF double wildtype tumours have metagene scores higher
than CIMP-N KRAS/BRAF double wildtype, and are comparable
to BRAF mutant CIMP-H tumours. CIMP-H KRAS/BRAF double
wildtype tumours have higher metagene scores than CIMP-N
KRAS/BRAF double wildtype tumours (p value < 0.01, 95% CI;
0.135 - 0.591). CIMP-H KRAS/BRAF double wildtype tumours have
comparable metagene scores to CIMP-H BRAF mutant tumours. **, p
value < 0.01.
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wildtypes (p value = 9.844-11, 95% CI; 0.379 - 0.607) (Figure 4.10).
In summary, RAS/RAF pathway activity is significantly different
between CIMP-H KRAS/BRAF double wildtype and CIMP-N
KRAS/BRAF double wildtype tumours, while CIMP-H BRAF mutant
tumours do not differ in metagene scores compared to CIMP-H
KRAS/BRAF double wildtype tumours (p value = 0.335, 95% CI -0.145 -
0.373). This data supports the hypothesis that even in the absence of
BRAF or KRAS mutations, the remaining CIMP-H tumours have
upregulation of the RAS/RAF pathway. Thus a common feature of
CIMP-H is activation of the RAS/RAF signalling pathway. In the
majority of cases this is explained by activating mutations in RAS or


















































































Figure 4.9: Mg3 metagene scores differ between mutation subtypes and
between methylation subtypes. Metagene scores were compared between
tumour subgroups using the Welch t-test. (A) BRAF mutant tumours
have higher metagene scores than KRAS mutants (p value < 0.01, 95%
CI; 0.187 - 0.464) and KRAS/BRAF double wildtypes (p value < 0.01,
95% CI; 0.286 - 0.549). (B) CIMP-H tumours have higher metagene
scores than CIMP-L (p value < 0.01, 95% CI; 0.239 - 0.551) and CIMP-




































































Figure 4.10: Mg3 metagene scores for combined mutation and CIMP
subtypes. CIMP-H KRAS/BRAF double wildtype tumours have
metagene scores higher than CIMP-N KRAS/BRAF double wildtype,
and are comparable to BRAF mutant CIMP-H tumours. CIMP-H
KRAS/BRAF double wildtype tumours have higher metagene scores
than CIMP-N KRAS/BRAF double wildtype tumours (p value < 0.01,
95% CI; 0.379 - 0.607). CIMP-H KRAS/BRAF double wildtype tumours
have comparable metagene scores to CIMP-H BRAF mutant tumours.
**, p value < 0.01.
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4.2.3 RAS/RAF pathway is activated in an
independent set of CIMP-H BRAF/KRAS
double wildtypes
The data above support the hypothesis that even in the absence of
BRAF or KRAS mutations, CIMP-H tumours have high RAS/RAF
pathway activity. To validate these findings, an independent CRC data
set was downloaded from The Cancer Genome Atlas (TCGA). The
validation data set was comprised of 221 colorectal tumours, of which 204
had the requisite mutation and CIMP status data (Table 4.4) [3]. Half of
the CIMP-H tumours (n=14) are BRAF wildtype, and four CIMP-H
tumours are wildtype for both BRAF and KRAS. RNA seq data was
available for 29 of the 32 genes in the mg2 gene list, and metagene scores
were calculated for each of the TCGA tumours.
Metagene scores were compared between methylation and mutation
subtypes of tumours. CIMP-H tumours have higher metagene scores than
CIMP-N (p value = 2.2e-16, 95% CI; 0.387 - 0.513), and BRAF mutant
tumours have higher metagene scores than KRAS/BRAF double
wildtype tumours (p value = 1.33e-10, 95% CI; 0.332 - 0.536) (Figure
4.11), validating the findings in the original dataset. When the
methylation and mutation subtypes were combined, CIMP-H BRAF
mutants have higher metagene scores than CIMP-N KRAS/BRAF
double wildtype samples (p value = 2.2e-16, 95% CI; 0.459 - 0.611).
CIMP-H KRAS/BRAF double wildtype tumours have higher metagene
scores than CIMP-N KRAS/BRAF double wildtype (p value = 1.275e-6,
95% CI; 0.447 - 0.666), and are not statistically different from BRAF
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CIMP-H 13 10 4 27
CIMP-L 3 25 16 44
CIMP-N 3 49 81 133
Total 19 84 101 204
TCGA colorectal and adenocarcinoma (COAD) CIMP and mutation data.
CIMP status is taken from the TCGA CRC publication [3].
mutant CIMP-H tumours (p value = 0.637, 95% CI; -0.0868 - 0.129)
(Figure 4.12). The analysis of this publicly available dataset supports the
original finding that CIMP-H tumours lacking mutations in KRAS or
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Figure 4.11: Validation of the mg2 metagene in a publicly available
dataset. Metagene scores were compared between tumour subgroups
using the Welch t-test. (A) BRAF mutant tumours have higher
metagene scores than KRAS mutants (p value < 0.01, 95% CI; 0.209 -
0.404) and KRAS/BRAF double wildtypes (p value < 0.01 , 95% CI;
0.332 - 0.536). (B) CIMP-H tumours have higher metagene scores than
CIMP-L (p value < 0.01, 95% CI; 0.207 - 0.385) and CIMP-N (p value <




































































Figure 4.12: Validation of mg2 metagene scores for combined CIMP
and mutation subtypes. CIMP-H KRAS/BRAF double wildtype
tumours have metagene scores higher than CIMP-N KRAS/BRAF
double wildtype, and are comparable to BRAF mutant CIMP-H tumours.
CIMP-H KRAS/BRAF double wildtype tumours have higher metagene
scores than CIMP-N KRAS/BRAF double wildtype tumours (p value
< 0.01, 95% CI; 0.447 - 0.666). CIMP-H KRAS/BRAF double wildtype
tumours have comparable metagene scores to CIMP-H BRAF mutant
tumours. **, p value < 0.01.
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4.3 Discussion
BRAF and KRAS mutations have been associated with CIMP-H and
CIMP-L tumours respectively, and two recent publications linked these
mutations to the mechanism of CIMP development in CRC [163], [166].
However, 20-30% of CIMP-H tumours are BRAF wildtype, which begs
the question of how CIMP-H develops in these wildtype samples. Here
I have demonstrated that the subset of CIMP-H tumours which lack
characteristic BRAF or KRAS mutations nonetheless exhibit a high
level of activity through the RAS/RAF pathway. This finding extends
the model of BRAF -dependent CIMP-H development and links it to
the observation of a population of RAS/RAF activated BRAF/KRAS -
wildtype tumours [163], [189].
4.3.1 A BRAF metagene identifies a subset of
CIMP-H BRAF -like tumours
The BRAF -driven model of CIMP-H development involves stabilisation
of the MAFG protein without a change in the level of transcription of the
MAFG gene. Therefore expression of MAFG could not be used as a
measurement of RAS/RAF pathway activity in this analysis. An
alternative approach was to assess the activity of a set of genes which are
under the control of the RAS/RAF pathway. A metagene is a powerful
tool which can combine information from a collection of genes and
produce a single value that is informative about the combined activity of
the genes. Metagenes were created on the basis of previous analyses
which have analysed large numbers of BRAF mutant and BRAF
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wildtype CRC tumours [190], [189]. The metagene analysis establishes
that CIMP-H tumours have greater activation of the pathway than
CIMP-L and CIMP-N tumours. In addition, the metagene data
demonstrates that CIMP-H tumours which lack characteristic
BRAF /KRAS mutations also have high activity through the RAS/RAF
signalling pathway. Upregulation of the RAS/RAF pathway in all
CIMP-H tumours supports the model in which stabilised MAFG is the
principle mechanism responsible for the methylator phenotype in these
wildtype tumours. This is the first time BRAF wildtype tumours have
been linked to the MAFG mechanism of CIMP.
4.3.2 A model of DNA methylation
We now understand that activation of the RAS/RAF pathway is found
in all CIMP-H tumours (studied so far) and appears to play a much
greater role in CIMP-H than previously thought. The usual mechanism
of RAS/RAF pathway activation is through a BRAF or KRAS
mutation, which are common in the earliest known precursors to
CIMP-H. BRAF mutations have been linked with the MAFG protein,
which targets DNA methylation to a large set of loci, resulting in the
CIMP-H phenotype [163]. KRAS mutations are linked to the ZNF304
protein which targets methylation to a smaller set of loci than MAFG,
resulting in the less severe CIMP-L phenotype.
In cells which acquire a BRAF mutation, the result is an initial burst
of proliferation followed by p16/INK4a- and p53 -induced
senescence [15], [180]. Studies of early lesions in both CRC and
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melanoma have noted a high frequency of small, senescent lesions
carrying BRAF mutations, indicating BRAF -induced senescence is a
significant barrier to the evolution of a tumour [191], [192]. Escape from
senescence is associated with methylation of the p16/INK4a locus and
the p53-response gene IGFBP7 [180], [182]. I hypothesise that BRAF
mutant cells are therefore under considerable selection pressure to silence
key loci in order to escape senescence, which they achieve through the
MAFG/CHD8/DNMT3B protein complex. The characteristic CIMP-H
subtype occurs as a result of this increased MAFG activity.
CIMP-L is often described as exhibiting hypermethylation which
occurs at a subset of the loci hypermethylated in CIMP-H tumours.
When the number of hypermethylated CGIs in KRAS and BRAF
mutants were compared I observed that, although the two groups of
tumours differ in the number of hypermethylated CGIs (p < 0.001,
Welch t-test), there was an overlap between the two groups (data not
shown). This finding suggests that within a mutation subclass there is
considerable variation in the frequency and distribution of CGI
hypermethylation. One result of this variation is that, while BRAF and
KRAS mutations are primarily associated with CIMP-H and CIMP-L
respectively, a small number of tumours are discordant for their mutation
and CIMP subtypes. In our data, five CIMP-H tumours carried
mutations in KRAS instead of BRAF. Similarly, six CIMP-N tumours
had mutations in KRAS, and a further three CIMP-N tumours had
mutations in BRAF.
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MAFG, and it’s associated complex of proteins including CHD8 and
DNMT3B, targets hundreds of loci and is capable of inducing localised
chromatin remodelling, silencing and DNA methylation [163]. Tumours
which have escaped BRAF -induced senescence through methylation and
silencing of p16/INK4a and IGFBP7 demonstrate the selective
advantage of stabilised MAFG. The data in Chapter 3 demonstrate that
CIMP-H tumours vary widely in frequency and distribution of
hypermethylation. I characterised the observed hypermethylation
patterns as being comprised of a moderate number of loci which were
consistently methylated in tumours and a much larger set of loci which
were methylated sporadically. This view is consistent with a model in
which stabilised MAFG leads to methylation accumulating throughout
the genome, the majority of which is probably neutral and a small
amount of which provides a selective advantage.
One prediction of this model is that methylator-type tumours would
have poorer prognosis due to their epigenetic diversity providing a diverse
substrate for tumour evolution, yet CIMP-H tumours have a good
prognosis. Approximately 60% of CIMP-H tumours are MSI, which is
associated with high immune cell infiltration and is hypothesised to
contribute to the good prognosis of these cancers [193], [194]. However, a
subset of CIMP-H tumours remain microsatellite stable (MSS), and in
this subpopulation of CIMP-H tumours survival is poor, which I believe
reflects the selective advantage provided by an increase in the variance of
DNA methylation.
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I predicted CIMP-N tumours would have universally low levels of
RAS/RAF pathway activity, therefore a surprising finding here was the
range of RAS/RAF pathway activity in CIMP-N tumours. A small
number of CIMP-N tumours exhibit very high RAS/RAF pathway
activity, which raises the question of why these individuals do not display
a methylator phenotype. The difference between CIMP-H and CIMP-N
tumours with high RAS/RAF activity could be due to the genetic
background of these two subtypes. In the serrated pathway, BRAF
mutations are thought to be early events which lock cells in a senescent
state until the key loci p16/INK4a and the p53-response gene IGFBP7
become methylated. In contrast, CIMP-N tumours arise through the
conventional CRC pathway, accumulating mutations in APC, p53, and
SMAD4. In CIMP-N tumours lacking p53, upregulation of the RAS/RAF
pathway could provide proliferation signals without p53 -dependent
senescence. Without senescence, CIMP-N tumours are under no selective
pressure to upregulate their methylation machinery and, as a result,
exhibit much lower levels of DNA hypermethylation.
4.3.3 Implications and further directions
This model, whereby RAS/RAF induced senescence creates a selective
pressure for upregulation of DNA methylation machinery, raises a
number of questions. For example, there appears to be a discrepancy
between activation of the RAS/RAF pathway, hypermethylation and
escape from senescence. Serrated polyps exist in the colon which, despite
activation of the RAS/RAF signalling pathway, have not yet progressed
to carcinoma. It is currently unclear as to what differentiates a polyp
160
which does not progress from one which goes on to develop dysplasia.
The existence of serrated polyps with high levels of DNA methylation
indicate that once MAFG or ZNF304 have started to accumulate and
cause hypermethylation there may be a lag period before cells start to
escape senescence. Alternatively, in these polyps the key loci involved in
escape from senescence might not have become hypermethylated yet. An
analysis and comparison of the level of MAFG and the DNA methylation
profiles in serrated adenomas which have failed to progress to dysplasia
and those which have begun to develop dysplasia will refine our view of
cancer progression.
Further, MAFG and ZNF304 have consensus binding sites, but this
does not explain why certain CGIs are hypermethylated much more
frequently than other CGIs. In the absence of other factors CGIs which
have the consensus binding sequences are predicted to become
hypermethylated at similar rates, but this does not appear to be the case.
Similarly, what is the mechanism of hypermethylation at loci which do
not have the consensus binding sites?
Although CIMP-L is often described as having a “similar but less
severe” phenotype than CIMP-H in terms of the DNA methylation,
CIMP-H and CIMP-L are mediated by different effector proteins
(MAFG/DNTM3B and ZNF304/DNMT1 complexes,
respectively) [163], [166]. The identification of two independent pieces of
epigenetic machinery suggests methylation plays an important role in
tumorigenesis, possibly by facilitating the escape from
RAS/RAF -induced signalling. Further study is required to understand
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the difference between RAS and RAF mutations and how they propagate
their signal. We do not understand, for example, why one mutation leads
to MAFG-dependent methylation while another mediates DNA
methylation through ZNF304, nor why one of these mutations leads to a
more severe methylation phenotype than the other.
A final consideration is the existence of alternative mechanisms or
pathways which can drive hypermethylator phenotypes in CRC or other
cancer types. The hypermethylator phenotype in glioma, for example, is
driven by disruption of TET-mediated active demethylation either
through mutation of IDH1 or through the exclusion of TET1 from the
cell nucleus [120,195]. Although IDH1 mutation has not been observed in
CRC, TET-mediated demethylation can be inhibited through alternative
mechanisms. A recent study demonstrated a link between hypoxia and a
reduction in the activity of TET, leading to hypermethylation of cells in
vitro [196]. Interestingly, hypoxia was associated with increased
hypermethylation of mouse breast tumours and substantially higher
methylation of tumour suppressor gene promoters in cancer patients [196].
To the best of my knowledge, hypoxia has only been linked to
hypermethylation through the disruption of TET and not through an
active methylation pathway. However, one study has demonstrated a link
between hypoxia and an increase in the level of the activated form of the
KRAS protein in KRAS wildtype CRC cell lines [197]. Although the
authors detected no phosphorylation of the downstream protein ERK,
they did detect an increase in phosphorylated AKT, indicating RAS
signalling was occurring. As this effect was observed in KRAS wildtype
cells, the finding suggests hypoxia is a plausible driver of the CIMP-L
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phenotype in KRAS wildtype tumours.
This bioinformatics based approach to analysing RAS/RAF pathway
activity in CIMP-H tumours would benefit from further refinement. Two
limitations of this analysis are the low number of CIMP-H KRAS/BRAF
double wildtype samples included in the study, and the potential for
mis-classification of mutation status. BRAF V600E mutations make up
approximately 90% of all BRAF mutations in CRC, but other mutations
in BRAF could explain the high RAS/RAF activity in some of the
CIMP-H wildtype samples. Sequencing the RAS/RAF genes in the
available samples will confirm their wildtype status. Finally, while the
metagene analysis of RAF signatures has provided a strong indication of
MAFG stabilisation in KRAS/BRAF wildtype tumours, a more accurate
measurement could be provided through detection of stabilised
(phosphorylated) MAFG with Western blot analysis.
This bioinformatics based approach to analysing RAS/RAF pathway
activity in CIMP-H tumours would benefit from further refinement. Two
limitations of this analysis are the low number of CIMP-H KRAS/BRAF
double wildtype samples included in the study, and the potential for
mis-classification of mutation status. BRAF V600E mutations make up
approximately 90% of all BRAF mutations in CRC, but other mutations
in BRAF could explain the high RAS/RAF activity in some of the
CIMP-H wildtype samples. Sequencing the RAS/RAF genes in the
available samples will confirm their wildtype status. Finally, while the
metagene analysis of RAF signatures has provided a strong indication of
MAFG stabilisation in KRAS/BRAF wildtype tumours, a more accurate
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measurement could be provided through detection of stabilised
(phosphorylated) MAFG with Western blot analysis. As to the cause of
RAS/RAF pathway activation, it is interesting to speculate on which
pathway members might be playing a role. As the focal pathway
members, ERK and MEK genes are prime candidates as the cause of
upregulated pathway activity. BRAF is one of three RAF proteins which
share sequence homology and substrate specificity, though ARAF and
CRAF do not have the same biological functions as BRAF [198].
Whatever the mechanism of activation, CIMP-H RAS/RAF activated
tumours point to RAS/RAF signalling as the central pathway in the
development of the methylator phenotypes.
4.3.4 Conclusion
The data here link two previously published findings: the observation of
a BRAF -like subpopulation of CRC tumours, and the BRAF -centric
model of hypermethylation in CIMP-H tumours. I show for the first time
that KRAS/BRAF double wildtype CIMP-H tumours are RAS/RAF
activated and most likely use stabilised MAFG to gain the
hypermethylator phenotype. The data provide further validation of the
BRAF -like subtype through the use of the original classification system
in a novel dataset. The data here suggest RAS/RAF pathway activation
and MAFG activity as the mechanism of hypermethylation in the 20-30%
of CIMP-H tumours lacking characteristic BRAF /KRAS mutations. As
a consequence, I propose a revised model in which activation of the
RAS/RAF pathway is crucial to the development of all CIMP-H
tumours, and DNA methylation is an adaptation which allows tumours
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CRC is a worldwide health problem and is the third most common cause
of cancer in the Western world. One step towards a reduction in the
mortality from advanced CRC is the development of an accurate and
reliable method of early detection. Current established methods of CRC
detection, namely stool testing and colonoscopy, lack either the accuracy
or the public uptake and are therefore not suitable as a public screening
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test. In addition, physical examination tests such as the colonoscopy,
sigmoidoscopy or CT colonography are expensive and require specialist
knowledge. Blood-based biomarkers are a potential new method for the
detection of CRC. The observation from Chapter 3, that EYA4, TFPI2
and TLX1 are hypermethylated in more than 90% of tumours analysed
(page 99) prompted an investigation into the clinical utility of these loci
as potential markers for the detection of CRC. While hypermethylation
of EYA4 and TFPI2 has been described before, and EYA4 has been
investigated as a biomarker [151], frequent hypermethylation of TLX1 is
a novel finding. In this chapter, I demonstrate the level of DNA
methylation at select nucleotides in TLX1 can accurately differentiate
CRC from non-cancerous tissue. I also, through the use of a large
candidate screen, identify additional nucleotides located in ADHFE1
which are able to discriminate CRC from non-cancerous tissue and from
other types of tumours. These aberrant hypermethylation marks could
provide useful novel markers for the non-invasive detection of CRC.
5.1.1 Physical examination for the detection of
CRC
New Zealand experiences one of the highest rates of CRC in the world,
with a rate of 50.5 (male) and 38.5 (female) cases per 100,000 in 2014
[http://www.health.govt.nz/publication/new-cancer-registrations-2014].
Improvement in screening is a critical step towards reducing CRC
incidence and mortality. The current methods for the physical detection
of CRC are either colonoscopy, sigmoidoscopy, or CT colonography.
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Colonoscopy
Colonoscopy is currently the gold standard method for CRC detection.
Case-control studies have been carried out to assess the effect of
colonoscopy followed by surgical removal of polyps when necessary, and
indicate this technique reduces CRC incidence and mortality in the
population. Individuals who underwent colonoscopy in the previous 10
years have shown a 48-77% reduction in risk of CRC, and overall an 81%
decrease in CRC-related mortality [199,200]. The effect of a colonoscopy
on CRC incidence has been shown to persist for up to 20 years following
the procedure [201].
When colonoscopy data was analysed for right- and left-sided CRC
individually, colonoscopy more effectively reduces the risk of left-sided
CRC (OR 0.16, 95% CI 0.12 - 0.20) compared to right-sided CRC (OR
0.44, 95% CI 0.35 - 0.55) [200]. Individuals who received a complete
colonoscopy were substantially less likely to go on to die from CRC which
developed in the left side of the colon (adjusted odds ratio 0.33, 95% CI
0.28 - 0.39), however colonoscopy does not appear to reduce the number
of deaths from right-sided CRC (adjusted OR 0.99, 95% CI 0.86 -
1.14) [202]. This is most likely due to the right-side of the colon being
more difficult to reach endoscopically, as well as the types of lesions
found in the right-side of the colon. SSAs (sessile serrated adenomas) are
more common in the right-side of the colon and, due to their flat
appearance, are more difficult to detect by colonoscopy.
A colonoscopy is an invasive test requiring a fasting hospital visit and
has minor (irritation) to significant (perforation and bleeding)
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complications. Colonoscopy also requires specialist knowledge, and the
effectiveness of colonoscopy varies depending on procedural practices
(e.g., skill of endoscopist, use of sedatives, preparation of the colon) [203].
Public uptake of colonoscopy testing is poor, and is not well suited for
screening large populations.
Sigmoidoscopy
A sigmoidoscopy is a visual examination of the sigmoid section of the
colon only (i.e., does not assess the right-side of the colon).
Sigmoidoscopy and subsequent removal of polyps reduces the burden of
CRC, as shown by a recent randomised population study [204]. The
study, which involved over 160,000 participants divided into control and
intervention arms, found sigmoidoscopy reduced the incidence of CRC by
23% and reduced mortality by 31%. The effectiveness of sigmoidoscopy
was supported by a recent meta-analysis, which found a 33% reduction in
left-sided CRC and a 28% reduction in CRC mortality [205].
Sigmoidoscopy, by definition, is not able to detect right-sided CRC. A
study of tumours which were missed by sigmoidoscopy indicates a further
15-19% of cancers would have been detected had a full colonoscopy been
carried out [206]. The inability to detect right-sided CRC must be
weighed against the benefits of sigmoidoscopy over colonoscopy, namely
that the procedure is briefer and safer. In addition, a patient who tests




A CT colonography is the least invasive of the physical tests, and detects
adenomatous polyps and carcinomas with accuracy comparable to
colonoscopy [207]. In a study of 2,500 participants who underwent both
colonoscopy and CT colonography, CT colonography identified 90% of
patients (n=282) who had lesions detected by the colonoscopy [207]. In
addition, CT colonography identified a further 30 lesions which were
present in the patient but were not detected by the initial
colonoscopy [207]. Four independent meta-analyses which looked at CT
colonography detection found that this technique achieves a sensitivity
between 85-96%, with specificity between 92-97% [208–211]. CT
colonography has a higher public uptake (34% of invitees) than
traditional colonoscopy (22% of invitees) [212].
While CT colonography has demonstrated positive detection rates and
could benefit from greater acceptance from the public, the technique
has not been standardised across studies or clinics. No long term study
of patients who have undergone CT colonography has been carried out,
and the current proposed interval time between screening is five years
[213]. An expert panel stated that due to the lack of consensus on CT
colonography, colonoscopy remained the preferred physical screening
method for CRC detection [213].
5.1.2 Stool testing
While physical screening techniques achieve high sensitivity and
specificity, they suffer from low patient compliance and high cost, and are
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therefore not well suited as a population level screen. An ideal screening
method would have high public uptake and low cost, and would be used
in conjunction with a follow-up secondary test (e.g., colonoscopy) to
confirm a positive diagnosis. Such a test would require high accuracy,
detecting a high percentage of true tumours from both sides of the colon,
while producing few false positives. To be deployed as a population
screen, the test would need to be cost-effective and easy to perform.
Finally, any screening method must have high uptake by the general
public and must therefore be non-invasive and preferably lack any
specific requirements such as fasting or diet restrictions. Biomarkers -
any measurable molecule such as aberrantly methylated or mutated DNA
which can be used to obtain information about a disease state - represent
an alternative to physical screening methods which are more suited to
population screening.
The strength of a biomarker can be described using two measurements:
sensitivity/specificity and positive predictive value (PPV)/negative
predictive value (NPV). Sensitivity, the proportion of true cases which
are correctly identified as cases, and specificity, the proportion of true
controls (disease free) who are identified as controls, are characteristics of
the biomarker or test [214]. PPV is the probability that patients with a
positive test result do have the disease being tested for, while NPV is the
probability that patients with a negative test result do not have the
disease, and is impacted by the prevalence of the disease in the
population. When measuring the level of a metabolite or other biomarker
a threshold for detection of cases is set. Sensitivity can often be increased
by decreasing the threshold of detection, but this comes at the cost of
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specificity (increased false detection rate). The challenge for the
development of a biomarker is selecting a threshold of detection which
achieves the optimum balance of sensitivity and specificity.
Currently, several clinical tests exist which aim to identify CRC by
detecting cancer-enriched markers present in the stool, the three most
important of which are described in detail below. Two of these tests, the
fecal occult blood test (FOBT) and fecal immunochemical test (FIT)
detect the presence of blood (heme or globin, respectively), while the
third (Cologuard, Exact Sciences [http://www.exactsciences.com/
our-products/screening-test]) is designed to detect a range of markers
including KRAS mutations, aberrant DNA methylation, and hemoglobin.
The advantages of stool testing are the noninvasive nature of the test and
the lack of preparation required prior to sample collection. Stool samples
can be collected from home and sent away, or taken in a clinical setting.
Stool testing suffers from the requirement for more regular screening
(annually for FOBT and FIT, every three years for Cologuard) and has
reduced sensitivity compared to colonoscopy, particularly for
pre-cancerous lesions. Also, some cultures and many individuals are
hesitant to handle stool samples and these tests may suffer from low
public uptake.
FOBT
FOBT detects the presence of heme in the stool and has successfully
reduced mortality from CRC, according to a large randomized control
trial [215]. A recent meta-analysis reported that FOBT screening reduced
the relative risk of CRC mortality by 16% [216]. A substantial
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disadvantage of FOBT is a high rate of false positives as a result of
non-cancer related heme present in the stool, which may originate from
bleeding in the upper gastrointestinal tract, from hemorrhoids, or from
animal meat consumed by the patient. Prior to testing, patients must
restrict their intake of red meat or other sources of heme. In addition,
testing requires three stool samples in order to improve sensitivity and
specificity.
FIT
FIT specifically detects human-derived hemoglobin and so avoids false
positives originating from the patient’s diet. FIT was more accurate than
FOBT in a screening study involving over 700 patients (sensitivity and
specificity for FIT was 85%/95%, and 31%/92% for FOBT), although a
previous study has demonstrated sensitivity and specificity of FIT may
vary (sensitivity ranged from 11-58%, specificity ranged from 59-97%)
[217,218].
Cologuard
Cologuard is a test which interrogates DNA released from cells in the
colon and preserved in the stool [219]. DNA is shed from both healthy
cells and cells from a cancer or pre-cancerous lesion, and Cologuard tests
for the presence of cancer-specific markers. The cancer-specific DNA
markers are KRAS mutation, hypermethylation of BMP3 and
hypermethylation of NDRG4, which are combined with an
immunochemical assay to detect human hemoglobin [220].
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The effectiveness of Cologuard was compared to FIT in a large study
of almost 10,000 patients who received a colonoscopy (0.7% tested
positive for CRC (n=65), 7.6% positive for advanced precancerous lesions
(defined as advanced adenomas or sessile polyps measuring > 1cm in
dimension) (n=757)) [220]. Cologuard tested favourably against FIT
when detecting CRC (sensitivity of 92.3% compared to 73.8% (p =
0.002)) or advanced precancerous lesions (42.4% compared to
23.8%) [220]. FIT had a lower rate of false positives (specificity 96.4%)
than Cologuard (89.8%) (p < 0.001) among patients who had tested
negative for cancer during colonoscopy [220].
While Cologuard posted positive results in the initial study, which
included a screen of 10,000 individuals, only 65 cases of CRC were
identified and the test could therefore benefit from further validation.
Because of the low sensitivity for advanced precancerous lesions,
Cologuard screening is recommended every three years. Cologuard could
be improved with the inclusion of novel markers which are sensitive to
precancerous lesions, thereby reducing the frequency of necessary
screenings.
5.1.3 Emerging biomarkers
The identification of novel biomarkers is an important step towards
reducing the global burden of cancer. Blood samples are an alternative
source of biological material which may be better suited to biomarker
development than stool samples. Blood samples contain three biological
materials which are potential biomakrers for the detection of cancer:
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tumour cells which have sloughed off from the original tumour mass,
tumour-derived exosomes and tumour-derived DNA [221].
Circulating tumour cells (CTCs) are cells which originate from a
tumour and have been shed into the bloodstream. CTCs can be detected
in a blood sample by testing for cell-surface epithelial markers such as
EpCam, using physical properties such as cell size, or detecting
cancer-specific markers such as over-expressed HER2 in breast cancer
cells [221, 222]. Veridex CellSearch [http://cellsearchctc.cllstg.net/] is a
commercially available platform which uses magnetic beads coated in
EpCam antibodies to isolate circulating cells followed by immunostaining
to differentiate CTCs from non-cancerous cells. Veridex has been
successfully used in the detection of CTCs for the purpose of prognostic
studies in metastatic CRC [223,224]. Numerous studies suggest that CTC
monitoring in peripheral blood can provide important prognostic
information in a clinical setting [225,226].
Exosomes are extracellular vesicles which can be found in fluids such
as blood or urine. Tumour-derived exosomes contain potentially useful
molecular markers (e.g., DNA, microRNA), which could be monitored in
order to predict tumour recurrence [221,227].
Circulating tumour DNA (ctDNA) originates from tumour cells which
undergo necrosis or apoptosis and can be detected in the blood (serum or
plasma) of a patient. ctDNA retains both mutations and aberrant
methylation marks which are specific to the tumour, and is thus a strong
candidate substrate for the development of biomarkers. SEPT9
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hypermethylation has been suggested as a plasma CRC biomarker, with
reported sensitivities of 48-72% and specificity of 84-93% [228–230].
However, a subsequent study analysed SEPT9 hypermethylation levels in
plasma from asymptomatic individuals who were due to receive a
colonoscopy and found the test had a sensitivity of only 48%, with 91%
specificity [231]. In recent years a number of potential biomarkers have
been published, including those that detect cancer-specific mutations
(e.g., KRAS ) or aberrant hypermethylation (e.g., TFPI2 or
SEPT9 ) [228, 229, 231–234]. Despite the number of publications, few of
these biomarkers have made it to the clinic (Cologuard, described
previously, is an exception).
DNA methylation has a number of characteristics which make it
attractive for biomarker development. DNA methylation is a chemically
stable modification which, following bisulfite conversion, provides a
substrate for differential amplification through methylation-specific PCR.
Unlike mutations, which can be shared between tumour types (e.g.,
BRAF mutation which is shared by colorectal and melanoma), DNA
methylation profiles have enough tissue specificity to differentiate healthy
tissue types and between cancer types [98]. Methylation-based
biomarkers could therefore be informative regarding the type and
location of the cancer detected. Future biomarker tests could combine
mutation markers which indicate the presence of a range of cancers with
methylation markers which refine the diagnosis.
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5.1.4 Aims
The aims of this chapter were to investigate the potential of
hypermethylation of TLX1 as a blood-based marker to differentiate CRC
tumour from non-cancerous tissue, and to identify additional DNA
methylation marks which could be used in the detection of CRC.
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5.2 Results
5.2.1 TLX1 is a potential CRC biomarker
The three CpG islands EYA4, TLX1 and TFPI2, were each
hypermethylated in more than 90% of all colorectal tumours. Given the
high frequency of these aberrant events, hypermethylated EYA4, TLX1
and TFPI2 represent potential biomarkers for the detection of CRC.
Although hypermethylation of EYA4 and TFPI2 have previously been
proposed as biomarkers for CRC, hypermethylation of TLX1 is a novel
discovery.
TLX1 methylation varies across the promoter
The TLX1 CpG island was identified as a candidate cancer marker on
the basis of total DNA methylation across the length of the island.
However, a practical methylation based biomarker would most likely rely
on methylation-specific qPCR, which interrogates DNA methylation at a
small number of adjacent loci. To identify individual CpG dinucleotides
with the ability to differentiate tumour from non-cancerous tissue,
methylation was plotted across the TLX1 CpG island (Figure 5.1).
Individual probes from the island (n=22) vary in the level of methylation
in non-cancerous and tumour samples, although methylation is generally
low in non-cancerous tissue samples (Figure 5.1A, B). The majority of
CpG loci have an increase in DNA methylation of approximately β-value
0.3 (β-values range from 0 (unmethylated) to 1 (fully methylated)) in
tumour samples relative to non-cancerous samples (Figure 5.1C). An
exception to this general trend are the two probes cg00741609 and
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cg01175020, which are found at the furthest edge from the TLX1 CpG
island and do not exhibit differential methylation.
Receiver operator characteristic curve
To identify the probes with the greatest ability to discriminate tumour
from non-cancerous tissue, receiver operator characteristic (ROC) curves
were generated for each probe. The process for generating a ROC curve
is outlined in the review by Xia et al., 2013 [235]. Briefly, non-cancerous
and tumour tissue samples are ranked from those with the lowest DNA
methylation score to the highest. To begin, the lowest DNA methylation
score is treated as the threshold, and any sample higher DNA
methylation is classified as a tumour and those below are classified as
non-cancerous. At this point the sensitivity (number of true tumours
classified as tumour) and 1 minus the specificity (number of false
positives) are recorded. This processes is then repeated, treating each
DNA methylation score as the threshold for detection. The recorded
sensitivity and 1-specificity scores at each threshold are then plotted on a
scatterplot, and these dots are connected to form a ROC curve.
To assess a biomarker, the partial area under the ROC curve (pAUC)
is calculated. The pAUC is a numerical value between 0.5 and 1
indicating the strength of a candidate biomarker, and in this case
represents the likelihood that a given tumour sample will have a higher
DNA methylation than a given non-cancerous tissue sample. The R
package pROC [85] was used to generate ROC curves and calculate
pAUC values for each CpG loci in the TLX1 CpG island and island




























































































































































































































































































































































































Figure 5.1: DNA methylation varies across the 22 CpG probes in
the TLX1 CpG island. DNA methylation is relatively low at most
CpG sites for 92 non-cancerous tissue samples (A), and is higher in
matched tumour tissue samples (B). The level of hypermethylation
(DNA methylation in tumour sample minus methylation in non-cancerous











































































































Figure 5.2: Probes at the edge of the TLX1 CpG island have poor (A,
B) or intermediate (C) pAUC values, while probes in the center of the
CpG island (D, E, F) have high pAUC values.
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Table 5.1: AUC, partial AUC and confidence intervals for TLX1 CpG
island probes
Probe AUC (95 % CGI) Partial AUC (95 % CI)
cg19008088 59.8% (51.3% - 67.8%) NA (48.2% - 53.4%)
ch11498156 50.4% (42.4% - 59.5%) NA (47.4% - 49.3%)
cg11196237 94.0% (89.3% - 97.7%) 70.3% (54.5% - 88.2%)
cg08908184 92.4% (87.2% - 96.7%) 64.3% (50.1% - 84.8%)
cg18964775 92.8% (88.0% - 97.5%) 64.6% (49.9% - 86.3%)
cg02567119 93.4% (89.3% - 97.3%) 69.5% (56.0% - 87.8%)
cg00299972 97.7% (94.7% - 99.5%) 88.2% (72.1% - 97.1%)
cg15325875 97.8% (94.7% - 99.5%) 88.5% (73.2% - 97.4%)
cg00741609 97.1% (94.2% - 98.9%) 85.3% (72.4% - 95.5%)
cg12118269 98.6% (96.2% - 99.6%) 92.5% (80.3% - 98.3%)
cg24812837 98.8% (96.3% - 99.6%) 93.8% (81.3% - 97.9%)
cg25266629 98.8% (96.5% - 99.7%) 93.8% (81.6% - 98.5%)
cg04273871 96.5% (93.4% - 98.3%) 83.2% (70.9% - 93.5%)
cg07416656 98.2% (95.7% - 99.7%) 90.6% (77.2% - 98.5%)
cg14861089 98.6% (96.2% - 99.7%) 92.5% (80.9% - 98.4%)
cg23340017 97.0% (93.9% - 99.0%) 84.9% (71.5% - 94.9%)
cg20572816 94.4% (90.0% - 97.6%) 72.7% (58.7% - 88.9%)
cg27521476 97.9% (95.4% - 99.3%) 89.3% (76.8% - 97.2%)
cg01175020 98.8% (95.7% - 99.8%) 93.6% (77.4% - 98.8%)
cg04552206 96.4% (93.5% - 98.6%) 82.9% (70.3% - 93.0%)
cg06382559 96.9% (93.8% - 98.9%) 84.8% (73.3% - 95.1%)
cg20120208 96.0% (92.9% - 98.3%) 81.1% (67.1% - 93.8%)
confidence intervals were generated on the basis of non-parametric
stratified resampling using 10,000 reiterations. The first two probes,
which are the furthest from the TSS of TLX1 and represent the very
edge of the CpG island shore region, have poor pAUC values while
probes in the center of the CpG island have higher pAUC values (Figure
5.1, 5.2), ranging from 64.3% - 93.8% (Table 5.1). The highest
performing probe (cg25266629, scoring a pAUC of 93.8% (81.6% - 98.5%
CI)), was selected for further study.
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TLX1 methylation discriminates non-cancerous from tumour
tissue
The optimal threshold for differentiating tumour from non-cancerous
tissue was calculated to be β-value 0.41, determined using a function
from the pROC package. When DNA methylation at cg25266629 was
plotted for non-cancerous and tumour tissue samples it was clear that the
threshold of β-value 0.41 could differentiate these two tissue types, with a
sensitivity of 97% and specificity of 99% (Figure 5.3). Hypermethylation
of cg25266629 occurs in both left and right sided tumours (which have
traditionally been more difficult to detect), and in early (e.g., Stage 1)
CRC tumours, and indicates a very promising biomarker for the
detection of colorectal cancer.
5.2.2 Validation of TLX1 cg25266629 in an
independent data set
To validate the ability of cg25266629 to differentiate CRC from
non-cancerous colon tissue, an independent dataset was examined. The
dataset, obtained from The Cancer Genome Atlas (TCGA), contained
369 colorectal tumour samples and 45 colorectal non-cancerous tissue
samples with DNA methylation values for the TLX1 CpG island [3].
DNA methylation at TLX1 cg25266629 was plotted for each tissue
sample in the validation dataset (Figure 5.4). Using the pre-determined
threshold of 0.41 as the cutoff for predicting a positive sample, 349/369
tumour samples are correctly identified (sensitivity = 95%). At this



























Figure 5.3: DNA methylation at cg25266629 accurately differentiates
non-cancerous from tumour colorectal tissue. Methylation values at
cg25266629 for 92 non-cancerous tissue samples (circles) and 92 matched
tumour tissue samples (triangles), coloured by CIMP status. Horizontal
line (β-value 0.41) indicates the threshold for detection of a tumour
sample.
be a tumour sample (specificity = 98%). The positive predictive value
(PPV) of cg25266629 was 100% while the negative predictive value
(NPV) was 69% (i.e., 100% of samples which tested positive were in fact
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Figure 5.4: DNA methylation at cg25266629 accurately differentiates
non-cancerous from tumour colorectal tissue in an independent dataset.
Each symbol represents the DNA methylation values at cg25266629 for
45 non-cancerous tissue and 369 tumour tissue samples, divided by black
vertical line. Horizontal line (β-value 0.41) indicates the threshold for
detection of a tumour sample.
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TLX1 cg25266629 methylation level in non-colorectal clinical
samples
The aim of this study was to identify hypermethylated loci which could
be used to detect CRC using a blood or stool test. In addition to having
high methylation in CRC tumours and low methylation in non-cancerous
colon tissue, a locus should meet two additional criteria to be considered
as a potential CRC biomarker: the locus should preferably not be
methylated in non-CRC tumours so as to avoid non-specific positives,
and it is critical that the locus is not methylated in haemopoetic cells.
To assess the level of TLX1 cg25266629 methylation in non-CRC
tumour types, Illumina 450K HumanMethylation array data for a series
of glioblastoma multiformes, liver hepatocellular carcinomas, lung
adenocarcinomas, prostate adenocarcinomas and pancreatic
adenocarcinomas was downloaded from The Cancer Genome Atlas
(TCGA). For each dataset, a subset of patients had matching
non-cancerous tissue DNA methylation data available which was also
downloaded. Using the threshold of β-value 0.41, the sensitivity and
specificity of cg25266629 was calculated for each of the tumour types
(Table 5.2). The specificity of cg25266629 is high (> 94%) in each tissue
type, indicating methylation at this locus is low in the majority of
non-cancerous tissue types analysed. However, this locus is frequently
hypermethylated in non-CRC tumours (sensitivity ranging from
36%-65%) (Figure 5.5). While this finding does not directly impact on
the ability of this locus to detect CRC, it does mean that a proportion of
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Figure 5.5: Sensitivity and specificity of TLX1 cg25266629 over
multiple tissues: Glioblastoma multiforme (GBM), liver hepatocellular
carcinoma (LIHC), lung adenocarcinoma, prostate adenocarcinoma
(PRAD) and pancreatic adenocarcinoma (PAAD).
To address the question of whether TLX1 cg25266629 is likely to be
hypermethylated in the blood of healthy individuals, publicly available
DNA methylation data for serum (n=40, GSE68777) and whole blood
(n=479, GSE100227) was accessed. Serum samples were taken from 20
individuals with acute mania and 20 control samples, aged 18-65 [81].
Whole blood DNA methylation was measured using blood spots from
twins and their siblings, aged between 40-78 years old (mean 56 years,
SD 8 years) [78]. In serum samples, TLX1 cg25266629 has a mean DNA
methylation level of β-value 0.114 (SD β-value 0.012) while the mean
DNA methylation in whole blood was β-value 0.104 (SD β-value 0.016)
(Figure 5.6). This indicates that DNA methylation is found on
approximately 10-11% of cell free DNA (cfDNA) molecules in healthy
samples. Since ctDNA can make up only a small fraction of the total
amount of cfDNA in a blood sample, such a high level of background
noise would pose a significant barrier to the detection of individuals with
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CRC. Therefore, due to the lack of specificity from non-CRC tumours
and the background level of methylation, cg25266629 is unlikely to be a
useful blood biomarker for CRC.















92 92 89 1 97% 99%
CRC
(Validation)
369 45 349 1 95% 98%
GBM 140 2 51 0 36% 100%
LIHC 377 50 151 1 40% 98%
Lung 830 75 486 0 59% 100%
PAAD 184 10 75 0 41% 100%
PRAD 498 50 326 3 65% 94%
Glioblastoma multiforme (GBM), liver hepatocellular carcinoma (LIHC),



































Figure 5.6: DNA methylation at cg25266629 is low in an independent
dataset of non-cancerous tissue and blood samples. A) DNA methylation
level of cg25266629 in 187 non-cancerous tissue samples from patients
with glioblastoma multiforme (GBM), liver hepatocellular carcinoma
(LIHC), lung adenocarcinoma, prostate adenocarcinoma (PRAD) and
pancreatic adenocarcinoma (PAAD). B) cg25266629 DNA methylation
is found at approximately 11% of cfDNA molecules in serum (n=40) and
whole blood (n=479) samples.
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5.2.3 Additional candidate biomarkers for CRC
To identify loci which are hypermethylated specifically in CRC and not
hypermethylated in other tumour types, a further set of candidate loci
were tested for the ability to differentiate CRC from non-cancerous
tissues and other tumour types. The loci used were the 50 top scoring
CpG sites identified during the SAM analysis (chapter 3) i.e., 50 loci
which were most significantly differentially methylated between CRC and
non-cancerous CRC tissue. ROC and pAUC values were generated for
each of these 50 loci (Table 5.3). For each locus with a pAUC value
greater than 95% (n = 14), the optimal threshold for discriminating
tumour from non-tumour tissue was identified using a function from the
pROC R package. Using the optimal threshold values, the 14 candidate
loci were tested for the ability to discriminate CRC tumour from
matched non-cancerous tissue and the sensitivity and specificity scores
were calculated (Table 5.4). All 14 loci had sensitivity scores greater than
95%, and 13 out of 14 candidates showed specificity scores greater than
95% (Table 5.4). Thus, these loci were all able to accurately discriminate
CRC from non-cancerous colon tissue and have potential as biomarkers.
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Table 5.3: Partial AUC values for 50 candidate biomarkers
Gene Probe Partial AUC 95% CI
FLI1 cg11017065 94.84% 86.63% - 99.78%
PPP2R5C cg05920961 95.93% 90.12% - 99.63%
PRKAR1B cg18601167 98.26% 95.27% - 100%
GSG1L cg03394150 91.02% 77.84% - 99.19%
Orphan* cg18456523 78.30% 58.24% - 95.5%
SYT9 cg18560328 87.13% 70.24% - 99.24%
DRD4 cg12928379 95.20% 89.78% - 99.07%
GRASP cg00817367 91.79% 79.27% - 99.56%
Orphan* cg07923233 85.27% 69.6% - 97.54%
FLI1 cg13755070 88.19% 72.61% - 98.84%
FLI1 cg02526522 91.67% 79.49% - 98.88%
PRKAR1B cg13895235 96.95% 91.67% - 99.88%
CRHR2 cg24610236 94.92% 89.6% - 98.87%
LMO1 cg21842523 86% 69.17% - 98.51%
GSG1L cg10471437 84.77% 68.05% - 97.3%
Orphan* cg03061682 94.43% 86.35% - 99.81%
BEND5 cg11666087 96.77% 91.05% - 99.94%
OPLAH cg17698295 97.25% 93.77% - 99.75%
ANKRD13B cg21101720 96.75% 92.96% 99.44%
GRASP cg04034767 92.09% 83.72% - 98.32%
Orphan* cg15684724 93.38% 82.36% - 99.56%
C1orf70 cg15487867 97.76% 94.59% - 99.81%
FLI1 cg17872757 93.46% 82.69% - 99.56%
HS3ST4 cg27014135 73.38% 53.74% - 90.7%
NTNG1 cg07155336 63.16% 47.37% - 86.74%
Orphan* cg09667303 85.50% 70.08% - 97.45%
ZNF568 cg20680720 83.61% 66.33% - 96.74%
USP44 cg13879483 94.86% 85.81% - 99.75%
DBX2 cg13186327 80.75% 64.08% - 94.73%
BEND5 cg16573178 96.89% 91.35% - 99.94%
MIR124-3 cg02650317 91.72% 79.55% - 99.07%
TLX1 cg14861089 93.33% 82.97% - 99.38%
SLC35F3 cg00662647 80.26% 58.86% - 99.96%
Orphan* cg03414318 91.42% 78.14% 99.32%
ADHFE1 cg20295442 95.77% 87.38% - 100%
ST8SIA2 cg08769966 86.95% 69.82% - 99.13%
ADD2 cg15170605 84.21% 69.34% - 96.39%
SND1 cg09296001 97.08% 92.08% - 99.81%
C1orf70 cg16601494 98.88% 97.02% - 99.94%
Continued on next page
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Gene Probe Partial AUC 95% CI
CCDC48 cg20506715 86.72% 74.02% - 96.67%
VWC2 cg04904331 86.08% 70.74% - 97.29%
C17orf46 cg13001868 96.80% 92.35% - 99.69%
GATA5 cg20265733 84.85% 69.94% - 96.67%
ADHFE1 cg20912169 95.62% 87.03% - 100%
VWC2 cg02467990 83.01% 66.55% - 96.23%
FLI1 cg06072021 89.78% 75.69% - 98.88%
ADHFE1 cg18065361 94.19% 83.2% - 99.88%
GDF1 cg03351460 86.48% 71.61% - 97.44%
VWC2 cg01893212 85.25% 71.85% - 96.21%
CHST10 cg19283506 74.57% 53.23% - 93.77%
Partial AUC and confidence intervals were calculated for
50 additional loci to determine their ability to differentiate
CRC from non-cancerous colon tissue. The loci are the top 50
differentially methylated loci identified in the SAM analysis
(chapter 3). * Orphan CpGs are loci which were not designated
a local gene name in the Illumina 450K humanMethylation
array manifest.
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Table 5.4: Candidate biomarkers have high sensitivity and specificity for
colorectal cancer
Gene Probe Sensitivity Specificity
PPP2R5C cg05920961 95.65% 98.91%
PRKAR1B cg18601167 97.83% 98.91%
DRD4 cg12928379 94.57% 96.74%
PRKAR1B cg13895235 97.83% 96.74%
BEND5 cg11666087 96.74% 98.91%
OPLAH cg17698295 98.91% 95.65%
ANKRD13B cg21101720 97.83% 96.74%
C1orf70 cg15487867 96.74% 97.83%
BEND5 cg16573178 98.91% 96.74%
ADHFE1 cg20295442 95.65% 100%
SND1 cg09296001 94.57% 100%
C1orf70 cg16601494 95.65% 100%
C17orf46 cg13001868 95.65% 100%
ADHFE1 cg20912169 97.83% 97.83%
Differentially methylated loci which scored high partial AUC values were
tested for the ability to differentiate CRC from non-cancerous colon tissue.
For each loci, the optimal threshold for differentiating CRC from colon was
calculated, and the sensitivity and specificity were calculated using the optimal
threshold in a set of 92 CRC and their matched non-cancerous colon samples.
Validation of candidate biomarkers
The 14 loci identified above were then tested for the ability to
discriminate CRC from non-cancerous colorectal tissue in a validation
dataset (obtained from the TCGA). DNA methylation data was available
for 10/14 loci. Using the optimal threshold of detection calculated in the
test dataset, the sensitivity and specificity of each of the 10 candidate
markers was calculated (Table 5.5). All 10 loci achieved high sensitivity
(range 78.8-97.6%) and specificity (97.8-100%) scores, accurately
discriminating CRC from non-cancerous tissue in an independent dataset.
Four loci (cg17698295, cg20295442, cg16601494, cg20912169) achieved
very high sensitivity (> 95%) and specificity (> 95%) in the validation
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data set.
The results from this analysis were compared with data from
publications that reported on the hypermethylation frequency of BMP3
and NDRG4, which form part of the Cologuard test for CRC. The top
four loci (cg17698295, cg20295442, cg16601494, cg20912169) compare
favorably to the hypermethylation frequencies of both NDRG4 (range:
70-84% of CRC cases) [236–238] and BMP3 (range: 41-66%) [239–241].
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Table 5.5: Candidate biomarkers have high sensitivity and specificity in
an independent validation set of CRC tissue samples
Gene Probe Sensitivity Specificity
PPP2R5C cg05920961 82.66% 97.78%
DRD4 cg12928379 78.86% 100%
BEND5 cg11666087 83.74% 100%
OPLAH cg17698295 97.29% 97.78%
ANKRD13B cg21101720 93.50% 97.78%
BEND5 cg16573178 84.28% 95.56%
ADHFE1 cg20295442 95.93% 100%
C1orf70 cg16601494 96.75% 100%
C17orf46 cg13001868 88.89% 100%
ADHFE1 cg20912169 97.56% 97.78%
Differentially methylated loci which scored high partial AUC values were
tested for the ability to differentiate CRC from non-cancerous colon tissue. For
each loci, using the optimal threshold calculated in the test data set (Table
5.4), the sensitivity and specificity were calculated using in an independent
dataset of 369 CRC and 47 non-cancerous colon samples.
Candidate biomarker sensitivity and specificity in non-CRC
tissue types
DNA methylation at the four loci with the highest sensitivity and
specificity described above were examined in other common tumour types
and in a set of matching non-cancerous tissue types. Using the
differentiation thresholds identified in the CRC test set, the four loci were
screened for the ability to accurately discriminate tumour from
non-cancerous tissue in glioblastoma multiforme (GBM), liver
hepatocellular carcinoma (LIHC), lung adenocarcinoma, prostate
adenocarcinoma (PRAD) and pancreatic adenocarcinoma (PAAD) cancer
types with corresponding non-cancerous tissue. Sensitivity and specificity
were calculated for each probe (Table 5.6). The locus cg16601494 was
frequently hypermethylated in non-cancerous pancreatic tissue, indicating
DNA methylation at this locus may be part of the normal methylome.
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Cg17698295 is frequently hypermethylated in GBMs, lung
adenocarcinomas, liver adenocarcinomas and pancreatic adenocarcinomas,
which would reduce the specificity of this locus as a potential CRC
biomarker. The remaining two candidate loci cg20295442 and cg20912169
retain 100% specificity across all non-cancerous tissue types analysed,
indicating very little or no methylation occurs in the non-cancerous
tissues studied. Cg20295442 and cg20912169 were rarely hypermethylated
in non-CRC tumour types and have low sensitivity scores (ranges of
1-18% and 1-22%, respectively), indicating hypermethylation at these loci
is enriched in CRC (Table 5.6). Notably, cg20295442 and cg20912169 are
both located in the ADHFE1 CpG island.
These data demonstrate that cg20295442 and cg20912169 are highly
sensitive and specific in both test and validation CRC datasets, and were
rarely methylated in non-CRC tumours.
Whole blood and serum DNA methylation is detectable at very
low levels for ADHFE1 probes cg20295442 and cg20912169
DNA methylation of cg20295442 and cg20912169 was assessed in the
whole blood (n=479, GSE100227) and serum samples (n=40, GSE68777)
as described earlier. The mean DNA methylation of cg20295442 in serum
was β-value 0.0379 (SD β-value 0.0088) and β-value 0.0613 (SD β-value
0.0147) in whole blood samples (Figure 5.7). Cg20912169 exhibited lower
methylation, with a mean of β-value 0.0337 (SD β-value 0.0088) in serum
and mean β-value 0.0342 (SD β-value 0.0158) in whole blood (Figure
5.8). These values indicate that at the cg20912169 locus, DNA
methylation is present at ≈ 3% of cfDNA molecules in serum or whole
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Table 5.6: Probes cg20295442 and cg20912169 are rarely methylated in
non-CRC tumours
cg17698295 cg20295442 cg16601494 cg20912169
Glioblastoma
multiform
Sensitivity 88% 1% 0% 1%
Specificity 100% 100% 100% 100%
Lung
adenocarcinoma
Sensitivity 78% 18% 39% 22%




Sensitivity 100% 2% 78% 2%
Specificity 100% 100% 98% 100%
Pancreatic
adenocarcinoma
Sensitivity 84% 7% 52% 8%
Specificity 20% 100% 60% 100%
Prostate
adenocarcinoma
Sensitivity 0% 7% 15% 11%
Specificity 12% 100% 100% 100%
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blood. As a comparison, the mean serum and whole blood DNA
methylation values were calculated for all CpG loci across the array (data
not shown). DNA methylation was detectable at the majority of the
genome, with only nine loci exhibiting a methylation level below 1%.
This was a surprising finding, however, as detailed in the discussion
below, there is evidence from the literature to suggest the 1-3%
methylation at cg20295442 and cg20912169 is an artifact of the Illumina
450K array.
These data demonstrate that the ADHFE1 probes cg20295442 and
cg20912169 are promising candidates for biomarker development,
although the detectable background methylation at these loci may impact
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Figure 5.7: DNA methylation at cg20295442 is detected at a very
low level in an independent dataset of serum (n=40) and whole blood
(n=479) samples. A) Cg20295442 methylation plotted at the range of 0
- 80% methylation B) cg20295442 DNA methylation plotted at the fine










Figure 5.8: DNA methylation at cg20912169 is detected at a very
low level in an independent dataset of serum (n=40) and whole blood
(n=479) samples. A) Cg20912169 methylation plotted at the range of 0
- 80% methylation B) cg20912169 DNA methylation plotted at the fine
scale resolution (0 - 10%) methylation.
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5.3 Discussion
CRC, and cancer in general, is a well studied disease yet there has been
only modest improvement in the survival of cancer patients. Colonoscopy
is a proven method to reduce CRC mortality, but public uptake is low
and tumours in the right side of the colon are frequently missed. This
chapter describes the identification of cancer-specific DNA methylation
marks which are able to accurately differentiate CRC from non-cancerous
tissue and non-CRC tumours. These loci could be developed into
biomarkers for the detection of CRC. DNA methylation can be accurately
quantified in blood or stool samples using established molecular
techniques. Once a test protocol has been established it can be carried
out with minimal equipment, at an affordable price, and requires no
specialist knowledge. The loci presented here could form the basis of a
new screen for the detection of CRC, or could be incorporated into
existing panels to improve their sensitivity.
The two CpG loci identified in the candidate screen (cg20295442 and
cg20912169) are both located in the ADHFE1 CpG island.
Hypermethylation of ADHFE1 (alcohol dehydrogenase, iron containing 1)
has been described previously in a genome-wide screen for
hypermethylation in CRC, where it was both hypermethylated and
downregulated in tumour samples relative to non-matched non-cancerous
tissue [242]. These findings have subsequently been validated in two
independent studies, one of which found ADHFE1 was hypermethylated
in 95% of tumours (n=73) [243,244].
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While the data demonstrate DNA methylation level at cg20295442 and
cg20912169 can discriminate tumour from non-cancerous tissue, this is
based on measurements drawn from DNA extracted directly from tissue
samples. Clinically useful markers would need to have significantly
different DNA methylation levels in the serum or whole blood of
individuals with CRC compared to those without. When cg20295442 and
cg20912169 were examined in healthy individuals a low level of
background methylation was detected, which corresponds to
approximately 3% of cfDNA molecules from this locus carrying DNA
methylation in healthy serum or whole blood samples. The contribution
of circulating tumour DNA to the overall pool of cfDNA varies
dramatically between patients, with observations as low as 0.03% or in
excess of 50%. In cases where ctDNA makes up only a small part of the
total cfDNA in serum or blood, a background methylation level of 3%
would make detection of ctDNA difficult. However, a number of
publications have demonstrated that the Illumina 450K
HumanMethylation beadchip, which was used in this analysis,
significantly over-estimates DNA methylation when the actual level is
very low [245–247]. Compared to DNA methylation measurements called
by bisulfite pyrosequencing, the Illumina 450K array over-estimated DNA
methylation by 5-10%, and this over-estimation was most pronounced
when DNA methylation was very low or very high [245, 246]. A more
recent publication tested the accuracy of a range of techniques and
platforms for measuring DNA methylation and also found that the
Illumina array over-estimates methylation when the actual DNA
methylation level is low [247]. This publication calculated a “consensus
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corridor” of DNA methylation measurements called by amplicon bisulfite
sequencing, EpiTyper, pyrosequencing, and enrichment bisulfite
sequencing, and observed the Illumina 450K array over-estimated
methylation by up to 20% when the consensus methylation level was low
(< 20%) [247]. On the basis of the above results, the background
methylation of cg20295442 and cg20912169 observed in serum or whole
blood may be an artifact of the Illumina 450K array. Before these loci
can proceed for further testing this will need to be analysed using more
accurate and reliable methods such as bisulfite pyrosequencing or
quantitative methylation-specific PCR.
The data presented here demonstrate that cancer-specific DNA
methylation marks, which were identified on the basis of a genome-wide
analysis, can generate novel candidates for the detection of CRC. The
two candidate probes identified above (cg20295442 and cg20912169) had
high sensitivities and specificities in both discovery and validation
datasets. Cg20295442 and cg20912169 had sensitivity scores of 95% and
97% respectively, higher than the two Cologuard DNA methylation
markers BMP3 (range 76% - 86%) and NDRG4 (41% - 66%) [236–241].
These data indicate that, if they were incorporated into the Cologuard
test, the candidate markers presented here could offer an improvement in
the sensitivity of the test. Genome-wide DNA methylation analyses
represent a wealth of potential markers for CRC, and hypothetically for
numerous other cancers (see Tables 5.2, 5.6).
One of the strengths of DNA methylation-based biomarkers is the
consistency with which these aberrant marks occur across varied tumours.
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For example, EYA4, TFPI2 and TLX1 were hypermethylated in more
than 90% of tumours analysed here and, as noted above, ADHFE1 was
hypermethylated in 95% of tumours analysed in an independent
study [244]. In contrast, the three most frequently mutated genes in CRC
were APC (81%), TP53 (60%) and KRAS (43%) in non-hypermutated
tumours and ACVR2A (63%), APC (51%) and TGFBR2 (51%) in
hypermutated tumours [3]. Because hypermethylation is such a prevalent
feature, it potentially allows for the detection of a much greater
proportion of CRC cases using a single marker. This study involved a
varied cohort of tumours including CIMP-N tumours and early stage
tumours (6 stage 1, 33 stage 2A), which were correctly classified using
the candidate biomarkers cg20295442 and cg20912169. Our control tissue
samples, as well as the controls retrieved from the Cancer Genome Atlas,
indicate that the biomarker candidates are almost exclusively devoid of
methylation in non-cancerous tissue. A future experiment could assess
the methylation status of cg20295442 and cg20912169 in individuals with
non-malignant disease, which might generate false positive results.
Specifically, inflammation (such as that in inflammatory bowel disease) is
associated with increased DNA methylation and could lead to
hypermethylation of the loci identified here [248].
While the data presented here demonstrate cg20295442 and
cg20912169 are excellent candidate biomarkers, it is important to
acknowledge the gap which exists between a lab analysis and a clinical
output. Unsurprisingly, the number of published articles identifying
candidate biomarkers severely outweighs the number of commercially
available tests. This difference indicates the existence of numerous
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challenges which prevent the translation of a candidate marker to the
clinic. These challenges, and a discussion of potential solutions, are
addressed below.
5.3.1 The challenge of analysing cfDNA in clinical
samples
Biomarkers have been referred to as ‘liquid biopsies’, and as such they
offer a number of advantages over traditional biopsies: they do not
involve a surgical procedure and the associated potential for
complications, they are cheap to perform, theoretically sample the entire
tumour burden (including any metastases) and therefore are less likely to
be affected by tumour heterogeneity and subclonal evolution. Despite
these advantages, liquid biopsies present a number of unique challenges
stemming from the need to collect a biological material (from here on
referred to as the biomarker substrate) and extract cfDNA which is
present in limited quantities. The optimisation of the protocols involved
in the collection and analysis of cfDNA is critical to the development of
biomarkers.
The choice of biomarker substrate is critical and has been the subject
of much debate. An ideal biomarker substrate would be easy to collect
and store long term, would relate to the cancer of interest (e.g., urine for
bladder cancer, stool for CRC, sputum for lung cancer), and would
contain large quantities of target material (in this instance cfDNA, but
plausibly protein or RNA). Traditionally, investigations into the clinical
utility of biomarkers for CRC detection have used either stool or blood
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(serum or plasma) samples. Stool samples have the advantage of having
been in direct contact with CRCs and adenomas and may therefore
contain a higher concentration of tumour-derived material. While stool
samples do have a higher yield of cfDNA, only a small fraction (0.01%) of
DNA extracted from stool samples originates from the patient, with the
rest derived from the gut microflora [249]. Stool samples are also
considered highly unappealing to collect and work with, which could
hinder public uptake in the setting of a public screen. Blood samples are
unlikely to be contaminated with non-human DNA, and present less of a
challenge with regards to handling and processing. Blood samples are
more easily collected and stored, and we believe blood sampling would be
more generally accepted by the public. Since a population-level screen is
the end goal in mind for a CRC biomarker, public uptake is of the
utmost importance.
Within blood samples, both serum and plasma have previously been
used as substrates for the extraction of cfDNA. Initially, serum appeared
to have higher concentrations of cfDNA but this is now known to be an
artifact of contamination from lysed blood cells [250,251]. For this reason,
plasma is considered to be a superior substrate for a CRC biomarker. A
critical step in the development of cancer biomarkers will be the
establishment of a consensus protocol for the storage of plasma and the
extraction and subsequent handling of cfDNA. It is generally accepted
that blood should be collected in tubes containing an appropriate
anticoagulant. Anticoagulants such as heparin contain PCR inhibitors
which can interfere with downstream analysis [252], and the quantity of
cfDNA extracted from plasma samples can vary significantly depending
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on the type of collection tube used [253]. A comparison of Roche, Qiagen
and Streck cell free blood collection tubes found that mutant DNA
spike-ins (1-3ng) could be detected in all three tubes after a period of 7
days storage, although Roche and Qiagen tubes allowed the detection of
lower concentrations of mutant DNA (0.5ng spike-in) [254]. Recent
publications which compared different collection tubes found that Streck
blood collection tubes have a high yield of cfDNA and can be used to
stored blood for an extended period of time (48hr - 1 week) without
cfDNA loss [255, 256]. Samples stored in Streck blood collection tubes were
stable at room temperature and showed no evidence of contamination
with genomic DNA due cell lysis or apoptosis [255].
Because cfDNA is present in such a small quantity, it will be important
to maximise the extraction yield by optimising collection, storage and
downstream analysis protocols. This includes the use of DNA extraction
kits such as the QIAamp circulating nucleic acid or NucleoSpin Plasma
SX, which have been designed specifically for highly fragmented cfDNA.
The use of specialised kits increased the yield of cfDNA from plasma by
2.2 - 2.4 fold relative to a non-specialised blood mini kit [257]. A
particular challenge when attempting to measure DNA methylation in
cfDNA samples is the bisulfite conversion process. Bisulfite conversion,
which is required for measuring DNA methylation in a PCR-based
setting, is a harsh process that severely degrades DNA samples. The
recovery of DNA post bisulfite conversion can vary depending on the
exact protocol used, such as the cycling or non-cycling protocol variants
(data not shown).
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5.3.2 Detecting rare methylated DNA
Cancer-specific methylation patterns make it possible to differentiate
circulating tumour DNA (ctDNA) from cfDNA, but the detection of
these molecules is still technically challenging. Most of the difficulty
involved in testing for ctDNA stems from the lack of available starting
material. The concentration of cfDNA per mL of plasma varies
drastically between patients and can be as low as 10ng/mL or as high as
700ng/mL [258,259]. Only a fraction of cfDNA originates from the tumour,
and although this can be a high proportion in late stage cancers (> 40%
ctDNA, personal communication Dr Donghui Zou), in early lesions
(Duke’s stage A, T2N0M0) the ctDNA fraction can be < 1% [260, 261].
Due to this limitation, highly specific techniques are required to
accurately quantify aberrant methylated DNA against a background of
non-methylated healthy DNA.
EpiProColon is a published biomarker which analyses methylation of
SEPT9 [228]. In this test, methylation of SEPT9 is measured using
real-time PCR (RT PCR). After initially promising reports, the
sensitivity and specificity of the test fell to 48% in a larger study
(n=8,000 individuals) [231, 262]. Sensitivity was lower for early (Stage 1
and stage 2) CRC, and was very low for advanced adenomas (11.2%),
which likely reflects the reduced quantity of ctDNA being shed from
these small lesions into the blood of patients [231]. This sensitivity might
be improved by the use of a more sensitive and specialised technique such
as methyl-BEAMing (beads, emulsion, amplification and magnetics).
Methyl-BEAMing applies a digital approach (the individual counting of
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DNA molecules) to the field of DNA methylation, and is able to detect a
single methylated DNA molecule against an excess of 5,000 unmethylated
molecules [263]. Using a combination of real-time PCR and BEAMing,
Diehl et al., (2008) monitored the number of mutant DNA molecules in a
population of 95 CRC patients undergoing treatment. The study
detected an average of 39 mutant DNA molecules in a background of
4,000 non-mutant DNA molecules [261]. This number is supported by
Warton and Samimi (2015), who calculated that a tumour containing half
a billion cells (approximately 1cm in diameter) would lead to 34-40
tumour copies of a genomic region in one mL of plasma [264].
Irrespective of the sensitivity of a given methodology, the detection of
a methylated allele is dependent on the presence of at least one molecule
of DNA from the tumour in the plasma sample. One method to increase
the likelihood of collecting tumour-derived DNA is to increase the volume
of sample being collected. Collecting 10 - 20mL of blood from a patient is
not much more technically or physiologically demanding than collecting
8mL, and would result in a larger volume of plasma and therefore a
greater yield of cfDNA. In the case of blood, collecting a larger sample
volume increases the abundance of blood-derived PCR inhibitors, and the
effect of this on downstream analysis would need to be considered.
An alternative to increasing the volume of blood being sampled is to
use a technique to enrich for the target DNA within the sample. This
approach has been taken in the field of circulating tumour cell (CTC)
biomarker analyses, which often start by enriching CTC numbers by
several log units [265]. One way in which an enrichment mechanism
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might be implemented is through the use of an in-dwelling device. An
in-dwelling device is any small instrument which could be temporarily
inserted into the blood vessel of an individual for the purpose of sampling
a high volume of blood. Blood flow through vessels is very high
(50mL/minute) and such a device would, in a short space of time, be
exposed to even rare genetic variants. If the instrument includes a way to
bind cfDNA, this could yield a high quantity of DNA with a greater
likelihood of detecting the rare ctDNA fraction. An example of a
proposed in-dwelling device in the biomarker field is the MagWIRE [266].
MagWIRE utilizes an inserted wire that captures CTCs which have been
labelled with magnetically charged antibodies. While MagWIRE is not
currently designed to isolate DNA fragments, it does raise the possibility
of a future device which could enrich for cfDNA within the bloodstream.
This could involve the use of an enrichment mechanism which is specific
for methylated DNA, e.g., through the use of methyl-binding domain
proteins to pull out methylated cfDNA.
In summary, aberrant DNA methylation marks are an attractive
platform for biomarker development. The identification of cancer-specific
marks are the first step in the development of tests which can detect




Key findings, limitations, and
future directions
This PhD project began with the characterisation of genome-wide DNA
methylation patterns in CRC using the Illumina 450K methylation
beadchip. This included the identification of 20,000 differentially
methylated CpG loci, and over 2,000 hypermethylated CGIs. A novel
approach in this analysis was to look at the frequency at which
hypermethylation of a CGI occurred in the tumour population. In doing
so, I observed that hypermethylation in CIMP-H CRC is reminiscent of
the mutation pattern of ‘hills’ and ‘mountains’ described by Wood et al.,
(2007). This observation focused the study to a shortlist of CGIs which
are consistently hypermethylated. This eventually led to the discovery of
two loci in the ADHFE1 CGI which accurately differentiate CRC from
non-cancerous tissues and could be incorporated into diagnostic tests for
the presence of CRC.
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6.1 A working definition of CIMP
One of the first, and most challenging, tasks of this project was to
categorise tumours into their CIMP subtypes. It was typical of
publications at the time to begin with the classification of tumours in the
dataset, yet I struggled to find an acceptable consensus on how to do
this [50], [108]. The small gene panels of the mid 2000s, which were
useful tools for classification, had been replaced by genome-wide
approaches [8], [9], [10]. Studies with access to genome-wide data were
clustering samples on the basis of methylation measurements from
thousands of CpG loci, but even these could not form a consensus on
CIMP [105], [106], [108]. With the decision to cluster based on loci which
were differentially methylated in tumour samples compared to matched
non-cancerous tissue, the result is a working categorisation of samples
into CIMP subtypes which are consistent with regards to the literature.
Notably, tumours are enriched for BRAF mutations and proximal
location among CIMP-H tumours, and KRAS mutations in CIMP-L
tumours. The CIMP-H and CIMP-N subtypes described here are
enriched for tumours which were classified as CIMP-H and CIMP-N
under the Weisenberger panel of genes.
When attempting to classify biological samples into strict groups, it is
to be expected that a small number of samples would naturally sit on the
boundary between groups. These samples might have been classified as
a different subtype if a different clustering method had of been chosen.
Clustering was carried out using the Euclidian distance method and,
in hindsight, this could have been done using a recursive-partitioned
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mixture model (RPMM) approach. RPMM had been used in at least
one major relevant publication, but was not widely used at the time and
therefore not chosen [50,145]. If RPMM had been used, or loci had been
chosen using different criteria, I anticipate a small number of tumours’
CIMP classification would change, however this would not significantly
alter the overall findings.
6.2 Mechanisms underlying CIMP
During this PhD a major shift in our understanding of CIMP came about
with the proposal of a new model mechanistically linking BRAF and
KRAS mutations with hypermethylation [163, 166]. Under this model,
activating mutations in BRAF/KRAS lead to the accumulation of
MAFG and ZNF304 through constitutive RAS/RAF signalling. MAFG
and ZNF304 mediate increased DNA methylation and the characteristic
CIMP-H and CIMP-L phenotypes respectively. Chapter five of this PhD
extends this model with the demonstration that CIMP-H tumours which
lack BRAF or KRAS mutations nonetheless have high RAS/RAF
pathway activity. The high level of RAS/RAF signalling is predicted to
lead to accumulation of MAFG and is the likely mechanism of
hypermethylation in CIMP-H BRAF/KRAS wildtype tumours.
Chapter 4 proposes a model in which increased DNA methylation in
CIMP-H and CIMP-L is a response to the selection pressure of
RAS/RAF signalling-induced senescence. Evidence from the literature
demonstrates that RAS/RAF induced senescence is a substantial barrier
to the development of early colorectal lesions, and DNA methylation can
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mediate escape from this senescence.
6.3 The practical applications of DNA
methylation analyses
The combined forces of mutation and natural selection have allowed life
to spread to every conceivable (and in fact, inconceivable) niche on earth,
adapting to all environmental challenges. In many ways, our lack of
progress in the treatment of cancer is a reflection of the power of
adaptation in response to selection. Perhaps one of the most effective
means we have of combating colorectal cancer is an appropriate program
of screening and detection. Our current gold standard, the colonoscopy, is
costly, must be carried out by a specialist, has modest accuracy for
right-sided cancers, and suffers low public uptake due to it’s highly
invasive nature. Biomarkers are a very promising technique for the
detection of many cancer types. This thesis describes the identification of
hypermethylation in the ADHFE1 gene which accurately discriminates
non-cancerous from tumour DNA, which could be developed into an
accurate test for the detection of CRC.
6.4 Limitations and future directions
The data discussed above suffer from certain limitations. The first
limitation is that of tissue purity. Tissue samples were collected by an
expert pathologist and have been analysed as though they are
homogenous samples of tumour or non-cancerous cells, when in fact this
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is not the case. Tissue is a complex mix of multiple cell types including
stromal tissue, as well as the different cell types which make up the
colonic crypt. Because the epigenome plays such an important role in
cellular differentiation, the presence of different cell types contributes
biological noise to our estimates of DNA methylation. Immune cell
infiltration, which is expected to occur in tumours, further complicates
any estimation of DNA methylation. Bioinformatic techniques have now
been developed which could be used to estimate tumour purity and
identify contamination with non-cancerous tissue or immune cell content
(reviewed in [267]). An additional issue is that a tumour itself is a
heterogenous mixture of cells which may carry different mutations, or
may have different epigenetic profiles dependent on e.g., cell
differentiation stage, location within the tumour mass or proximity to
immune cells. Single cell analysis of the epigenome may help to resolve
our understanding of cancer epigenetics, although our ability to analyse
such a tremendous amount of data may become a limiting factor.
DNA methylation was analysed in the form of β-values, which range
from 0-1 and in this sense are an approximation of the percentage of
cells in a sample with DNA methylation at a locus. This is an attractive
measurement from a biological point of view as it provides a framework
for relating methylation measurements to cell populations. The use of β-
values was recommended by Illumina at the time of this analysis, and the
majority of publications supported their use. However, β-values introduce
a number of statistical limitations such as heteroscedasticity (probes
with a very high or very low mean β-value tend to have lower standard
deviations) and a non-normal distribution [268]. M values (calculated as
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the log2 ratio of the intensity of a methylated probe divided by the ratio
of the intensity of the unmethylated probe) did not display such issues
and therefore could have been a more statistically sound choice.
A general limitation of studies which analyse DNA methylation is the
uncertainty relating to what biological effect this has. While we know
that transcription cannot be initiated from a methylated transcription
start site, many publications have shown that silencing can occur without
methylation and that methylation occurs at genes which were previously
silenced. The ENCODE project is providing publicly available
information such as expression (RNA-seq), histone modifications
(ChIP-seq) and chromatin accessibility (ATAC-seq) data which could be
used to investigate the relationship between methylation and expression.
The analysis of public data could also be used to validate and expand on
the analysis in Chapter 3, which focused on the identification of
frequently methylated genes. These hypermethylated genes need to be
validated in additional CRC datasets and further analysed in additional
tumour types. Gene ontology analysis points to these genes having a role
in development and cellular differentiation, but it is unclear how this
relates to tumorigenesis. To explore the hypothesis that
hypermethylation locks cells in an undifferentiated state, further research
could focus on the role of these genes in the regulation of colonic crypt
maintenance.
To understand the role of DNA methylation in the initiation and
progression of CRC, we need to better characterise the methylome of
(serrated) adenomas and adenomas showing the first signs of dysplasia.
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So far, these types of lesions have received relatively little attention.
However, by better understanding the way DNA methylation changes
with the progression from polyp to CRC, we can hope to identify the
ways in which the methylome contributes to carcinogenesis. Specifically,
isolating which aberrant methylation patterns are present in adenomas
but absent from healthy tissue, or are present in tissue with dysplasia but
not adenomas, could provide information about the processes being
disrupted during the progression of the disease.
While studying DNA methylation can give us insight into the
fundamental process of tumorigenesis, it is also important to focus on
how our knowledge of the epigenome can be used to influence cancer
treatment. Future efforts could be directed towards experimentally
repairing the methylome of cancer cells. Reducing hypermethylation,
either by inhibition of DNA methylation machinery or through chemical
mechanisms (e.g., 5-azacytidine), has been shown to reduce tumour
viability and enhance the effect of therapeutic effects. However, the
current mechanisms for reducing hypermethylation act genome-wide and
induce substantial cytotoxicity and adverse effects. Novel techniques are
being developed which might allow for the accurate demethylation of
specific regions of the genome [269, 270]. As we begin to isolate key
hypermethylation events which facilitate tumorigenesis, we can test the
effect of specifically demethylating these loci as part of a therapeutic
response. For example, targeting demethylation to p16/INK4a and p53,
which become hypermethylated and suppressed in BRAF mutant
tumours, could induce cellular senescence and halt tumour growth. More
broadly, genes which are involved in the control of differentiation
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programmes are hypermethylated in a wide range of tumour types. The
demethylation and potential reactivation of these genes could have a
dramatic effect on the tumour state and, since this more resembles the
methylome of corresponding healthy tissue, could form the basis of a well
tolerated treatment. While targeted demethylation would require
intensive study before it could see clinical use, the study of aberrant
DNA methylation in cancer will deepen our understanding of the
epigenome.
While the field of epigenetics is still relatively young it has already
begun to contribute to our understanding of diseases such as cancer. In
the future, knowledge of the epigenome will inform clinical decisions and
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Steingŕımur Einarsson, Xinmin Zhang, Joy C Lin, Gangning Liang,
Peter A Jones, and Amos Tanay. Frequent switching of polycomb
repressive marks and dna hypermethylation in the pc3 prostate
cancer cell line. Proceedings of the National Academy of Sciences,
105(35):12979–12984, 2008.
[131] Anders M Lindroth, Yoon Jung Park, Chelsea M McLean,
Gregoriy A Dokshin, Jenna M Persson, Herry Herman, Diego
Pasini, Xavier Miro, Mary E Donohoe, Jeannie T Lee, et al.
Antagonism between dna and h3k27 methylation at the imprinted
Rasgrf1 locus. PLoS Genet, 4(8):e1000145, 2008.
[132] Andrew P Feinberg, Rolf Ohlsson, and Steven Henikoff. The
epigenetic progenitor origin of human cancer. Nature reviews
genetics, 7(1):21–33, 2006.
247
[133] Peter W Laird. Principles and challenges of genome-wide dna
methylation analysis. Nature Reviews Genetics, 11(3):191–203, 2010.
[134] Pantelis S Karatzas, Maria Gazouli, Michael Safioleas, and
Gerasimos J Mantzaris. Dna methylation changes in inflammatory
bowel disease. Annals of gastroenterology: quarterly publication of
the Hellenic Society of Gastroenterology, 27(2):125, 2014.
[135] Paul Geeleher, Lori Hartnett, Laurance J Egan, Aaron Golden,
Raja Affendi Raja Ali, and Cathal Seoighe. Gene-set analysis is
severely biased when applied to genome-wide methylation data.
Bioinformatics, 29(15):1851–1857, 2013.
[136] Michael Ashburner, Catherine A Ball, Judith A Blake, David
Botstein, Heather Butler, J Michael Cherry, Allan P Davis, Kara
Dolinski, Selina S Dwight, Janan T Eppig, et al. Gene ontology: tool
for the unification of biology. Nature genetics, 25(1):25–29, 2000.
[137] Jingqi Chen and Weidong Tian. Explaining the disease phenotype
of intergenic snp through predicted long range regulation. Nucleic
acids research, 44(18):8641–8654, 2016.
[138] Hongzhi Zou, Neal K Osborn, Jonathan J Harrington, Kristie K
Klatt, Julian R Molina, Lawrence J Burgart, and David A Ahlquist.
Frequent methylation of eyes absent 4 gene in barrett’s esophagus
and esophageal adenocarcinoma. Cancer Epidemiology and
Prevention Biomarkers, 14(4):830–834, 2005.
[139] Christian Gerecke, Bettina Scholtka, Yvonne Löwenstein, Isabel
Fait, Uwe Gottschalk, Dorothee Rogoll, Ralph Melcher, and
248
Burkhard Kleuser. Hypermethylation of ITGA4, TFPI2 and
VIMENTIN promoters is increased in inflamed colon tissue:
putative risk markers for colitis-associated cancer. Journal of cancer
research and clinical oncology, 141(12):2097–2107, 2015.
[140] Rose K Lai, Yanwen Chen, Xiaowei Guan, Darryl Nousome, Charu
Sharma, Peter Canoll, Jeffrey Bruce, Andrew E Sloan, Etty Cortes,
Jean-Paul Vonsattel, et al. Genome-wide methylation analyses in
glioblastoma multiforme. PloS one, 9(2):e89376, 2014.
[141] Shumin Wang, Xue Xiao, Xiaoying Zhou, Tingting Huang,
Chunping Du, Nana Yu, Yingxi Mo, Longde Lin, Jinyan Zhang,
Ning Ma, et al. TFPI-2 is a putative tumor suppressor
gene frequently inactivated by promoter hypermethylation in
nasopharyngeal carcinoma. BMC cancer, 10(1):617, 2010.
[142] Kimberly D Siegmund. Statistical approaches for the analysis of dna
methylation microarray data. Human genetics, 129(6):585–595, 2011.
[143] Dan Wang, Li Yan, Qiang Hu, Lara E Sucheston, Michael J
Higgins, Christine B Ambrosone, Candace S Johnson, Dominic J
Smiraglia, and Song Liu. Ima: an r package for high-
throughput analysis of illumina’s 450k infinium methylation data.
Bioinformatics, 28(5):729–730, 2012.
[144] Xinhui Wang, Peter W Laird, Toshinori Hinoue, Susan Groshen,
and Kimberly D Siegmund. Non-specific filtering of beta-distributed
data. BMC bioinformatics, 15(1):199, 2014.
249
[145] E Andres Houseman, Brock C Christensen, Ru-Fang Yeh,
Carmen J Marsit, Margaret R Karagas, Margaret Wrensch,
Heather H Nelson, Joseph Wiemels, Shichun Zheng, John K
Wiencke, et al. Model-based clustering of dna methylation array
data: a recursive-partitioning algorithm for high-dimensional data
arising as a mixture of beta distributions. BMC bioinformatics,
9(1):365, 2008.
[146] Gilad Landan, Netta Mendelson Cohen, Zohar Mukamel, Amir Bar,
Alina Molchadsky, Ran Brosh, Shirley Horn-Saban, Daniela Amann
Zalcenstein, Naomi Goldfinger, Adi Zundelevich, et al. Epigenetic
polymorphism and the stochastic formation of differentially
methylated regions in normal and cancerous tissues. Nature genetics,
44(11):1207–1214, 2012.
[147] Suhaida A Selamat, Brian S Chung, Luc Girard, Wei Zhang, Ying
Zhang, Mihaela Campan, Kimberly D Siegmund, Michael N Koss,
Jeffrey A Hagen, Wan L Lam, et al. Genome-scale analysis of dna
methylation in lung adenocarcinoma and integration with mrna
expression. Genome research, 22(7):1197–1211, 2012.
[148] Maria Moksnes Bjaanæs, Thomas Fleischer, Ann Rita Halvorsen,
Antoine Daunay, Florence Busato, Steinar Solberg, Lars Jørgensen,
Elin Kure, Hege Edvardsen, Anne-Lise Børresen-Dale, et al.
Genome-wide dna methylation analyses in lung adenocarcinomas:
Association with EGFR, KRAS and TP53 mutation status, gene
expression and prognosis. Molecular oncology, 10(2):330–343, 2016.
250
[149] Jian Qi, You-Qing Zhu, Jun Luo, and Wen-Hui Tao.
Hypermethylation and expression regulation of secreted frizzled-
related protein genes in colorectal tumor. World journal of
gastroenterology: WJG, 12(44):7113, 2006.
[150] Yoshimitsu Akiyama, Neil Watkins, Hiromu Suzuki, Kam-Wing
Jair, Manon van Engeland, Manel Esteller, Hidekazu Sakai, Chun-
Yan Ren, Yasuhito Yuasa, James G Herman, et al. GATA-4 and
GATA-5 transcription factor genes and potential downstream
antitumor target genes are epigenetically silenced in colorectal and
gastric cancer. Molecular and cellular biology, 23(23):8429–8439,
2003.
[151] Yanqun Liu, Chee Kian Tham, Simon YK Ong, Kok Sun
Ho, Jit Fong Lim, Min Hoe Chew, Che Kang Lim, Yi Zhao,
Choong Leong Tang, and Kong Weng Eu. Serum methylation
levels of TAC1 SEPT9 and EYA4 as diagnostic markers for early
colorectal cancers: a pilot study. Biomarkers, 18(5):399–405, 2013.
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Koch, and Jürgen Weitz. Circulating tumor cells and prognosis of
264
patients with resectable colorectal liver metastases or widespread
metastatic colorectal cancer: a meta-analysis. Annals of surgical
oncology, 20(7):2156–2165, 2013.
[225] Xuanzhang Huang, Peng Gao, Yongxi Song, Jingxu Sun, Xiaowan
Chen, Junhua Zhao, Huimian Xu, and Zhenning Wang. Meta-
analysis of the prognostic value of circulating tumor cells detected
with the cellsearch system in colorectal cancer. BMC cancer,
15(1):202, 2015.
[226] Yan-jun Lu, Peng Wang, Jing Peng, Xiong Wang, Yao-wu Zhu, and
Na Shen. Meta-analysis reveals the prognostic value of circulating
tumour cells detected in the peripheral blood in patients with non-
metastatic colorectal cancer. Scientific reports, 7(1):905, 2017.
[227] T Matsumura, K Sugimachi, H Iinuma, Y Takahashi, J Kurashige,
G Sawada, M Ueda, R Uchi, H Ueo, Y Takano, et al. Exosomal
microrna in serum is a novel biomarker of recurrence in human
colorectal cancer. British journal of cancer, 113(2):275, 2015.
[228] Catherine Lofton-Day, Fabian Model, Theo DeVos, Reimo Tetzner,
Juergen Distler, Matthias Schuster, Xiaoling Song, Ralf Lesche,
Volker Liebenberg, Matthias Ebert, et al. Dna methylation
biomarkers for blood-based colorectal cancer screening. Clinical
chemistry, 54(2):414–423, 2008.
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Table 7.1: Core genes hypermethylated in > 90% of CIMP-H tumours
ADCYAP1 MSX1 TMEM90B ANKS1B NKX2-2
ALX4 NELL2 TWIST1 BNC1 NRG1
BDNF NEUROG1 UNCX CLDN11 OLIG1
BRUNOL4 NKX2-1 VAX1 CRMP1 ONECUT2
CALCA NKX2-3 VAX2 DAB1 PCDH10
CALCR NKX6-1 VCAN EDIL3 PCDH7
CCDC140 NKX6-2 VSTM2A EDNRB RNF182
CCNA1 NPR3 WNT3A ESR1 SLC10A4
CHRM2 NR2E1 WT1 FEV SLC1A2
CIDEA NR5A2 ZIC1 FGF12 SLC8A3
COL12A1 NRG2 ZIC4 FLJ42875 SORCS3
COMP NRN1 ZNF331 FOXL2 STK33
CYP26C1 NXPH1 ACTA1 GDF7 TACR1
DBX1 OLIG2 ARHGAP20 HCG4 TAL1
DGKG ONECUT1 ASCL1 HLA-DQB1 TBX18
DLX5 OTP CDK5R2 HOXA2 TCF21
DLX6AS OTX2 CNPY1 HOXC9 TFAP2B
EBF1 PAX1 CTNNA2 ISM1 ZNF529
EBF2 PAX2 CTNND2 KL
EMX2 PAX3 DLX1 MAGI2
EMX2OS PAX5 DMRTA2 NBLA00301
EN1 PAX6 EMX1 NDRG4
ESRRG PAX9 EN2 NEUROD2
EVX2 PCDH8 EPHX3 NKX1-2
EYA4 PDGFRA FAM155A NKX2-5
FEZF2 PHF21B FLJ32063 NKX2-6
FGF14 PRDM13 FLRT2 ONECUT3
FGF3 PRDM6 FOXF1 POU3F1
FLJ41350 PRDM8 FOXF2 PRDM14
FLJ42709 PRMT8 GATA2 PRICKLE1
FLJ45983 RASGRF1 GATA5 RAX
FOXG1 RFX4 HAND2 SDC2
GALR1 RGS20 HIC1 SHISA9
GATA4 RNF220 HLX SIX3
GDF6 ROBO3 HMX2 SOX17
GDNF RORA HOXD11 SOX2OT
GFRA1 RUNX3 HRK SYNE1
GRID1 SALL1 ICAM5 TLX2
GSC SFRP2 IGF2AS ADAMTS19
Continued on next page
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HAND1 SFTA3 IGFBP3 ANK1
HELT SHISA3 IRX3 BARHL2
HLA-L SHOX2 IRX6 BHLHE22
HPSE2 SIM1 LHX2 CHST2
INS-IGF2 SIM2 LHX6 COL25A1
IRX4 SIX6 LIN28 DCHS2
ISL2 SLC32A1 MEF2C DPP10
ISLR2 SLC6A15 NKX3-2 EPHA5
LBXCOR1 SLITRK5 NR3C1 FAM5B
LHX1 SNCA PAX7 FOXI2
LHX4 SOX21 RPRM FREM2
LHX5 T RSPO3 GUCY1A2
LHX8 TBR1 SLC35F1 HS3ST3B1
LHX9 TBX1 SOX1 INSM2
LMX1A TBX15 SPTBN4 ISL1
LMX1B TBX2 ST8SIA4 LINGO3
LOC401463 TBX5 TBX20 LOC283392
LOC645323 TFPI2 UNC5C LOX
MKX TLX1 VENTX MAR11
MPPED2 TLX3 WNT5A MFSD2B
MSC TMEM200B WNT6 MGC45800
Core subset of 298 genes hypermethylated in > 90% of CIMP-H tumours.




Table 7.2: Mg1 Affymetrix array probe ID
Gene name Affymetrix probe ID
ACSL6 229725 at
















ASXL1 242439 s at
ASXL1 244519 at
AXIN2 222696 at
AXIN2 224498 x at
AXIN2 224176 s at
AXIN2 222695 s at
CEBPA 204039 at
CEP68 212677 s at
CEP68 212675 s at
CEP68 207971 s at
CEP68 1559159 at
CEP68 239442 at
DIDO1 218325 s at






DUSP18 1553701 a at
Continued on next page
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Gene name Affymetrix probe ID
EPDR1 223253 at
ETV5 203349 s at
ETV5 203348 s at
ETV5 230102 at
ETV5 216375 s at
ETV5 231083 at
GGT7 226470 at
GGT7 226469 s at
GGT7 226471 at
GGT7 229788 s at
GPR143 206696 at
HOXD1 205975 s at
HOXD1 205974 at
KCNK5 219615 s at
LOC157860 232040 at
MLH1 202520 s at
MOCS3 206141 at
MORC4 219038 at
PLAGL2 202925 s at




PRDX5 1560587 s at





RAB27B 207018 s at
RAB27B 207017 at
RAB27B 228708 at
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SLC7A11 207528 s at
SMCR7L 221516 s at
SMCR7L 204594 s at
SMCR7L 204593 s at
SMCR7L 224319 s at
SOX8 226913 s at
SPINK1 206239 s at
TFF2 214476 at
TNNC2 205388 at
TNNT1 213201 s at
TRIM7 223694 at
TRIM7 239694 at
TRIM7 1554735 a at
UNKL 221064 s at
UNKL 235087 at
UNKL 229908 s at
VAV3 218807 at
VAV3 218806 s at





Table 7.3: Mg2 Affymetrix array probe ID
Gene name Affymetrix probe ID
DDC 205311 at







SPINK1 206239 s at
PTPRO 208121 s at
PTPRO 211600 at
PTPRO 1554199 at
ZSWIM1 223607 x at
ZSWIM1 217592 at
RNF43 218704 at
CELP 207412 x at
CBFA2T2 207625 s at
CBFA2T2 209145 s at
CBFA2T2 209144 s at
CBFA2T2 238549 at







TSPAN6 209109 s at
VAV3 218807 at
VAV3 218806 s at
VAV3 224221 s at
CFTR 215703 at
CFTR 234702 x at
CFTR 205043 at
CFTR 215702 s at
CFTR 234706 x at
Continued on next page
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ACOX1 209600 s at
ACOX1 213501 at
ACOX1 209601 at








CTTNBP2 232136 s at
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Table 7.4: Mg3 Affymetrix array probe ID
Gene name Affymetrix probe ID




REG43 1554436 a at








MLPH 218211 s at
RBM8A1 217857 s at
RBM8A2 222443 s at
RBM8A3 214113 s at
RBM8A4 1554602 at
RBM8A5 217856 at
SOX8 226913 s at
PIWIL1 214868 at
S100A16 227998 at
RBBP8 203344 s at
OSBP21 221237 s at
OSBP22 223432 at
OSBP23 1569617 at
KLK101 209792 s at
KLK102 215808 at
DUSP41 226034 at
DUSP42 204015 s at
DUSP43 204014 at
HOXD31 217076 s at
HOXD32 206601 s at
HOXD33 206602 s at
CD551 1555950 a at
CD552 201926 s at
CD553 201925 s at
TRNP11 227862 at
TRNP12 236052 at
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Gene name Affymetrix probe ID
FSCN11 201564 s at
FSCN12 210933 s at
PLLP 204519 s at
IRX3 229638 at
SLC25A371 221920 s at
SLC25A372 218136 s at
SLC25A373 222529 at
SLC25A374 226179 at
SLC25A375 222528 s at
SLC25A376 218978 s at
SLC25A377 242335 at
SLC25A378 231078 at
SLC25A379 226928 x at
SLC25A3710 228527 s at
PIK3AP11 1554508 at
PIK3AP12 226459 at
TPK11 221218 s at
TPK12 223686 at
ZIC2 223642 at
SERPINB51 204855 at
SERPINB52 1555551 at
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